sampleid,patientcode,age,gender,diagnosis,diagnosis_simple,disease_duration,bmi,nice_therapy,ethnicity,cohort_split,t25fw,sdmt,bpfr,t2ll,cel,brain_damage,combiwise,GMSdis,edss,snrs,ipec,hauser,neurex,sc_disability,sc_volume,DRB1_1,DRB1_2,nfl_csf_age,smoking
S-181218-03136,pt1,56.75290897,Male,RR-MS,RR-MS,5.546885695,29.56790123,fingolimod (Gilenya),W,validation,3.8,38,0.705509291,8.705993714,0,1.010921018,25.66665808,0.561163469,4,83,1,1,31.05,-22.37873057,80.72308019,*04:03:01,*11:03:01,1105.282902,past
S-181218-03137,pt2,62.02600958,Female,PP-MS,prog-MS,23.4661191,26.39131597,ocrelizumab (Ocrevus),W,validation,30.45,47,0.786242767,9.056139691,NA,-0.913703466,53.2580412,0.365972009,6.5,54,16,6,177.6222201,22.69524819,67.96264766,*15:01,*15:01,139.3650906,past
S-181218-03138,pt3,32.21081451,Male,RR-MS,RR-MS,28.02190281,30.18392952,Untreated,W,validation,7.8,7,NA,NA,NA,NA,49.19343322,NA,5.5,44,10,2,161.988888,NA,54.78205443,*03:01,*11:04:01,128.5605544,past
S-181218-03139,pt4,64.35865845,Female,PP-MS,prog-MS,26.6201232,19.14781965,Untreated,W,validation,12.15,58,0.778125008,7.005789019,0,-1.338772292,46.98006119,-0.313280448,6,59,14,4,239.2888802,20.27844029,55.03711078,*04:04,*15:01,192.5017147,past
S-181218-03140,pt5,65.58521561,Female,PP-MS,prog-MS,5.475701574,33.26970713,ocrelizumab (Ocrevus),W,training,9.45,47,0.759686213,7.099201744,NA,-0.434443645,44.17747636,0.300946596,6,63,10,4,140.083332,9.261259743,70.4366456,*03:01,*13:02:01,-93.62739067,past
S-181218-03141,pt6,34.64202601,Male,RR-MS,RR-MS,0.396988364,37.6581209,Untreated,AA,validation,4.7,43,0.781536012,8.480944059,2.772588722,-0.620918834,19.88015893,-1.104766373,2.5,84,2,0,71.438888,-13.34218424,68.58292804,*07,*11:021:01,2657.714849,no
S-181218-03142,pt7,45.86447639,Female,RR-MS,RR-MS,1.327857632,38.0591716,Untreated,AA,validation,3.6,52,0.74154172,9.047939083,1.098612289,-0.366797969,25.81801952,-0.586352466,4.5,86,1,1,65.94444408,-9.712666051,62.18055398,*01,*15:03,605.6232497,past
S-181218-03143,pt8,36.16974675,Male,HD,HD,NA,26.57439446,Untreated,W,HD,3.9,61,NA,NA,NA,NA,12.25004422,NA,1.5,95,0,0,18.80000004,NA,67.65872494,*13:01:01,*13:01,53.37019067,past
S-181218-03146,pt9,65.18001369,Female,SP-MS,prog-MS,19.75633128,28.11313793,glatiramer acetate (Glatopa),W,training,13.3,44,0.721103074,9.725854985,0,0.417739306,46.86780397,1.153886173,6,60,11,4,170.966664,4.210664353,26.96734811,*15:01,*15:01,175.1345464,current
S-181218-03147,pt10,59.93976728,Female,SP-MS,prog-MS,17.77412731,27.93603946,Untreated,W,training,3.95,48,0.7439768,9.847023016,1.098612289,-0.202900336,39.68377225,0.264047805,5.5,61,9,2,122.383332,2.664299611,61.27130022,*07,*15:01,961.1176115,no
S-181218-03148,pt11,59.15400411,Female,PP-MS,prog-MS,10.87200548,22.90625467,dimethyl fumarate (Tecfidera),W,training,5.9,50,0.764810943,8.712101864,0,-0.682810637,33.13875528,-0.474923229,4,67,7,2,96.4888881,0.478614967,69.20828956,*01,NA,-54.23662851,no
S-181218-03150,pt12,40.14784394,Male,SP-MS,prog-MS,11.80835044,26.2962963,ocrelizumab (Ocrevus),W,validation,23.2,15,0.651056584,8.490438454,0,3.18871301,60.29436745,4.167891134,6.5,41,14,6,187.827776,-7.533299277,71.44313715,*13:01:01,*15:01,250.169511,no
S-181218-06025,pt13,62.10540726,Female,SP-MS,prog-MS,26.84462697,22.52313714,glatiramer acetate (Glatopa),W,training,13.95,33,NA,NA,0,NA,50.09099232,NA,6,53,14,3,177.133332,NA,51.4271628,*15:01,*15:01,26.33263576,past
S-181218-03152,pt14,40.09034908,Female,HD,HD,NA,23.11104842,Untreated,W,HD,3.25,55,0.74705754,5.493061443,NA,-0.62222287,1.99886509,-2.025297204,0,100,0,0,0,-31.21163268,68.03380301,*13:01:01,*13:01,-68.26085739,no
S-181218-05783,pt15,61.16632444,Male,RR-MS,RR-MS,23.94798084,27.06207219,fingolimod (Gilenya),W,training,4.05,57,0.658060565,7.104144093,0,0.879962924,19.101509,0.113774309,3,89,3,0,29.938888,-27.75430348,NA,*11:04:01,*15:01,552.4765623,no
S-181218-05778,pt16,54.2477755,Female,SP-MS,prog-MS,24.94729637,19.69963084,teriflunomide (Aubagio),W,validation,4.4,52,0.74913213,9.570598887,0.693147181,-0.503780295,36.58154477,-0.147771094,5,65,4,2,104.605554,2.295157312,64.49649198,*01:03:01,*15:01,7970.100775,past
S-181218-06020,pt17,50.02874743,Female,HD,HD,NA,26.01656805,Untreated,AA,HD,3.3,44,0.783833923,8.750683035,NA,-0.714349423,12.74011523,-1.550246979,1.5,88,0,1,9.75,-19.63353811,68.26298981,*13:01:01,*16:02:01,-29.81744237,past
S-181218-06164,pt18,46.22587269,Male,HD,HD,NA,36.68625335,Untreated,W,HD,4.05,54,NA,NA,NA,NA,16.48579303,NA,2.5,90,0,0,24.2,NA,54.76756798,*03:01,*15:01,277.1125434,past
S-181218-03153,pt19,58.35455168,Male,PP-MS,prog-MS,1.733059548,25.43870723,Untreated,W,training,7.5,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07:01,*13:02,30.06662879,NA
S-181218-03154,pt19,60.82409309,Male,PP-MS,prog-MS,4.202600958,24.20780205,Untreated,W,training,9.7,46,0.761346371,8.651724084,0,-0.412443386,44.02313337,0.311458959,6,69,NA,5,104.3,8.907074326,NA,*07:01,*13:02,58.52049504,NA
S-181218-03155,pt19,62.80082136,Male,PP-MS,prog-MS,6.179329227,24.61810377,Untreated,W,training,5.6,53,0.763330937,7.850882665,0,-0.811983528,39.48155397,-0.257102294,6,73,NA,5,NA,7.994773673,NA,*07:01,*13:02,121.2201849,NA
S-181218-03156,pt19,63.66324435,Male,PP-MS,prog-MS,7.041752225,23.79750032,Untreated,W,training,7.05,51,0.765231658,7.524561226,0,-0.742363917,37.95478263,-0.277227113,6,80,NA,5,46.6,5.835602859,NA,*07:01,*13:02,-55.18860101,NA
S-181218-03157,pt19,64.75564682,Male,PP-MS,prog-MS,8.134154689,25.12309052,Untreated,W,training,4.8,53,0.765814923,8.712924435,NA,-0.856811433,33.29898142,-0.612594519,5.5,74,10,5,NA,2.219401669,NA,*07:01,*13:02,24.24918113,NA
S-181218-03160,pt20,40.19712526,Male,RR-MS,RR-MS,0.410677618,28.91017549,Untreated,W,training,4.3,NA,NA,NA,0,NA,9.666731881,NA,1.5,98,NA,0,4.8,NA,NA,*04:01,*15:01,498.9767492,NA
S-181218-03163,pt21,27.99178645,Female,RR-MS,RR-MS,4.372347707,23.42355741,interferon beta-1b (Betaseron),NA,training,4.3,NA,0.812894967,9.310004695,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07:01,*15:01,475.2600269,NA
S-181218-03164,pt22,59.95345654,Female,PP-MS,prog-MS,6.688569473,26.43320714,Untreated,W,validation,8.9,NA,NA,NA,NA,NA,38.54927796,NA,5.5,65,NA,2,NA,NA,NA,*07:01,*15:01,213.3179525,NA
S-181218-03165,pt23,61.30869268,Female,SP-MS,prog-MS,9.968514716,NA,Untreated,W,validation,5.5,NA,0.733890244,9.380758024,0,NA,17.08714597,NA,2,84,NA,1,20.438888,NA,NA,*01,*07,-45.22783488,current
S-181218-03167,pt23,69.9137577,Female,SP-MS,prog-MS,18.57357974,25.10683761,natalizumab (Tysabri),W,validation,4.65,34,0.745845672,8.748622322,0,0.490822876,20.48051781,-0.141635433,2.5,69,5,2,81.877776,-22.84048663,64.6305329,*01,*07,318.7110144,current
S-181218-03168,pt23,71.25530459,Female,SP-MS,prog-MS,19.91512663,24.07955293,natalizumab (Tysabri),W,validation,4.8,23,0.736761807,8.941021984,NA,1.226325324,38.54283488,1.403872175,5,63,11,2,184.305554,-11.4592089,60.15928857,*01,*07,-100.3981288,current
S-181218-03169,pt24,44.45448323,Male,RR-MS,RR-MS,3.772758385,25.39940861,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04:08,*16:01,410.1024968,NA
S-181218-03170,pt25,23.80013689,Male,RR-MS,RR-MS,0.470910335,21.89664528,interferon beta-1b (Betaseron),W,training,NA,NA,0.725409427,10.22734484,1.386294361,NA,NA,NA,2.5,80,NA,2,NA,NA,NA,*15:01,*15:01,6777.334906,current
S-181218-03179,pt26,31.22245038,Female,RR-MS,RR-MS,1.42642026,22.28254008,Untreated,W,validation,3.95,NA,0.746697868,10.18043724,2.48490665,NA,2.820061924,NA,0,100,NA,0,1.25,NA,NA,*03:01,*13:02,2013.047137,NA
S-181218-03181,pt27,29.04859685,Female,RR-MS,RR-MS,0.5229295,19.39393939,Untreated,W,training,3.55,NA,0.770576066,8.228977643,0.693147181,NA,2.347777172,NA,0,100,NA,0,6,NA,NA,*11:01,*13:05,621.0957561,no
S-181218-03185,pt28,24.11225188,Female,RR-MS,RR-MS,5.560574949,22.10044999,Untreated,W,training,4.5,NA,0.815943152,8.853808275,0,NA,19.16898146,NA,2,80,NA,1,25.75000006,NA,NA,*07:01,*12:01,256.9906035,no
S-181218-03186,pt28,31.26351814,Female,RR-MS,RR-MS,12.7118412,20.28596313,glatiramer acetate (Copaxone),W,training,5.05,50,0.794935497,8.249836485,0,-1.226461307,21.85557249,-1.510975831,3,71,7,2,NA,-5.866240945,73.39955323,*07:01,*12:01,-33.73076436,no
S-181218-03187,pt29,23.94524298,Male,RR-MS,RR-MS,0.150581793,26.13018846,Untreated,W,training,4.1,NA,NA,NA,0,NA,13.05826811,NA,2,96,NA,0,5,NA,NA,*04:03,*11:04,388.4442283,no
S-181218-03188,pt29,26.2477755,Male,RR-MS,RR-MS,2.453114305,22.83500983,interferon beta-1a (Rebif),W,training,5.45,63,0.762094757,8.985820874,0,-1.30928184,8.574480571,-2.263325518,1,94,NA,0,4.5,-18.39502098,NA,*04:03,*11:04,663.0073686,no
S-181218-03189,pt30,30.57905544,Female,RR-MS,RR-MS,2.570841889,17.0798004,Untreated,W,validation,4.85,58,0.76549828,7.186144305,1.386294361,-1.110900731,3.325190091,-2.366884231,0,100,NA,0,0,-25.44633399,NA,*03:01,*03:01,156.0711503,NA
S-181218-03190,pt31,48.93086927,Male,RR-MS,RR-MS,2.069815195,26.66580579,Untreated,W,validation,3.6,58,0.76994747,10.10487617,0,-1.191194206,12.17558363,-1.979137128,2,NA,NA,NA,NA,-15.86658344,NA,*13:02,*16:02,-137.1368584,past
S-181218-03192,pt32,34.17932923,Female,RR-MS,RR-MS,0.161533196,22.19880532,Untreated,W,training,3.85,51,0.799226119,9.452266423,0.693147181,-1.355853879,12.44875853,-2.103167627,1.5,93,NA,0,4.25,-14.09769939,NA,*15:01,*15:01,780.1239763,NA
S-181218-03193,pt33,67.816564,Male,RR-MS,RR-MS,33.0568104,24.80055498,Untreated,W,training,4.15,NA,0.70760238,9.905086274,0.693147181,NA,15.864028,NA,2,86,NA,0,17.50000007,NA,NA,NA,NA,844.9786757,past
S-181218-03195,pt33,74.58453114,Male,RR-MS,RR-MS,39.82477755,25.17607832,Untreated,W,training,5.3,51,0.707292157,9.704304639,0.693147181,0.303256494,19.3769079,-0.355667389,1.5,79,2,2,45.35,-22.24031108,NA,NA,NA,422.1811568,past
S-181218-03196,pt33,76.42436687,Male,RR-MS,RR-MS,41.66461328,NA,Untreated,W,training,4.35,50,NA,NA,NA,NA,34.5180619,NA,4.5,63,5,2,100.577776,NA,NA,NA,NA,291.1694633,past
S-181218-03197,pt33,77.67008898,Male,RR-MS,RR-MS,42.91033539,24.07792808,hydroxychloroquine,W,training,5.3,54,0.668856986,9.777130364,NA,0.841004686,39.17010154,1.113011443,5,62,6,2,115.794442,-7.331828346,53.26872542,NA,NA,1042.239294,past
S-181218-03198,pt34,25.23750856,Female,RR-MS,RR-MS,18.74058864,23.38868656,Untreated,W,validation,4.65,NA,0.790691147,7.860570786,0,NA,3.406672424,NA,0,100,NA,0,0,NA,NA,*07:01,*15:01,1958.342944,past
S-181218-03200,pt35,33.24845996,Female,RR-MS,RR-MS,5.196440794,21.51005917,Untreated,AA,validation,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*08:04,*13:02,587.8705206,past
S-181218-03201,pt35,42.80903491,Female,RR-MS,RR-MS,14.75701574,25.24810851,glatiramer acetate (Copaxone),AA,validation,8.4,42,0.78461923,9.404919826,NA,-0.624600201,46.91423721,0.282210452,6,56,19,4,215.811108,13.72533426,53.50447318,*08:04,*13:02,-32.50825308,past
S-181218-03203,pt36,49.33607118,Male,PP-MS,prog-MS,11.56194387,34.82834186,Untreated,W,validation,5.9,NA,0.734260104,9.559446746,0,NA,44.98602626,NA,6.5,82,NA,5,NA,NA,NA,*03:01,*13:01,218.9651166,NA
S-181218-03204,pt37,29.27583847,Female,RR-MS,RR-MS,5.560574949,23.52623039,interferon beta-1b (Betaseron),W,training,3.7,NA,NA,NA,NA,NA,35.80028567,NA,4,59,NA,1,NA,NA,NA,*01:01:01,*11:03:01,NA,no
S-181218-03205,pt37,44.61054073,Female,RR-MS,RR-MS,20.89527721,18.74176583,fingolimod (Gilenya),W,training,4.2,51,0.766529142,6.81563999,NA,-0.765779302,35.64703329,-0.41552434,5.5,69,8,2,110.02222,3.740550448,49.67869385,*01:01:01,*11:03:01,370.5763931,no
S-181218-03206,pt38,29.78507871,Female,RR-MS,RR-MS,0.407939767,25.74839302,Untreated,AA,training,4.2,58,0.774715612,9.426096705,0,-1.277243732,3.35840079,-2.504665007,0,96,NA,0,3,-23.90212338,NA,*03:01,*07:01,595.9434272,NA
S-181218-03208,pt39,49.36071184,Female,RR-MS,RR-MS,14.770705,23.31428571,interferon beta-1b (Betaseron),W,training,6.1,NA,0.781667555,8.722254235,0,NA,17.75504976,NA,2.5,87,NA,0,17.30555405,NA,NA,*04:04,*15:01,3458.733794,no
S-181218-03209,pt40,57.27857632,Female,PP-MS,prog-MS,0.046543463,33.20477502,Untreated,W,training,8.85,46,0.708254423,9.694924685,0,0.545694387,35.46366958,0.674795475,5,77,NA,2,93.333332,-8.355767905,NA,*07:01,*15:01,-152.4494955,no
S-181218-03210,pt40,59.40314853,Female,PP-MS,prog-MS,2.171115674,30.85399449,Untreated,W,training,8.15,47,0.704144623,9.630168503,0,0.567902235,44.23653495,1.144509577,6.5,63,NA,5,NA,0.215369369,NA,*07:01,*15:01,-275.6825096,no
S-181218-03211,pt40,61.14989733,Female,PP-MS,prog-MS,3.917864476,35.62901745,Untreated,W,training,9.5,54,0.706511532,9.460554195,NA,0.16146204,46.59282081,0.924843197,6.5,71,NA,5,NA,6.263611575,NA,*07:01,*15:01,-314.407253,no
S-181218-03212,pt40,62.12731006,Female,PP-MS,prog-MS,4.895277207,NA,Untreated,W,training,9.7,47,0.709424075,9.292473202,NA,0.472625219,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07:01,*15:01,-165.9758332,no
S-181218-03213,pt40,63.48528405,Female,PP-MS,prog-MS,6.253251198,33.60881543,Untreated,W,training,9.8,67,0.702984315,9.685704607,NA,-0.450372678,48.8080802,0.52568994,6.5,61,12,5,NA,14.03655718,NA,*07:01,*15:01,-13.8849191,no
S-181218-03215,pt41,43.29637235,Female,RR-MS,RR-MS,2.061601643,21.86851211,Untreated,W,training,4.85,53,0.806815435,10.14815773,0,-1.596737933,11.046228,-2.377279785,1.5,93,NA,0,8.6,-13.31212592,NA,*15:01,*15:01,387.5508188,no
S-181218-03217,pt42,24.11772758,Female,RR-MS,RR-MS,2.798083504,26.7504931,Untreated,W,training,5.65,NA,0.809739852,8.829372735,0.693147181,NA,4.088491009,NA,0,98,NA,0,1,NA,NA,*11:01,*13:01,1310.789826,NA
S-181218-03218,pt43,66.02327173,Male,SP-MS,prog-MS,17.51950719,39.99465401,Untreated,W,validation,6.45,34,0.591268212,8.406261631,0,3.280445575,32.33883183,2.807370074,5.5,83,NA,4,NA,-36.32210048,NA,*04:02,*07,173.538785,past
S-181218-03220,pt44,40.01916496,Male,PP-MS,prog-MS,6.655715264,30.59949511,Untreated,W,training,5.05,34,0.671718578,10.99495773,0,1.828576932,35.99503749,1.777890674,5,69,NA,2,101.938888,-19.47764298,NA,NA,NA,388.0534046,past
S-181218-03221,pt44,40.41889117,Male,PP-MS,prog-MS,7.055441478,29.66904571,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,291.402511,past
S-181218-03222,pt44,40.59685147,Male,PP-MS,prog-MS,7.23340178,29.36814261,Untreated,W,training,NA,38,NA,NA,0,NA,NA,NA,NA,67,NA,2,107.938888,NA,NA,NA,NA,188.6396324,past
S-181218-03223,pt44,40.89801506,Male,PP-MS,prog-MS,7.534565366,29.82731554,Untreated,W,training,NA,NA,NA,NA,0,NA,NA,NA,NA,56,NA,2,129.038888,NA,NA,NA,NA,257.001507,past
S-181218-03224,pt44,42.77891855,Male,PP-MS,prog-MS,9.415468857,28.16688806,Untreated,W,training,4.15,0,NA,NA,0,NA,NA,NA,NA,61,NA,2,136.288888,NA,NA,NA,NA,170.2519018,past
S-181218-03225,pt44,43.03080082,Male,PP-MS,prog-MS,9.667351129,28.24808146,Untreated,W,training,4.4,NA,NA,NA,0,NA,NA,NA,4,61,NA,2,147.888888,NA,NA,NA,NA,151.5579449,past
S-181218-03226,pt44,43.26078029,Male,PP-MS,prog-MS,9.897330595,28.87515304,rituximab,W,training,4.45,NA,NA,NA,0,NA,NA,NA,NA,61,NA,2,140.038888,NA,NA,NA,NA,36.89187753,past
S-181218-03227,pt44,48.21902806,Male,PP-MS,prog-MS,14.85557837,28.31783601,oral steroids,W,training,5.55,36,0.600135845,9.750219816,NA,3.016492037,45.19918112,3.247295068,6,45,17,4,185.038888,-21.06409232,61.87642564,NA,NA,137.7631042,past
S-181218-03228,pt45,19.51540041,Female,RR-MS,RR-MS,0.095824778,32.90657439,Untreated,AA,validation,4.2,74,0.819317798,7.841885929,0.693147181,-2.91354056,3.067521233,-3.891753308,0,96,NA,0,8,-9.329471893,NA,*07,*13,60.70058105,current
S-181218-03230,pt46,39.94798084,Male,RR-MS,RR-MS,21.92744695,20.82644628,Untreated,AA,validation,4.35,51,0.766366958,9.345133468,0,-0.762852406,15.9455627,-1.426098859,2,81,NA,0,31.444442,-15.98750701,NA,*04:03,*07:01,203.5022031,past
S-181218-03231,pt46,49.45379877,Male,RR-MS,RR-MS,31.43326489,18.84297521,natalizumab (Tysabri),AA,validation,8.25,44,0.754804243,9.003316203,NA,-0.190457685,45.22219046,0.559261341,5.5,54,7,2,155.122216,8.089693255,66.14082057,*04:03,*07:01,-70.32315902,past
S-181218-03232,pt47,54.76249144,Female,RR-MS,RR-MS,12.78302533,39.23895416,Untreated,W,validation,4.4,43,0.764538045,9.134430778,1.791759469,-0.314160561,26.01050462,-0.532315507,3.5,75,NA,2,64.45,-9.998320209,NA,*04:03,*15:01,2352.114424,past
S-181218-03233,pt48,51.06639288,Male,PP-MS,prog-MS,15.19780972,NA,Untreated,W,training,49.5,46,0.724227751,10.68592684,0,0.257427531,61.35871116,1.764562482,7,56,NA,6,157.1888881,20.15778597,NA,*13:01,*13:02,52.20442333,past
S-181218-03234,pt48,52.8678987,Male,PP-MS,prog-MS,16.99931554,28.59675713,Untreated,W,training,179.9,46,0.712702915,9.761808774,0,0.465413508,73.98273732,2.588085159,7.5,46,NA,9,301.3666641,30.89254242,NA,*13:01,*13:02,671.5713264,past
S-181218-03235,pt48,60.25735797,Male,PP-MS,prog-MS,24.38877481,NA,Untreated,W,training,179.9,13,0.689314758,9.775938232,0,2.602198304,81.8197288,4.782875333,8,26,27,9,543.0555381,19.31975042,43.69340533,*13:01,*13:02,240.969032,past
S-181218-03238,pt49,27.13483915,Female,RR-MS,RR-MS,3.263518138,39.4980296,Untreated,AA,validation,NA,NA,NA,NA,NA,NA,8.34324296,NA,1,99,NA,0,3.00000002,NA,NA,*03:02,*08:04,618.047023,NA
S-181218-03247,pt50,33.23750856,Male,RR-MS,RR-MS,0.290212183,30.47935326,interferon beta-1b (Betaseron),W,training,5.2,82,0.814860479,9.002577923,0,-3.24878627,10.28807225,-3.801603508,1.5,95,NA,0,7.166666,0.936330405,NA,*04:01,*15:02,726.1386702,past
S-181218-03248,pt50,42.13004791,Male,RR-MS,RR-MS,9.18275154,31.29551323,fingolimod (Gilenya),W,training,3.75,83,NA,NA,NA,NA,14.29043767,NA,1.5,89,2,0,23.2,NA,62.99459968,*04:01,*15:02,835.3461239,past
S-181218-03250,pt51,50.29705681,Female,PP-MS,prog-MS,10.20670773,18.94703532,Untreated,AA,training,NA,NA,0.720900481,8.641709066,NA,NA,29.68497643,NA,5,80,NA,2,58.644444,NA,NA,*11:01,*13:02,319.0024415,no
S-181218-03251,pt51,52.31211499,Female,PP-MS,prog-MS,12.22176591,19.65903247,Untreated,AA,training,9.45,47,0.797230425,9.075665469,1.791759469,-1.11199512,38.54025414,-0.557080389,6,68,NA,4,88.866664,9.778671089,NA,*11:01,*13:02,-67.85125218,no
S-181218-03252,pt51,53.28952772,Female,PP-MS,prog-MS,13.19917864,20.37102963,Untreated,AA,training,14.6,50,0.774546329,9.282847063,1.791759469,-0.858502836,44.00356562,-0.0635944,6,75,NA,4,82.288888,12.93934996,NA,*11:01,*13:02,-154.4815211,no
S-181218-03253,pt51,54.26694045,Female,PP-MS,prog-MS,14.17659138,20.45040951,Untreated,AA,training,16.15,46,0.777971719,9.11316846,NA,-0.712477092,44.4052589,0.079511461,6,68,13,4,100.233332,12.01459798,NA,*11:01,*13:02,164.8029892,no
S-181218-03254,pt51,56.95003422,Female,PP-MS,prog-MS,16.85968515,19.43696869,Untreated,AA,training,40.65,40,0.751396904,9.120634459,NA,0.078876696,50.3777127,1.050205666,6.5,72,14,6,95.87777601,10.79867899,52.05007334,*11:01,*13:02,59.73271525,no
S-181218-03255,pt51,57.98494182,Female,PP-MS,prog-MS,17.89459274,NA,ocrelizumab (Ocrevus),AA,training,46.4,44,0.715345867,8.848509301,NA,0.521638253,52.48318434,1.529748531,6.5,58,15,6,149.477776,8.882264109,54.33408534,*11:01,*13:02,44.08478786,no
S-181218-03256,pt52,53.97672827,Male,PP-MS,prog-MS,17.13620808,21.30488909,Untreated,W,training,5.5,58,0.642495658,10.62510071,0,1.108898367,26.56940425,0.689741525,3.5,76,NA,2,75.249996,-22.36597534,NA,*01:03,*08:01,441.7000053,past
S-181218-03257,pt52,61.79603012,Male,PP-MS,prog-MS,24.95550992,20.6258488,interferon beta-1a (Rebif),W,training,4.5,52,0.718969813,10.13384502,NA,0.040551874,36.43795121,0.301300165,4,52,10,2,164.555548,-2.792953625,53.40816946,*01:03,*08:01,193.8807357,past
S-181218-03258,pt52,62.7926078,Male,PP-MS,prog-MS,25.95208761,20.25803531,interferon beta-1a (Rebif) & pioglitazone,W,training,5.1,47,0.707920626,9.746190261,NA,0.499757606,44.54792938,1.103377853,5.5,52,13,2,180.68888,1.145765066,52.0964297,*01:03,*08:01,378.8069676,past
S-181218-03261,pt53,49.5797399,Male,PP-MS,prog-MS,6.102669405,NA,Untreated,W,validation,NA,NA,0.751533915,9.742026886,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01:03,*03:01,176.6639158,past
S-181218-03262,pt54,56.02737851,Female,SP-MS,prog-MS,21.22655715,23.67409069,Untreated,W,training,20.5,47,0.753728789,11.5365541,NA,-0.326931429,47.66517572,0.570435775,6.5,65,NA,6,140.655552,11.77235686,NA,*08:01,*15:01,-73.65914019,past
S-181218-03264,pt54,57.61806982,Female,SP-MS,prog-MS,22.81724846,22.51241788,Untreated,W,training,26.25,46,0.783710243,8.845057054,0,-0.816038871,52.00297597,0.383335409,6.5,59,NA,6,157.855552,20.55303295,NA,*08:01,*15:01,-58.77240908,past
S-181218-03265,pt54,57.86721424,Female,SP-MS,prog-MS,23.06639288,22.91299471,rituximab,W,training,21.45,NA,NA,NA,NA,NA,NA,NA,6.5,59,NA,6,NA,NA,NA,*08:01,*15:01,-182.9938784,past
S-181218-03266,pt54,58.53798768,Female,SP-MS,prog-MS,23.73716632,24.03440715,rituximab,W,training,53,44,0.753909315,8.614138397,0,-0.174307132,54.29945346,1.03954785,6.5,61,NA,6,166.055552,17.02025045,NA,*08:01,*15:01,-77.98956964,past
S-181218-03267,pt54,64.21355236,Female,SP-MS,prog-MS,29.41273101,21.67120654,Untreated,W,training,31.35,42,0.734137847,9.27322127,NA,0.286425326,55.07285112,1.465666535,6.5,52,17,6,226.988884,13.6085204,52.68017207,*08:01,*15:01,-81.81271591,past
S-181218-03270,pt55,52.87611225,Female,RR-MS,RR-MS,16.61601643,NA,Untreated,W,training,4,60,0.77142554,8.688959234,0,-1.321790056,10.15985526,-2.192296098,1.5,95,NA,0,16.5,-16.69602615,NA,*03:01,*15:01,642.5637232,NA
S-181218-03271,pt56,32.67351129,Male,RR-MS,RR-MS,3.685147159,NA,Untreated,NA,validation,5.35,45,0.736557509,9.662625451,2.397895273,0.086876053,14.79045215,-0.772945905,1.5,NA,NA,NA,NA,-24.86124484,NA,*15:01,*15:02,2522.766716,past
S-181218-03272,pt57,38.92950034,Male,RR-MS,RR-MS,9.289527721,21.67426215,Untreated,AA,validation,4.4,60,0.761965984,9.929350212,1.386294361,-1.151075696,15.93858741,-1.75200569,2,94,NA,0,5.2,-12.46800176,NA,*07:01,*08:04,996.5081256,past
S-181218-03273,pt58,54.31074606,Male,PP-MS,prog-MS,8.643394935,29.01219659,glatiramer acetate (Copaxone),W,validation,4.95,37,0.735531374,7.855157006,0,0.521080354,21.25692388,-0.076340766,2.5,83,NA,2,35.944444,-22.3389286,NA,*08:01,*14:01,1001.433857,past
S-181218-03274,pt58,56.31485284,Male,PP-MS,prog-MS,10.64750171,31.54812221,Untreated,W,validation,4.7,43,0.746159675,7.891704659,0,0.017509516,23.06302259,-0.405746975,3,73,NA,2,NA,-15.95857377,NA,*08:01,*14:01,674.9784639,past
S-181218-03275,pt58,57.5687885,Male,PP-MS,prog-MS,11.90143737,NA,Untreated,W,validation,5.75,43,0.742234479,8.101374671,0,0.088346596,NA,NA,NA,NA,NA,NA,NA,NA,NA,*08:01,*14:01,620.7839418,past
S-181218-03276,pt58,58.62286105,Male,PP-MS,prog-MS,12.95550992,29.49523004,Untreated,W,validation,6.55,48,0.737667726,8.382060517,NA,-0.089041977,39.76207878,0.363551206,6,65,9,4,108.688888,1.70835781,NA,*08:01,*14:01,814.6097833,past
S-181218-03277,pt58,61.7467488,Male,PP-MS,prog-MS,16.07939767,27.31481481,Untreated,W,validation,5.8,27,NA,NA,NA,NA,41.97635806,NA,6,58,13,4,133.233332,NA,65.58611004,*08:01,*14:01,652.7175772,past
S-181218-03278,pt58,62.53251198,Male,PP-MS,prog-MS,16.86516085,26.95930443,hydroxychloroquine,W,validation,6.2,36,0.71934162,8.404472321,NA,0.865213735,47.55364222,1.564385005,6,51,13,4,187.616664,0.83180606,56.18429492,*08:01,*14:01,836.7212239,past
S-181218-03279,pt59,27.92060233,Male,RR-MS,RR-MS,0.114989733,25.45709838,Untreated,W,training,5.2,58,0.776460813,8.351374707,2.48490665,-1.30873896,9.488275761,-2.215883894,1,94,NA,0,2.5,-17.48615711,NA,*12:01,*16:01,2941.931034,past
S-181218-03280,pt59,33.03764545,Male,RR-MS,RR-MS,5.232032854,27.59378529,interferon beta-1a (Rebif),W,training,4.6,68,0.790543513,8.23562572,0,-2.08249346,9.282515609,-2.875302734,1,95,0,0,6,-10.66341006,NA,*12:01,*16:01,138.3878865,past
S-181218-03281,pt59,36.81314168,Male,RR-MS,RR-MS,9.00752909,29.27796045,interferon beta-1a (Rebif),W,training,5.15,70,0.752311762,7.872836175,NA,-1.496455604,19.19243867,-1.874317543,3,90,0,0,38.80000001,-6.076843817,67.21791156,*12:01,*16:01,141.6348822,past
S-181218-03282,pt60,51.19507187,Female,RR-MS,RR-MS,0.517453799,26.78200692,Untreated,AA,training,3.9,50,0.782230683,8.295798111,NA,-0.997180547,10.94462365,-1.879739878,1.5,87,NA,0,12.3,-18.85989363,NA,*03:01,*15:03,1782.335196,no
S-181218-03283,pt61,49.045859,Male,SP-MS,prog-MS,32.78850103,22.82035576,Untreated,W,training,10.15,45,0.709050357,9.820594954,1.609437912,0.583291091,44.48187196,1.170029013,6,NA,NA,NA,NA,0.320919557,NA,*13:03,*15:01,207.917501,current
S-181218-03284,pt61,50.17932923,Male,SP-MS,prog-MS,33.92197125,23.31170313,daclizumab (Zinbryta),W,training,12.1,42,0.692909455,9.703083488,0,1.030464322,46.51579912,1.649592586,6,66,NA,4,124.97222,-1.70711386,NA,*13:03,*15:01,-10.4760363,current
S-181218-03285,pt61,52.0164271,Male,SP-MS,prog-MS,35.75906913,NA,daclizumab (Zinbryta),W,training,12.45,45,0.713744743,9.221675882,0,0.498572622,50.48758435,1.407794984,6,66,NA,4,132.52222,7.096184006,NA,*13:03,*15:01,44.82065045,current
S-181218-03286,pt61,52.97467488,Male,SP-MS,prog-MS,36.71731691,24.58691716,daclizumab (Zinbryta),W,training,18.3,43,0.69214526,9.595670798,0,0.992294832,49.62691784,1.777555665,6,63,14,4,152.52222,1.750722762,NA,*13:03,*15:01,-86.62668544,current
S-181218-03292,pt62,39.55099247,Female,RR-MS,RR-MS,5.971252567,45.47722104,not untreated,AA,training,5.95,44,0.74852861,9.378985498,0,-0.077202827,31.17625774,-0.067994854,4,65,NA,2,92.4444421,-6.985005804,NA,*08,*15:03,208.7546983,no
S-181218-03293,pt62,46.48323066,Female,RR-MS,RR-MS,12.90349076,44.0907204,not untreated,AA,training,4.55,40,0.741569571,9.851509813,0,0.25622824,23.97730055,-0.158556008,2.5,68,2,2,87.3555521,-17.21273071,NA,*08,*15:03,113.6172031,no
S-181218-03294,pt63,43.44421629,Female,RR-MS,RR-MS,0.235455168,31.23139946,Untreated,W,training,3.6,71,0.80459956,6.165417854,0,-2.492041808,9.046755829,-3.230855745,1.5,97,NA,0,2.75,-7.178980151,NA,*13:01,*15:01,3717.823995,past
S-181218-03295,pt64,37.50581793,Male,RR-MS,RR-MS,8.388774812,22.97577855,Untreated,W,training,6.7,37,0.780145192,8.632484236,0,-0.284054621,31.69057598,-0.215006603,5,72,NA,1,48.894444,-4.59172037,NA,*15:01,*15:01,518.2398085,no
S-181218-03296,pt64,38.82546201,Male,RR-MS,RR-MS,9.708418891,23.87543253,Untreated,W,training,5.4,46,0.786235613,9.723642926,0,-0.861613624,35.63237775,-0.496640655,5,68,NA,1,62.733332,4.596419368,NA,*15:01,*15:01,126.6041614,no
S-181218-03297,pt64,39.8220397,Male,RR-MS,RR-MS,10.70499658,24.18685121,daclizumab (Zinbryta),W,training,6.15,42,0.776793025,8.874447967,0,-0.483362538,37.61235961,-0.077646184,5,68,NA,2,69.983332,3.140504599,NA,*15:01,*15:01,89.75397029,no
S-181218-03298,pt64,44.26830938,Male,RR-MS,RR-MS,15.15126626,25.81314879,natalizumab (Tysabri),W,training,20,41,0.767293633,8.846784667,0,-0.259968532,49.64560988,0.728419962,6,61,14,4,107.67222,13.14452417,62.22243186,*15:01,*15:01,34.47913017,no
S-181218-03299,pt65,61.17727584,Male,PP-MS,prog-MS,9.440109514,34.33922997,Untreated,W,training,7.7,53,0.718387969,9.664976524,0,-0.000908461,37.58941638,0.325740352,6,77,NA,4,80.277776,-1.264877701,NA,*08:02,*12:01,167.2154049,past
S-181218-03300,pt65,63.14852841,Male,PP-MS,prog-MS,11.41136208,35.7266736,Untreated,W,training,15.75,48,0.731983313,7.920083199,0,0.013543274,48.14547216,0.88064027,6.5,63,NA,5,NA,9.159903717,NA,*08:02,*12:01,179.274079,past
S-181218-03301,pt65,64.47638604,Male,PP-MS,prog-MS,12.73921971,NA,Untreated,W,training,27.45,49,0.727453664,8.072155308,NA,0.043328038,50.69530631,1.036726345,6.5,59,NA,6,NA,11.4391838,NA,*08:02,*12:01,236.7165248,past
S-181218-03302,pt65,65.58795346,Male,PP-MS,prog-MS,13.85078713,31.84828261,Untreated,W,training,27.85,50,0.728121007,8.095903533,NA,-0.020676078,54.13535158,1.159938621,6.5,59,20,6,140.255552,15.46061941,NA,*08:02,*12:01,440.8946492,past
S-181218-03303,pt65,68.65160849,Male,PP-MS,prog-MS,16.91444216,33.52988785,dimethyl fumarate (Tecfidera),W,training,179.9,42,0.707061651,8.585972707,NA,0.775063003,64.50322761,2.36031814,7.5,56,21,8,178.766664,18.60028823,57.50305619,*08:02,*12:01,579.5727158,past
S-181218-03307,pt66,54.19028063,Female,SP-MS,prog-MS,0.31211499,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,13.12357879,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,48.88669627,past
S-181218-03308,pt66,62.04791239,Female,SP-MS,prog-MS,8.169746749,31.22730574,interferon beta-1a (Avonex),W,validation,5,65,0.717772261,9.679406061,0,-0.613325755,35.28808888,-0.306139577,6,79,NA,4,30.799998,1.996772924,NA,NA,NA,133.6467474,past
S-181218-03309,pt66,69.40451745,Female,SP-MS,prog-MS,15.52635181,31.27002435,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,NA,4,53.644444,NA,NA,NA,NA,-75.92184613,past
S-181218-03310,pt66,70.99794661,Female,SP-MS,prog-MS,17.11978097,30.4156521,Untreated,W,validation,6.6,64,NA,NA,NA,NA,39.46840323,NA,6,70,9,4,96.238888,NA,68.23700207,NA,NA,-43.55742926,past
S-181218-03311,pt67,50.63381246,Male,SP-MS,prog-MS,1.199178645,NA,Untreated,W,validation,4.5,28,NA,NA,0,NA,23.64097408,NA,2.5,NA,NA,NA,NA,NA,NA,*04:02,*13:02,2437.335393,current
S-181218-03313,pt68,29.9028063,Female,RR-MS,RR-MS,2.825462012,33.15185218,glatiramer acetate (Copaxone),W,training,3.65,69,0.760571783,8.166784289,1.945910149,-1.593561504,8.222528001,-2.519807846,1,94,NA,0,5.5,-16.16467946,NA,*13:05,*15:01,119.5651409,no
S-181218-03314,pt68,30.72963723,Female,RR-MS,RR-MS,3.65229295,34.72222222,Untreated,W,training,3.9,66,0.749775614,8.919988071,0,-1.2428434,13.41011912,-1.958969513,2,95,NA,0,6.5000002,-14.16288528,NA,*13:05,*15:01,552.2211579,no
S-181218-03315,pt68,31.68788501,Female,RR-MS,RR-MS,4.610540726,34.43458251,daclizumab (Zinbryta),W,training,3.85,57,0.758823253,8.791333993,0,-0.938477369,13.16704985,-1.716238977,1.5,90,NA,0,10.2,-17.17070595,NA,*13:05,*15:01,-17.23434602,no
S-181218-03316,pt68,38.71868583,Female,RR-MS,RR-MS,11.64134155,32.08620413,alemtuzumab (Lemtrada),W,training,6.3,44,0.727492334,8.67692825,NA,0.302433849,29.68920803,0.1738904,3.5,71,2,1,64.1277761,-11.92053834,71.80466044,*13:05,*15:01,176.2611001,no
S-181218-03319,pt69,60.1615332,Female,PP-MS,prog-MS,30.25051335,38.54318418,Untreated,W,validation,7.15,57,0.749791419,8.307459327,0,-0.775482007,29.34516358,-0.747696144,4,76,NA,2,54.022222,-2.473183392,NA,*03:01,*15:01,-0.237112299,past
S-181218-03320,pt69,62.0752909,Female,PP-MS,prog-MS,32.16427105,37.50260146,Untreated,W,validation,6,60,0.753311891,8.478868077,0,-0.994897336,32.97139092,-0.745232067,4,69,NA,2,NA,3.146133773,NA,*03:01,*15:01,-127.6185756,past
S-181218-03321,pt69,62.97604381,Female,PP-MS,prog-MS,33.06502396,38.54318418,Untreated,W,validation,7.6,51,0.750089494,8.188966864,NA,-0.46909688,35.80694157,-0.158516283,4.5,71,NA,2,55.44444401,1.205502461,NA,*03:01,*15:01,342.5152352,past
S-181218-03322,pt69,64.03011636,Female,PP-MS,prog-MS,34.11909651,40.70759625,Untreated,W,validation,6.25,50,0.74455074,8.587465244,NA,-0.317179567,36.29751639,-0.005899798,4.5,67,10,2,60.00000001,0.316115121,NA,*03:01,*15:01,176.9820342,past
S-181218-03323,pt69,65.37166324,Female,PP-MS,prog-MS,35.46064339,36.21227888,Untreated,W,validation,13.1,52,0.755316554,8.449770515,0,-0.615389126,39.69890211,-0.081070459,4.5,69,10,3,77.00000001,6.426329073,NA,*03:01,*15:01,186.7762298,past
S-181218-03324,pt70,39.24982888,Male,RR-MS,RR-MS,0.851471595,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*15:01,*15:01,NA,past
S-181218-03325,pt70,46.76249144,Male,RR-MS,RR-MS,8.364134155,28.52916314,Untreated,W,training,NA,NA,0.752868889,9.392995207,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*15:01,*15:01,314.3349926,past
S-181218-03326,pt70,53.5633128,Male,RR-MS,RR-MS,15.16495551,26.79111089,dimethyl fumarate (Tecfidera),W,training,4.85,49,0.757008919,9.05473864,0,-0.490048628,23.94421431,-0.786054519,2.5,69,2,0,58.45000005,-10.46690667,NA,*15:01,*15:01,308.7711404,past
S-181218-03328,pt71,65.15263518,Female,SP-MS,prog-MS,32.65708419,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04,*13,110.9022633,past
S-181218-03329,pt72,33.60985626,Female,RR-MS,RR-MS,0.692676249,27.63980131,Untreated,AA,training,5.3,65,0.801832158,7.664346632,0,-2.130334747,8.525637501,-2.954338357,1,92,NA,0,6.00000001,-10.98571515,NA,*07:01,*15:01,210.2432546,NA
S-181218-03330,pt73,57.48391513,Male,RR-MS,RR-MS,3.326488706,25.08857608,glatiramer acetate (Copaxone),W,training,3.3,48,NA,NA,0,NA,6.223706841,NA,1,93,NA,0,NA,NA,68.65753252,*04:02,*15:02,301.3562136,past
S-181218-03333,pt74,47.46885695,Male,RR-MS,RR-MS,7.885010267,25.2741368,interferon beta-1b (Betaseron),W,validation,4.85,53,0.743348387,11.09250407,0,-0.451363195,12.92504104,-1.320208796,1.5,79,NA,0,25.50000001,-21.83748448,NA,*03:01,*13:02,252.870195,past
S-181218-03334,pt74,54.10814511,Male,RR-MS,RR-MS,14.52429843,25.43673469,Untreated,W,validation,5.35,46,0.779518671,9.048762176,2.079441542,-0.740394567,16.31694948,-1.388170317,1.5,72,2,1,31.44444401,-15.82011915,NA,*03:01,*13:02,2731.074029,past
S-181218-03335,pt74,55.08281999,Male,RR-MS,RR-MS,15.49897331,25.82779244,teriflunomide (Aubagio),W,validation,5.65,50,NA,NA,NA,NA,19.32178805,NA,1.5,69,2,1,32.96666601,NA,60.2958847,*03:01,*13:02,552.8310551,past
S-181218-03336,pt75,33.45106092,Female,RR-MS,RR-MS,13.32511978,24.85856465,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07:01,*15:01,161.7939749,NA
S-181218-03339,pt76,24.59958932,Female,RR-MS,RR-MS,0.635181383,19.15708812,interferon beta-1a (Rebif),NA,training,4.8,74,0.788648719,9.423433587,2.302585093,-2.360062978,3.546045225,-3.40302445,0,95,NA,0,11.1,-13.87853892,NA,*11:01,*15:01,3361.23173,no
S-181218-03340,pt77,41.10882957,Female,RR-MS,RR-MS,0.117727584,35.56394252,interferon beta-1a (Avonex),W,validation,4.8,64,0.802991707,8.282988693,0,-2.099300116,7.88978118,-2.961009048,1,96,NA,0,3.722222,-11.90347888,NA,*01:03,*13:01,100.0481346,no
S-181218-03341,pt77,48.10677618,Female,RR-MS,RR-MS,7.115674196,28.59631296,Untreated,W,validation,4.8,68,NA,NA,0,NA,17.45823531,NA,2.5,81,7,1,17,NA,50.90318501,*01:03,*13:01,221.7958294,no
S-181218-03342,pt78,47.04175222,Female,PP-MS,prog-MS,5.552361396,45.53766718,Untreated,AA,validation,20.6,23,NA,NA,0,NA,44.89225307,NA,6,72,NA,5,110.511104,NA,NA,*03:01,*15:01,469.5271342,past
S-181218-03343,pt78,54.24503765,Female,PP-MS,prog-MS,12.75564682,42.80276817,Untreated,AA,validation,16.8,30,0.785090027,8.391403185,NA,-0.009567732,45.9023118,0.74591938,6.5,58,13,4,148.388888,7.126675418,73.96610289,*03:01,*15:01,578.758707,past
S-181218-03344,pt78,55.22245038,Female,PP-MS,prog-MS,13.73305955,43.52970705,ocrelizumab (Ocrevus),AA,validation,11.65,31,0.76958164,6.856461985,NA,0.218347708,46.50965191,0.968268734,6,61,14,4,159.611108,5.663713757,56.65919175,*03:01,*15:01,1313.660308,past
S-181218-03345,pt79,39.47980835,Male,RR-MS,RR-MS,0.281998631,26.92911484,Untreated,W,training,3.15,63,0.7660105,8.153349758,0,-1.379948323,NA,NA,1,96,NA,0,10.6,NA,NA,*07:01,*11:04,2293.283646,NA
S-181218-03348,pt80,48.06570842,Female,PP-MS,prog-MS,2.625598905,29.65862471,glatiramer acetate (Copaxone),NA,training,5.3,49,0.777917248,10.34692259,0,-0.867376274,NA,NA,2,89,NA,0,NA,NA,61.35414805,*08:02,*13:03,-92.25517438,NA
S-181218-03349,pt81,39.78370979,Male,RR-MS,RR-MS,4.268309377,28.66957326,Untreated,W,training,6.1,46,0.749953959,9.667448713,1.609437912,-0.206847233,21.33213116,-0.682883983,2.5,81,NA,1,25.15,-15.65148929,NA,*13:03,*15:01,1719.512752,current
S-181218-03350,pt81,40.66529774,Male,RR-MS,RR-MS,5.149897331,29.7311843,glatiramer acetate (Copaxone),W,training,5.3,47,0.761047991,9.684398272,1.098612289,-0.459019329,18.08852076,-1.061128221,2.5,83,NA,1,27.55,-16.60445919,NA,*13:03,*15:01,710.8412086,current
S-181218-03351,pt81,41.61259411,Male,RR-MS,RR-MS,6.097193703,29.52833928,daclizumab (Zinbryta),W,training,5.3,41,0.75382594,12.22264949,0,-0.016920275,19.87079618,-0.598759313,2.5,80,NA,1,34.66111,-18.83805235,NA,*13:03,*15:01,199.3398473,current
S-181218-03352,pt81,42.9705681,Male,RR-MS,RR-MS,7.455167693,27.82799587,daclizumab (Zinbryta),W,training,5.65,48,0.773420668,9.207837242,0,-0.734266827,19.25496984,-1.231961928,2.5,81,NA,1,NA,-12.93776097,NA,*13:03,*15:01,182.3221972,current
S-181218-03354,pt82,37.47022587,Male,RR-MS,RR-MS,0.473648186,34.72204999,not untreated,W,training,4.05,39,0.753733072,7.528331767,0.693147181,0.088677163,16.98243234,-0.658726252,2,82,NA,1,29.677776,-22.68562529,NA,*03:01,*15:01,877.2341917,past
S-181218-03355,pt82,44.19164956,Male,RR-MS,RR-MS,7.195071869,30.31979008,interferon beta-1a (Rebif),W,training,4.9,41,NA,NA,NA,NA,18.94101145,NA,2,75,2,1,55.55000007,NA,NA,*03:01,*15:01,1388.170792,past
S-181218-03356,pt83,40.53114305,Male,RR-MS,RR-MS,7.671457906,29.15918367,Untreated,W,validation,4.35,46,0.733546765,9.357811651,1.386294361,0.089249499,16.99958523,-0.657364331,2.5,88,NA,0,13.9,-22.67367129,NA,*03:01,*04:07,1638.068843,past
S-181218-03357,pt83,41.51676934,Male,RR-MS,RR-MS,8.657084189,27.13469388,daclizumab (Zinbryta),W,validation,4.2,51,0.737461893,9.397483619,0,-0.241209565,14.1924941,-1.078811456,2,88,NA,0,15.9,-22.4789913,NA,*03:01,*04:07,679.6940736,past
S-181218-03358,pt83,43.35386721,Male,RR-MS,RR-MS,10.49418207,28.04897959,daclizumab (Zinbryta),W,validation,4,51,0.746403894,9.391411147,NA,-0.402583733,17.19079667,-1.059963667,2,86,NA,0,23.588888,-18.01482392,NA,*03:01,*04:07,329.8565986,past
S-181218-03359,pt84,54.40109514,Male,PP-MS,prog-MS,12.0164271,18.82774473,Untreated,W,validation,33.4,36,0.696793903,9.863030075,0,1.272127027,50.5976302,2.062124505,6.5,63,NA,6,146.333332,0.17954025,NA,*01:03,*04:01,242.324168,past
S-181218-03360,pt84,56.25735797,Male,PP-MS,prog-MS,13.87268994,18.72633856,Untreated,W,validation,179.9,33,0.703253888,9.848186237,0,1.31142742,66.90614252,2.933646755,7,49,NA,7,NA,16.13106196,NA,*01:03,*04:01,129.2097201,past
S-181218-03361,pt85,52.48186174,Male,SP-MS,prog-MS,5.029431896,27.87054087,Untreated,W,validation,11.15,29,0.713775492,10.23480366,0.693147181,1.329389475,40.44792772,1.588255426,6,76,NA,4,64.50000002,-10.49031369,NA,*01:01,*12:01,1844.902784,no
S-181218-03362,pt85,57.24298426,Male,SP-MS,prog-MS,9.790554415,25.28010986,interferon beta-1a (Rebif),W,validation,87.3,18,0.717439012,9.992871114,0,1.834842894,59.48778958,2.991117654,6.5,57,13,6,179.888888,3.958191364,NA,*01:01,*12:01,610.0755641,no
S-181218-03363,pt85,58.50787132,Male,SP-MS,prog-MS,11.05544148,27.71449081,interferon beta-1a (Rebif),W,validation,77.25,23,0.699093627,10.22763414,0,1.90611402,58.78636931,3.014816413,6.5,50,14,6,190.3888881,2.609369857,NA,*01:01,*12:01,322.2397523,no
S-181218-03364,pt85,60.13689254,Male,SP-MS,prog-MS,12.6844627,26.09157018,interferon beta-1a (Rebif),W,validation,50.7,26,NA,NA,NA,NA,59.51322751,NA,6.5,45,15,6,218.3888881,NA,63.52761035,*01:01,*12:01,354.0787229,no
S-181218-03365,pt85,60.6954141,Male,SP-MS,prog-MS,13.24298426,25.87310009,interferon beta-1a (Rebif) & Pioglitazone,W,validation,43.2,20,0.521723653,9.921229234,NA,5.262950012,60.70344749,5.928295893,6.5,41,16,6,228.8777761,-25.96584109,50.97344938,*01:01,*12:01,1880.455579,no
S-181218-03366,pt86,39.60301164,Male,RR-MS,RR-MS,14.86105407,22.95159546,Untreated,W,training,4.9,64,0.730793926,7.456454555,0,-0.796363914,3.462615948,-2.09606023,0,93,NA,0,8.25,-28.1660473,NA,*04:04,*11:04,249.428782,no
S-181218-03370,pt87,42.11088296,Female,RR-MS,RR-MS,1.399041752,20.90429919,Untreated,W,training,3.35,51,NA,NA,0,NA,7.005919801,NA,1,89,NA,0,10.888888,NA,NA,*01:01,*14:01,487.0709083,past
S-181218-03371,pt88,51.28542094,Male,RR-MS,RR-MS,0.536618754,27.68116462,Untreated,W,validation,4.8,48,0.723334106,9.932706491,0,0.169633458,26.61053183,-0.095772867,3,71,NA,2,53.85,-13.79290363,NA,*04:02,*07:01,559.6594991,past
S-181218-03372,pt88,58.37645448,Male,RR-MS,RR-MS,7.627652293,24.49804772,interferon beta-1a (Rebif),W,validation,9.8,34,NA,NA,0,NA,47.57270585,NA,6.5,51,17,5,123.933332,NA,59.20643911,*04:02,*07:01,28.3711727,past
S-181218-03373,pt88,59.41136208,Male,RR-MS,RR-MS,8.66255989,NA,interferon beta-1a (Rebif),W,validation,10.2,35,0.653394483,9.501740524,NA,2.107306785,55.92237082,3.036264645,6.5,42,14,5,243.577772,-2.082191253,60.83507088,*04:02,*07:01,95.78219373,past
S-181218-03376,pt89,65.06228611,Male,RR-MS,RR-MS,1.023956194,31.0640887,Untreated,W,training,5.2,38,0.735576259,9.354267541,0,0.46830959,21.14735659,-0.126226005,2.5,75,NA,2,NA,-21.96914527,NA,*01:02,*13:01,913.9481226,past
S-181218-03378,pt90,52.72826831,Female,PP-MS,prog-MS,0.810403833,18.58683771,Untreated,W,validation,5.2,58,NA,NA,0,NA,13.59548958,NA,1.5,82,2,2,21.338888,NA,NA,*14:01,*15:01,20.9045513,past
S-181218-03377,pt90,58.15195072,Female,PP-MS,prog-MS,6.234086242,16.74489883,Untreated,W,validation,4.7,61,0.7927901,9.357811651,0,-1.759311931,18.14244337,-2.148727759,2,79,2,0,71.4,-4.739146911,NA,*14:01,*15:01,24.45415335,past
S-181218-03379,pt90,60.73921971,Female,PP-MS,prog-MS,8.821355236,18.86223027,Untreated,W,validation,4.85,51,0.786063722,10.07086466,NA,-1.118315227,42.58434544,-0.354437252,5.5,56,10,2,141.42222,13.88017196,56.8305352,*14:01,*15:01,418.1722788,past
S-181218-03381,pt91,59.92060233,Male,RR-MS,RR-MS,10.31348392,27.30084585,Untreated,W,training,4.7,43,0.771022294,9.021839764,0,-0.431180263,8.331937862,-1.539456749,1,94,NA,0,15.5,-26.61392215,NA,*11:02,*15:01,213.8440373,past
S-181218-03382,pt91,64.25462012,Male,RR-MS,RR-MS,14.64750171,25.83333333,Untreated,W,training,4.85,43,0.764025181,8.421342866,0,-0.304905026,8.622074036,-1.418649004,1,90,1,1,15.75000002,-27.47082474,NA,*11:02,*15:01,322.8513618,past
S-181218-03383,pt91,66.45585216,Male,RR-MS,RR-MS,16.84873374,25.43870723,Untreated,W,training,4.05,33,0.770427734,6.921658184,0,0.099156979,11.71196437,-0.920940226,2,88,1,1,15.50000002,-28.05128813,NA,*11:02,*15:01,374.3982093,past
S-181218-03385,pt92,51.18412047,Male,PP-MS,prog-MS,19.90143737,23.77988445,Untreated,AA,training,34.6,33,0.736998434,9.715771471,0,0.702447614,51.91947066,1.6523823,6.5,54,NA,6,217.399998,6.676143313,NA,*03:02,*15:03,-52.70229767,past
S-181218-03386,pt92,53.10335387,Male,PP-MS,prog-MS,21.82067077,23.81180376,Untreated,AA,training,40.05,27,0.733750629,10.12169896,0,1.072824395,55.51685768,2.147938973,6.5,62,NA,6,NA,6.909161059,NA,*03:02,*15:03,271.4161046,past
S-181218-03387,pt92,53.98494182,Male,PP-MS,prog-MS,22.70225873,25.43968847,Untreated,AA,training,65.35,31,0.746002916,9.801011761,0,0.643867338,57.6153837,1.896137134,6.5,65,NA,6,167.72222,12.90417848,NA,*03:02,*15:03,38.30789787,past
S-181218-03388,pt92,55.03901437,Male,PP-MS,prog-MS,23.75633128,23.30109483,Untreated,AA,training,179.9,29,0.733576525,10.17500213,NA,0.972044936,64.91044222,2.546437678,7,56,15,7,204.94444,17.2181899,NA,*03:02,*15:03,-15.14413489,past
S-181218-03389,pt93,43.69062286,Female,PP-MS,prog-MS,6.031485284,25.16069789,Untreated,W,training,8.45,46,0.752067291,8.211482916,0,-0.244986034,35.93123674,0.035805031,5.5,83,NA,1,30,-0.705944581,62.36184284,*01:03,*15:01,287.7770713,current
S-181218-03390,pt93,45.63175907,Female,PP-MS,prog-MS,7.972621492,26.70339761,Untreated,W,training,9.15,50,0.747486793,9.635346635,0,-0.370165818,37.35295133,0.003937454,5.5,71,NA,2,89,1.852858081,NA,*01:03,*15:01,627.4271954,current
S-181218-03391,pt93,46.49418207,Female,PP-MS,prog-MS,8.83504449,25.41781451,Untreated,W,training,8.3,50,0.75909111,8.360305436,0,-0.57958617,41.02996087,0.017394077,5.5,72,NA,2,78.1,7.432166674,NA,*01:03,*15:01,257.0188171,current
S-181218-03392,pt93,47.52908966,Female,PP-MS,prog-MS,9.869952088,26.07897153,Untreated,W,training,9.35,50,NA,NA,NA,NA,43.89792888,NA,6,67,12,2,98.344444,NA,NA,*01:03,*15:01,221.5457661,current
S-181218-03393,pt93,50.91854894,Female,PP-MS,prog-MS,13.25941136,25.67493113,Untreated,W,training,12.95,25,0.745634184,8.120588712,NA,0.962286172,51.29830358,1.838332527,6,47,17,4,213.51111,3.694696359,NA,*01:03,*15:01,2544.031633,current
S-181218-03394,pt94,48.93908282,Male,PP-MS,prog-MS,4.150581793,38.96072272,Untreated,W,validation,8.6,45,NA,NA,0,NA,34.52954161,NA,6,86,NA,4,NA,NA,NA,*03:01,*08:01,6.190248232,NA
S-181218-03395,pt95,29.10061602,Female,RR-MS,RR-MS,0.027378508,20.53639218,Untreated,W,validation,6,58,0.737247637,9.050054242,1.098612289,-0.601068089,15.83904581,-1.295910136,2,88,NA,0,23.2,-17.56361438,NA,*03:01,*03:01,2544.848877,no
S-181218-03397,pt96,56.10130048,Male,RR-MS,RR-MS,0.936344969,20.33730159,Untreated,AA,validation,6.95,36,NA,NA,0,NA,16.83246171,NA,2,86,NA,0,36.03333001,NA,NA,*11:01,*15:03,375.9505826,NA
S-181218-03403,pt97,42.21492129,Male,PP-MS,prog-MS,5.034907598,23.87871573,Untreated,W,training,12.75,NA,0.755413841,8.92585319,0,NA,55.92440242,NA,6.5,55,NA,5,137.777776,NA,NA,*03:01,*15:01,1467.950148,no
S-181218-03404,pt97,44.07118412,Male,PP-MS,prog-MS,6.891170431,23.51574975,Untreated,W,training,179.9,NA,0.750114354,9.169622539,0,NA,73.9497822,NA,7,47,NA,8,NA,NA,NA,*03:01,*15:01,863.5199783,no
S-181218-03405,pt97,44.97741273,Male,PP-MS,prog-MS,7.797399042,22.28189868,Untreated,W,training,179.9,NA,0.744154162,8.714567551,0.693147181,NA,80.0604877,NA,8.5,47,NA,8,243.777776,NA,NA,*03:01,*15:01,3901.801183,no
S-181218-03407,pt98,40.25462012,Female,SP-MS,prog-MS,6.034223135,32.90194328,Untreated,W,validation,5.95,26,0.712288004,10.24363161,1.609437912,1.512116025,17.82276,0.57812011,2,81,NA,1,16.5,-34.77530357,NA,*07:01,*15:01,2348.973229,NA
S-181218-03408,pt99,42.71868583,Female,PP-MS,prog-MS,5.158110883,27.30084585,Untreated,AA,training,8.5,24,0.70634628,9.394659931,NA,1.723266378,38.71935771,1.829663232,6,77,NA,4,NA,-15.79671962,NA,*08:04,*15:03,501.3594535,NA
S-181218-03409,pt100,42.30527036,Female,RR-MS,RR-MS,13.08692676,20.84636231,glatiramer acetate (Copaxone),W,validation,5.45,58,0.783296521,9.885781725,0,-1.432101359,12.86677124,-2.145611871,1.5,93,NA,0,9.5,-12.98708203,NA,*13:01,*14:01,181.8894052,no
S-181218-03410,pt100,43.27173169,Female,RR-MS,RR-MS,14.05338809,20.49435994,daclizumab (Zinbryta),W,validation,4.7,59,0.78201252,10.43561468,0,-1.460890033,17.48220318,-1.93243222,2,83,NA,1,21.038888,-8.110144137,NA,*13:01,*14:01,96.15679039,no
S-181218-03411,pt100,45.0349076,Female,RR-MS,RR-MS,15.816564,21.78503528,daclizumab (Zinbryta),W,validation,5.65,61,0.720159091,8.330381569,0,-0.448557366,23.28726487,-0.785041293,2.5,79,NA,1,36,-11.50074779,NA,*13:01,*14:01,-14.98012093,no
S-181218-03412,pt100,46.03148528,Female,RR-MS,RR-MS,16.81314168,21.64777022,daclizumab (Zinbryta),W,validation,5.1,66,0.781730904,8.675392806,NA,-1.819532927,24.75709172,-1.859108363,2.5,79,2,1,38,2.422527278,NA,*13:01,*14:01,23.36452793,no
S-181218-03413,pt101,65.7357974,Male,PP-MS,prog-MS,2.078028747,23.15541601,Untreated,W,training,11.15,57,0.751385479,8.484049973,0.693147181,-0.804249629,41.4496805,-0.149417967,6.5,76,NA,5,77.888888,9.892648246,NA,*04:01,*07:01,18.85433419,past
S-181218-03414,pt101,67.72621492,Male,PP-MS,prog-MS,4.06844627,22.94408888,Untreated,W,training,11.65,61,0.751185793,7.527255919,0,-1.008488886,44.11880561,-0.183441047,6.5,70,NA,5,NA,14.41700921,NA,*04:01,*07:01,51.07740606,past
S-181218-03415,pt101,68.6844627,Male,PP-MS,prog-MS,5.026694045,23.00446806,Untreated,W,training,13.35,59,0.75510853,8.363575703,NA,-0.975360117,44.47419876,-0.137386675,6.5,68,NA,5,102,14.47147256,NA,*04:01,*07:01,26.06416228,past
S-181218-03416,pt102,49.63723477,Female,RR-MS,RR-MS,0.65982204,30.71853741,glatiramer acetate (Copaxone),W,training,3.9,56,NA,NA,1.098612289,NA,11.39977794,NA,2,89,NA,0,13,NA,NA,*01:01,*13:02,622.6797325,current
S-181218-03417,pt102,55.96167009,Female,RR-MS,RR-MS,6.984257358,34.82851474,glatiramer acetate (Copaxone),W,training,4.25,55,0.768725231,6.909753282,0,-1.013254542,14.51649369,-1.709557072,1.5,81,2,2,31.5,-15.14201321,NA,*01:01,*13:02,170.1158034,current
S-181218-03418,pt103,60.56673511,Female,PP-MS,prog-MS,0.947296372,16.17125031,Untreated,W,training,5.35,40,0.745372142,7.995643604,0,0.187604145,15.84281113,-0.634368256,2,86,NA,1,24.40000001,-24.72386357,NA,*01:02,*13:01,-264.0563354,NA
S-181218-03419,pt104,62.31622177,Male,PP-MS,prog-MS,15.07186858,30.09473,Untreated,W,training,3.65,53,0.763336418,9.313167682,0,-0.812082442,28.92977869,-0.799746425,4,74,NA,2,57.944444,-2.556103105,NA,*03:01,*11:01,440.8028785,past
S-181218-03420,pt104,64.1615332,Male,PP-MS,prog-MS,16.91718001,28.5899935,Untreated,W,training,3.65,48,0.756778446,9.409437102,0,-0.433928601,25.01252315,-0.684063243,3.5,77,NA,2,NA,-9.908371946,NA,*03:01,*11:01,322.9132882,past
S-181218-03421,pt104,66.11635866,Male,PP-MS,prog-MS,18.87200548,29.0687733,Untreated,W,training,4.8,50,NA,NA,NA,NA,26.82277761,NA,4,73,2,2,NA,NA,NA,*03:01,*11:01,397.976095,past
S-181218-03422,pt104,69.48939083,Male,PP-MS,prog-MS,22.24503765,26.74327143,Untreated,W,training,6.4,32,NA,NA,NA,NA,41.28287207,NA,6,66,11,5,97.988888,NA,NA,*03:01,*11:01,1596.378145,past
S-181218-03423,pt105,44.84325804,Male,SP-MS,prog-MS,17.09514031,34.15365955,Untreated,W,validation,21,23,NA,NA,0,NA,55.16153428,NA,6.5,60,NA,6,NA,NA,NA,*04:04,*04:07,-41.57395078,NA
S-181218-03425,pt106,34.7926078,Female,RR-MS,RR-MS,0.112251882,22.14427438,Untreated,W,training,4.85,58,0.782962037,7.491645474,1.945910149,-1.426065005,7.810241067,-2.400551494,1,94,NA,0,6,-18.09844426,NA,*07:01,*10:01,253.1379487,past
S-181218-03426,pt107,42.20396988,Female,PP-MS,prog-MS,13.17180014,NA,Untreated,W,training,149.95,34,0.720471048,9.53870843,0,0.948752687,62.56924811,2.406524012,6.5,55,NA,7,212.716658,15.08857419,NA,*01:01,*15:01,180.7359749,no
S-181218-03427,pt108,27.60848734,Male,RR-MS,RR-MS,8.109514031,34.19855682,Untreated,W,validation,4.4,63,0.798813455,8.732143268,1.791759469,-1.971935459,10.32881457,-2.728793726,1.5,94,NA,0,4.5,-10.62138016,NA,*11:01,*13:03,294.5614283,no
S-181218-03428,pt108,27.91786448,Male,RR-MS,RR-MS,8.41889117,33.27519579,interferon beta-1a (Rebif),W,validation,4.25,85,0.805738017,8.422222954,0.693147181,-3.240037573,8.320126273,-3.895456921,1,91,NA,0,6,-1.111085586,NA,*11:01,*13:03,195.1085932,no
S-181218-03429,pt108,28.84325804,Male,RR-MS,RR-MS,9.344284736,33.75397558,daclizumab (Zinbryta),W,validation,4.85,57,0.798346575,8.71489585,0,-1.651745372,8.278087107,-2.565741666,1,92,NA,0,5,-15.58059905,NA,*11:01,*13:03,43.25882331,no
S-181218-03430,pt108,30.31622177,Male,RR-MS,RR-MS,10.81724846,NA,daclizumab (Zinbryta),W,validation,4.8,76,NA,NA,0,NA,10.4654015,NA,1.5,96,NA,0,NA,NA,NA,*11:01,*13:03,0.584426123,no
S-181218-03431,pt108,31.38945927,Male,RR-MS,RR-MS,11.89048597,33.17260012,daclizumab (Zinbryta),W,validation,4.2,74,0.810622441,7.758760544,0.693147181,-2.756617518,8.663709805,-3.472413935,1,93,2,0,NA,-5.158715716,NA,*11:01,*13:03,30.36479197,no
S-181218-03432,pt109,68.61601643,Female,RR-MS,RR-MS,8.117727584,31.40086819,Untreated,W,validation,22.45,36,0.716321155,9.999797233,1.098612289,0.919723349,50.39337127,1.756110418,6,NA,NA,NA,NA,3.176389406,81.07966956,NA,NA,1500.33901,NA
S-181218-03434,pt110,49.96303901,Female,PP-MS,prog-MS,15.23340178,22.1799308,Untreated,W,validation,14.05,50,0.757295711,9.03085479,0,-0.547185031,47.06862412,0.355066059,6.5,71,NA,5,88,13.17650965,NA,*03:01,*04:02,10.68155361,past
S-181218-03435,pt110,51.81930185,Female,PP-MS,prog-MS,17.08966461,22.38754325,Untreated,W,validation,19.15,44,0.750999501,9.023046474,0,-0.12179441,49.31570739,0.827323889,6.5,59,NA,5,NA,11.55949772,NA,*03:01,*04:02,-51.67148785,past
S-181218-03436,pt110,52.72005476,Female,PP-MS,prog-MS,17.99041752,23.07958478,Untreated,W,validation,27.9,42,0.750603225,8.941545475,NA,-0.010721439,52.39389056,1.07874208,6.5,57,NA,6,159.722222,13.62873404,NA,*03:01,*04:02,176.7538439,past
S-181218-03437,pt110,53.77412731,Female,PP-MS,prog-MS,19.04449008,NA,Untreated,W,validation,29.95,41,0.752830284,8.713417653,NA,0.001048092,52.80379439,1.109688351,6.5,57,18,6,159.522222,13.93172768,NA,*03:01,*04:02,255.9194926,past
S-181218-03440,pt111,22.58726899,Female,RR-MS,RR-MS,1.560574949,26.55647383,Untreated,W,validation,4.7,59,0.814832421,7.677863501,NA,-2.05318299,3.216009371,-3.162657543,0,94,NA,1,3,-16.99616205,NA,*04:07,*11:04,205.4157936,past
S-181218-03441,pt111,28.39972621,Female,RR-MS,RR-MS,7.37303217,27.77468356,Untreated,W,validation,4.55,65,0.803666117,7.636269603,0,-2.163431769,7.730373539,-3.022983802,1,95,0,0,9.722222,-11.48033768,72.31943067,*04:07,*11:04,157.4398271,past
S-181218-03442,pt111,29.43463381,Female,RR-MS,RR-MS,8.407939767,30.33976125,natalizumab (Tysabri),W,validation,5,70,0.799675386,7.800982071,0,-2.351215674,18.32693773,-2.635587518,2.5,85,3,2,22.072222,0.821987867,64.30046781,*04:07,*11:04,121.279742,past
S-181218-03445,pt112,26.2696783,Female,RR-MS,RR-MS,2.036960986,22.03856749,Untreated,W,training,4.3,66,0.771323934,6.940222469,0,-1.631720812,7.289677183,-2.599772888,1,95,NA,0,8.2,-16.75090487,NA,*10:01,*12:01,837.7948685,past
S-181218-03446,pt112,31.17590691,Female,RR-MS,RR-MS,6.943189596,23.03030303,Untreated,W,training,3.85,53,0.75346268,9.170871628,0.693147181,-0.633893438,18.65438483,-1.17867436,2.5,81,4,0,40.405554,-14.4501017,NA,*10:01,*12:01,2076.724888,past
S-181218-03447,pt113,37.77412731,Female,SP-MS,prog-MS,12.43531828,24.73577254,Untreated,AA,validation,3.4,NA,0.758837521,10.84634232,0,NA,23.78317046,NA,4,81,NA,2,NA,NA,NA,NA,NA,-33.19035569,no
S-181218-03448,pt114,43.6659822,Male,RR-MS,RR-MS,0.607802875,30.00985398,Untreated,W,training,4.55,NA,NA,NA,0,NA,NA,NA,1,96,NA,0,13.2,NA,NA,*14:01,*15:01,1.81752459,NA
S-181218-03449,pt115,48.80219028,Male,RR-MS,RR-MS,4.720054757,26.24742453,Untreated,W,training,2.95,54,NA,NA,0,NA,6.793608938,NA,1,97,NA,1,1,NA,NA,*15:01,*15:01,130.7189708,no
S-181218-03450,pt116,44.7063655,Female,RR-MS,RR-MS,19.06365503,22.55280073,Untreated,W,validation,4.85,55,0.785193426,9.385972941,3.36729583,-1.310452145,14.00543089,-1.985053135,2,91,NA,1,NA,-12.95344002,NA,*04:04,*15:01,813.907851,NA
S-181218-03451,pt117,57.63175907,Female,SP-MS,prog-MS,9.418206708,35.4296875,Untreated,W,training,7.2,31,0.766919674,9.387481869,1.098612289,0.266387576,23.4820869,-0.175500169,3,78,NA,2,36,-17.80022811,NA,*15:01,*15:01,192.8666115,past
S-181218-03452,pt118,57.46201232,Male,PP-MS,prog-MS,18.31348392,21.33703263,Untreated,W,validation,11.7,23,0.689683686,12.18463448,0,2.07593299,51.99268286,2.807895443,6.5,66,NA,5,102.433332,-5.726890952,NA,*04:04,*13:01,216.3068592,past
S-181218-03453,pt118,59.18412047,Male,PP-MS,prog-MS,20.03559206,21.83247457,Untreated,W,validation,16.2,20,0.7119551,10.57763029,0,1.829888279,53.37275492,2.672534267,6.5,50,NA,5,171.38333,-2.111837362,NA,*04:04,*13:01,659.0254876,past
S-181218-03454,pt119,32.30663929,Male,SP-MS,prog-MS,14.83367556,24.93372049,Untreated,W,training,11,55,0.705365483,10.22223215,1.791759469,0.130183778,43.86073126,0.758133355,6,60,NA,4,163.133332,3.81564249,NA,*15:01,*15:01,377.615654,no
S-181218-03455,pt119,33.2347707,Male,SP-MS,prog-MS,15.76180698,24.61810377,daclizumab (Zinbryta),W,training,14,44,0.673609649,10.4115995,NA,1.274841864,45.5306586,1.803862706,6.5,52,NA,5,169.133332,-4.912091958,50.24233564,*15:01,*15:01,670.2889829,no
S-181218-03456,pt120,59.25804244,Male,PP-MS,prog-MS,12.72826831,39.01960272,Untreated,W,training,6.8,44,NA,NA,NA,NA,44.78071477,NA,6.5,70,NA,5,87.677776,NA,NA,*03,*11,187.9426856,current
S-181218-03457,pt120,60.65708419,Male,PP-MS,prog-MS,14.12731006,39.74708684,Untreated,W,training,7.15,50,0.727738832,9.361944956,0,-0.013779057,46.03257987,0.749086182,6.5,62,NA,5,NA,7.295197645,NA,*03,*11,211.928202,current
S-181218-03458,pt120,61.5578371,Male,PP-MS,prog-MS,15.02806297,38.62857143,Untreated,W,training,7.05,47,0.730089149,9.530538036,NA,0.099687538,45.79244429,0.831887108,6.5,67,NA,5,95.61111,6.024372384,NA,*03,*11,152.594703,current
S-181218-03460,pt121,28.89253936,Male,SP-MS,prog-MS,2.01779603,21.2244898,Untreated,NA,validation,5.4,35,0.774662139,9.110851473,1.098612289,-0.081181794,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04:03,*04:03,494.4920451,NA
S-181218-03461,pt121,29.09240246,Male,SP-MS,prog-MS,2.217659138,21.55102041,Untreated,NA,validation,6.5,NA,0.772803298,8.843903651,0.693147181,NA,45.49320301,NA,6,67,NA,4,101.666666,NA,NA,*04:03,*04:03,432.5157943,NA
S-181218-03462,pt122,30.36824093,Male,RR-MS,RR-MS,1.659137577,27.3624619,Untreated,W,training,4,66,0.754038205,10.55124503,0.693147181,-1.319769367,7.911096535,-2.306230439,1,97,NA,0,2,-18.96314009,NA,*01:03,*07:01,937.2302248,no
S-181218-03463,pt123,39.97535934,Male,RR-MS,RR-MS,1.845311431,22.28395062,Untreated,W,validation,5.65,60,0.773462587,6.501289671,0,-1.35855216,13.27992512,-2.062692584,1.5,92,NA,0,21.222222,-13.24202258,NA,*07:01,*15:01,724.6537941,current
S-181218-03464,pt123,45.66735113,Male,RR-MS,RR-MS,7.537303217,NA,natalizumab (Tysabri),W,validation,7.9,59,0.779285941,5.043425117,0,-1.41168411,18.31811135,-1.848188627,2,86,NA,0,28.044444,-7.721204854,NA,*07:01,*15:01,26.47625334,current
S-181218-03465,pt124,37.93839836,Female,RR-MS,RR-MS,3.482546201,24.36889465,Untreated,W,training,5.95,59,NA,NA,0,NA,4.188804002,NA,0,100,NA,0,0,NA,NA,*13:01,*15:01,683.4069478,past
S-181218-03467,pt125,65.51129363,Female,PP-MS,prog-MS,9.612594114,28.09573361,Untreated,AA,training,12.8,28,0.729631775,10.22824862,0,1.095195638,47.40143174,1.749411917,6,67,NA,4,97.58888801,-1.409477203,NA,*07:01,*09:01,55.12433606,past
S-181218-03468,pt125,67.27446954,Female,PP-MS,prog-MS,11.37577002,25.3069719,Untreated,AA,training,20.65,26,0.726061867,10.25597374,0,1.263542392,48.94277292,1.96983476,6.5,69,NA,6,NA,-1.397337296,NA,*07:01,*09:01,-46.74839929,past
S-181218-03469,pt125,68.25188227,Female,PP-MS,prog-MS,12.35318275,27.72112383,Untreated,AA,training,31.72,23,0.730622808,10.41177997,NA,1.33711438,54.55840009,2.320278862,6.5,62,NA,6,125.61111,3.549988426,NA,*07:01,*09:01,3.332649321,past
S-181218-03470,pt125,69.28678987,Female,PP-MS,prog-MS,13.38809035,28.42872008,Untreated,AA,training,51.6,21,0.72564555,10.37791887,NA,1.530859245,55.98000483,2.5558428,6.5,61,14,6,NA,3.211684599,NA,*07:01,*09:01,50.63762964,past
S-181218-03471,pt126,36.38329911,Female,PP-MS,prog-MS,4.59137577,32.44672328,Untreated,NA,training,26.2,23,0.760474264,9.264544426,0,0.798392245,51.64507481,1.718728397,6,71,NA,6,NA,5.53022099,NA,*03:01,*13:03,322.2300312,NA
S-181218-03472,pt127,57.82340862,Female,SP-MS,prog-MS,41.82340862,29.30280957,Untreated,W,training,127.9,36,NA,NA,NA,NA,68.1961904,NA,6.5,59,NA,7,NA,NA,NA,*15:01,*15:01,-134.4920305,no
S-181218-03473,pt128,63.78370979,Male,SP-MS,prog-MS,39.59479808,NA,Untreated,AA,training,143.3,12,0.67552454,10.47381717,0,2.903027828,63.02627843,4.068799216,6.5,68,NA,6,108.688888,-2.206327,NA,*01:02,*11:02,611.3640138,past
S-181218-03474,pt128,64.72005476,Male,SP-MS,prog-MS,40.53114305,36.0891075,Untreated,AA,training,101.5,18,0.727767851,10.65864663,0,1.64844079,61.81628158,2.954537085,6.5,62,NA,6,161.266664,7.979892939,NA,*01:02,*11:02,109.3547919,past
S-181218-03475,pt128,64.95277207,Male,SP-MS,prog-MS,40.76386037,32.79117669,Untreated,AA,training,63.55,14,0.663817763,10.72128304,0,3.01037578,NA,NA,6.5,62,NA,5,NA,NA,40.83335995,*01:02,*11:02,38.35295489,past
S-181218-03476,pt128,65.63723477,Male,SP-MS,prog-MS,41.44832307,NA,Untreated,AA,training,45,11,0.631371142,10.85003587,0,3.751814448,56.58930915,4.449574763,6.5,58,NA,6,143.577776,-16.35336823,49.29332326,*01:02,*11:02,358.1189348,past
S-181218-03477,pt128,70.08898015,Male,SP-MS,prog-MS,45.90006845,32.51451285,Untreated,AA,training,76.85,13,0.653963953,10.9221363,NA,3.240165884,61.77453787,4.287146215,7,52,16,6,160.444444,-6.520508233,41.72167273,*01:02,*11:02,216.1223165,past
S-181218-03478,pt128,71.12388775,Male,SP-MS,prog-MS,46.93497604,33.61111111,Untreated,AA,training,63,9,NA,NA,NA,NA,61.50925582,NA,6.5,45,18,6,208.999992,NA,48.196398,*01:02,*11:02,211.3670467,past
S-181218-03480,pt129,60.82409309,Male,SP-MS,prog-MS,3.003422313,34.76474412,Untreated,NA,training,3.75,24,NA,NA,0,NA,22.3954483,NA,2.5,72,NA,1,NA,NA,NA,*01:02,*14:01,438.1729369,NA
S-181218-03483,pt130,56.18617385,Female,RR-MS,RR-MS,20.19986311,16.74884264,Untreated,AA,validation,6.4,40,NA,NA,0.693147181,NA,13.39394625,NA,1.5,88,NA,1,17.50000001,NA,NA,*07:01,*15:03,-78.71480308,current
S-181218-03484,pt131,47.66324435,Female,PP-MS,prog-MS,13.34428474,26.18261501,Untreated,W,training,10.25,38,0.764713907,9.055672892,0,-0.057530622,48.45559388,0.836986741,6.5,54,NA,5,128.055552,10.11563511,NA,*01:03,*04:01,-31.0502318,past
S-181218-03485,pt131,49.5633128,Female,PP-MS,prog-MS,15.24435318,26.26449164,Untreated,W,training,9,34,0.770045378,8.931948346,0,0.054096531,45.19655323,0.763016263,6.5,56,NA,5,NA,5.842613611,NA,*01:03,*04:01,-77.73721466,past
S-181218-03486,pt131,50.63655031,Female,PP-MS,prog-MS,16.31759069,26.31379962,Untreated,W,training,9.75,37,0.771579319,9.219894585,NA,-0.129468345,48.90288827,0.799662117,6.5,64,NA,5,126.333328,11.21638587,NA,*01:03,*04:01,-1.092068751,past
S-181218-03487,pt131,51.65229295,Female,PP-MS,prog-MS,17.33333333,25.98121028,Untreated,W,training,10.5,35,0.779168204,9.251098364,NA,-0.162501679,48.94741694,0.774251331,6.5,56,17,5,NA,11.56097744,NA,*01:03,*04:01,-49.71273927,past
S-181218-03488,pt132,49.46475017,Female,PP-MS,prog-MS,14.6255989,26.796875,Untreated,W,training,12.25,30,0.684926236,10.19133211,0,1.798064409,50.93480944,2.520491479,6,64,NA,3,NA,-4.260706263,NA,*10:01,*13:02,-237.2649539,current
S-181218-03491,pt133,59.89048597,Male,PP-MS,prog-MS,18.68856947,22.56659513,Untreated,W,training,5.95,NA,NA,NA,0,NA,27.45037385,NA,3,81,NA,2,62.466666,NA,NA,*01:02,*11:04,26.4881386,past
S-181218-03492,pt134,31.22518823,Female,RR-MS,RR-MS,5.645448323,27.34375,Untreated,AA,training,5.35,37,0.759317833,9.536762273,1.098612289,0.09181178,24.72179398,-0.258147856,3,84,NA,2,34.777776,-14.97473737,NA,*11:01,*15:01,287.4173662,current
S-181218-03493,pt134,37.11430527,Female,RR-MS,RR-MS,11.53456537,30.9375,Untreated,AA,training,5.45,39,0.755204487,10.08443316,0,0.062122886,27.71952276,-0.128903687,3.5,80,3,2,62.52222,-11.70732538,64.59417793,*11:01,*15:01,117.7806858,current
S-181218-03494,pt135,18.32169747,Male,RR-MS,RR-MS,0.120465435,25.0137741,Untreated,AA,validation,5.6,52,0.806905926,9.662243674,NA,-1.546410267,8.319740806,-2.475270167,1,97,NA,0,7,-16.49577151,NA,*15:03,*15:03,2131.923459,past
S-181218-03495,pt135,24.1670089,Male,RR-MS,RR-MS,5.965776865,23.89482842,Untreated,AA,validation,5.35,46,0.784247732,9.445807673,0,-0.825738808,9.911503938,-1.789097778,1,92,0,0,12.60000006,-21.45032835,NA,*15:03,*15:03,610.5468439,past
S-181218-03496,pt136,47.94250513,Male,RR-MS,RR-MS,36.29295003,30.73776747,not untreated,AA,training,5.15,49,NA,NA,1.098612289,NA,13.85072731,NA,1.5,84,NA,1,20.5,NA,NA,*03:01,*15:03,1541.114604,no
S-181218-03497,pt136,53.70020534,Male,RR-MS,RR-MS,42.05065024,28.96736974,glatiramer acetate (Copaxone),AA,training,4.8,44,0.771363108,7.856706793,0,-0.489291588,11.9248878,-1.403440823,1.5,88,1,1,21.6,-22.49310986,NA,*03:01,*15:03,602.9389026,no
S-181218-03498,pt136,55.04175222,Male,RR-MS,RR-MS,43.39219713,30.21885779,glatiramer acetate (Copaxone),AA,training,4.95,48,0.758461378,8.754160749,NA,-0.464300075,15.7656322,-1.184996925,2,88,3,1,33.194444,-18.87937936,64.60758901,*03:01,*15:03,466.4371703,no
S-181218-03499,pt137,36.21902806,Female,SP-MS,prog-MS,2.01779603,19.77769867,Untreated,W,validation,4.8,45,0.752191665,9.173468897,1.386294361,-0.195269846,22.85354539,-0.59494614,3,86,NA,2,54.177776,-14.23523987,NA,*14:01,*15:01,3199.701859,current
S-181218-03500,pt137,41.12525667,Female,SP-MS,prog-MS,6.924024641,23.8123492,dimethyl fumarate (Tecfidera),W,validation,5.25,46,0.73708054,9.050054242,0,0.025476301,25.0631853,-0.296220092,3,77,7,2,79.544442,-14.03077846,NA,*14:01,*15:01,390.3553313,current
S-181218-03501,pt137,42.42847365,Female,SP-MS,prog-MS,8.227241615,23.89497033,dimethyl fumarate (Tecfidera),W,validation,4.8,46,0.692445997,8.550821372,NA,0.830985295,26.43107348,0.449582169,3,71,7,2,83.144442,-19.97984387,53.23783542,*14:01,*15:01,144.2368415,current
S-181218-03580,pt137,43.90417522,Female,SP-MS,prog-MS,9.70294319,24.44523555,dimethyl fumarate (Tecfidera) & Pioglitazone,W,validation,7.05,49,0.729369265,9.814328416,NA,0.008757642,42.71543303,0.597420335,5.5,59,8,2,140.37222,3.77333555,55.98600548,*14:01,*15:01,100.0038231,current
S-181218-03507,pt138,59.35660507,Male,PP-MS,prog-MS,38.7980835,25.82779244,IV steroids,W,training,10.55,33,0.720604708,9.007612005,0,0.998301293,49.04917538,1.752885528,6.5,66,NA,5,159.22222,1.118419773,NA,*01:01,*04:04,53.7328715,past
S-181218-03508,pt138,61.27857632,Male,PP-MS,prog-MS,40.72005476,27.097464,Untreated,W,training,9.7,38,0.713121519,8.475746002,0,0.873544948,49.11436937,1.651622167,6.5,55,NA,5,218.944438,2.316855468,NA,*01:01,*04:04,35.86036603,past
S-181218-03509,pt138,62.33264887,Male,PP-MS,prog-MS,41.77412731,26.96381436,Untreated,W,training,8.9,39,0.718192968,8.81150325,NA,0.730060977,47.05555706,1.425440416,6.5,63,16,5,159.611108,1.561399873,NA,*01:01,*04:04,449.62837,past
S-181218-03510,pt138,63.40314853,Male,PP-MS,prog-MS,42.84462697,23.32186174,Untreated,W,training,8.7,36,0.715538451,8.723231275,NA,0.933848622,47.16347871,1.601877616,6.5,57,17,5,184.611104,-0.181812048,NA,*01:01,*04:04,307.5004627,past
S-181218-03511,pt139,23.93155373,Female,RR-MS,RR-MS,0.106776181,20.79272255,Untreated,AA,validation,4.55,48,0.806894367,9.179159254,0.693147181,-1.338358721,38.94182793,-0.726251143,5.5,73,NA,2,67.877776,12.2364503,NA,*08:04,*15:01,6714.88532,NA
S-181218-03512,pt140,25.50855578,Female,RR-MS,RR-MS,0.476386037,17.85455073,Untreated,W,validation,3.5,NA,NA,NA,0,NA,9.710793613,NA,1.5,96,NA,0,NA,NA,NA,*08:01,*13:03,906.0195078,NA
S-181218-03514,pt141,27.38945927,Male,SP-MS,prog-MS,1.448323066,20.54988662,Untreated,AA,training,41.5,17,0.745741783,10.43187801,2.890371758,1.376030245,62.99862541,2.786899622,6.5,68,NA,6,123.555552,11.63671605,NA,*03:01,*04:04,4752.267018,NA
S-181218-03515,pt141,28.61601643,Male,SP-MS,prog-MS,2.674880219,20.26643991,daclizumab (Zinbryta),AA,training,13.1,12,0.7275839,10.10626512,2.302585093,1.963524925,57.46729778,2.995133578,6.5,50,NA,5,147.394444,0.76879834,NA,*03:01,*04:04,1610.086373,NA
S-181218-03516,pt141,31.24435318,Male,SP-MS,prog-MS,5.303216975,22.67573696,natalizumab (Tysabri),AA,training,50.8,12,0.712790283,9.862405107,0,2.230501817,65.29912152,3.621713617,6.5,47,12,6,174.87222,6.175500153,NA,*03:01,*04:04,290.5304677,NA
S-181218-03517,pt142,50.22313484,Male,SP-MS,prog-MS,10.87474333,23.14671296,Untreated,W,training,7.3,NA,0.754879364,8.969541885,0,NA,48.40835544,NA,6.5,54,NA,5,147.6,NA,NA,*03:01,*15:01,373.5636798,no
S-181218-03518,pt142,51.18138261,Male,SP-MS,prog-MS,11.8329911,23.97338128,Untreated,W,training,8.7,33,0.738431459,9.207034915,0,0.676586153,54.05946796,1.740732347,6.5,46,NA,5,199.2,9.051056817,NA,*03:01,*15:01,467.4927909,no
S-181218-03519,pt142,51.41683778,Male,SP-MS,prog-MS,12.06844627,24.80907262,rituximab,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*03:01,*15:01,232.2041174,no
S-181218-03520,pt142,52.13963039,Male,SP-MS,prog-MS,12.79123888,NA,rituximab,W,training,10.2,34,0.673537919,10.40374756,0,1.795743717,56.2343386,2.791041657,6.5,45,NA,5,200.644444,1.059903226,NA,*03:01,*15:01,276.9811664,no
S-181218-03521,pt143,28.93908282,Female,HD,HD,NA,20.3620761,Untreated,W,HD,3.35,66,NA,NA,NA,NA,2.077406767,NA,0,100,NA,0,NA,NA,NA,*03:01,*16:01,-42.5220254,current
S-181218-03525,pt144,46.66940452,Male,PP-MS,prog-MS,0.503764545,25.15526981,Untreated,W,validation,6.3,50,0.775467229,9.826498511,0,-0.875122099,18.43841048,-1.39206402,2.5,79,NA,1,23.527776,-12.47484178,NA,*11:01,*13:02,736.0610735,no
S-181218-03526,pt145,45.67556468,Female,PP-MS,prog-MS,20.03285421,27.93102118,glatiramer acetate (Copaxone),W,training,5.4,53,0.742301984,8.857657449,NA,-0.432479009,40.83075364,0.130509098,6,67,NA,4,104.344444,5.896690977,NA,*01:02,*11:04,-128.7784346,no
S-181218-03527,pt145,47.59479808,Female,PP-MS,prog-MS,21.95208761,31.67316076,Untreated,W,training,6.2,58,0.752187194,9.171183657,0,-0.870678725,46.17187425,0.037687546,6.5,66,NA,5,114.4,15.21825998,NA,*01:02,*11:04,-42.71150112,no
S-181218-03528,pt145,48.61054073,Female,PP-MS,prog-MS,22.96783025,33.17773234,Untreated,W,training,6.5,61,0.748318198,8.742254902,NA,-0.95673808,46.57375572,-0.013813986,6.5,68,14,5,95.744444,16.40187364,NA,*01:02,*11:04,-118.6181292,no
S-181218-03529,pt145,49.57152635,Female,PP-MS,prog-MS,23.92881588,32.13610586,Untreated,W,training,7.35,56,0.768234983,8.948196083,NA,-1.056367889,45.85366569,-0.13438574,6.5,62,13,5,106.827776,16.58678491,NA,*01:02,*11:04,86.90729087,no
S-181218-03530,pt145,51.6386037,Female,PP-MS,prog-MS,25.99589322,33.38842975,Untreated,W,training,8,56,NA,NA,NA,NA,49.33338572,NA,6.5,58,15,5,187.322216,NA,55.0825586,*01:02,*11:04,105.483896,no
S-181218-03531,pt145,52.3504449,Female,PP-MS,prog-MS,26.70773443,34.06504379,pioglitazone,W,training,8.4,60,0.750289475,9.494089721,NA,-0.940352512,51.08119566,0.231694101,6.5,50,17,5,231.611104,20.76047298,48.60473541,*01:02,*11:04,110.9585872,no
S-181218-03533,pt146,52.45722108,Male,RR-MS,RR-MS,4.057494867,25.33304989,Untreated,NA,validation,7.1,47,0.738088043,9.722085573,0,-0.044666602,17.6707172,-0.735151995,2,85,NA,0,NA,-20.78609369,NA,*04:03,*04:07,1423.874466,current
S-181218-03534,pt146,53.66187543,Male,RR-MS,RR-MS,5.262149213,25.6164966,daclizumab (Zinbryta),NA,validation,8.3,46,0.732494139,10.20240626,0,0.10824599,22.00991457,-0.383808786,2.5,83,NA,1,27.933332,-17.83589924,NA,*04:03,*04:07,325.9370537,current
S-181218-03535,pt146,54.29431896,Male,RR-MS,RR-MS,5.894592745,25.22675737,daclizumab (Zinbryta),NA,validation,7.85,48,NA,NA,NA,NA,21.81619443,NA,2.5,77,NA,2,NA,NA,NA,*04:03,*04:07,246.9683038,current
S-181218-03536,pt146,55.23340178,Male,RR-MS,RR-MS,6.833675565,NA,daclizumab (Zinbryta),NA,validation,6.65,50,0.728881946,9.356084386,0,-0.034408564,21.32395868,-0.53870419,2.5,72,5,2,NA,-17.22603254,NA,*04:03,*04:07,288.2851189,current
S-181218-03539,pt147,38.0752909,Female,RR-MS,RR-MS,4.145106092,27.61664234,Untreated,W,training,3.9,64,NA,NA,0,NA,2.41275406,NA,0,98,NA,0,NA,NA,NA,*01:01,*07:01,-179.0492832,no
S-181218-03540,pt148,30.41478439,Male,SP-MS,prog-MS,10.20123203,NA,Untreated,W,training,179.9,NA,NA,NA,NA,NA,80.59954,NA,8,49,NA,8,NA,NA,NA,*04:05,*14:01,292.0712438,no
S-181218-03541,pt149,45.88637919,Male,PP-MS,prog-MS,5.453798768,NA,Untreated,AA,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*08:04,*10:01,122.0186527,past
S-181218-03542,pt149,50.50787132,Male,PP-MS,prog-MS,10.0752909,31.60588582,Untreated,AA,validation,7,44,0.790570908,8.529516941,0,-0.835930191,21.41431726,-1.206181293,2.5,84,5,2,48.094444,-9.854940174,65.18138385,*08:04,*10:01,-176.8694189,past
S-181218-03546,pt150,59.31279945,Female,SP-MS,prog-MS,13.52498289,22.99956264,Untreated,W,training,4.95,48,NA,NA,NA,NA,21.18860802,NA,2.5,74,NA,1,50.97221801,NA,NA,*14:01,*15:02,-220.6092928,past
S-181218-03547,pt150,64.38877481,Female,SP-MS,prog-MS,18.60095825,25.01562448,Untreated,W,training,5.55,50,0.76166388,9.216421842,0,-0.626016339,26.79781932,-0.753342111,3,78,6,2,80.561106,-6.378219943,62.82886052,*14:01,*15:02,-243.6658073,past
S-181218-03548,pt151,59.80835044,Female,PP-MS,prog-MS,2.458590007,NA,Untreated,W,validation,NA,NA,0.7962869,7.360103973,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04:02,*11:04,-61.87987432,past
S-181218-03549,pt151,63.42778919,Female,PP-MS,prog-MS,6.078028747,20.45859798,glatiramer acetate (Copaxone),W,validation,4.35,51,0.794859883,7.370860167,0,-1.277057455,9.814878429,-2.172523514,1,91,1,0,21,-17.44733782,NA,*04:02,*11:04,48.56030713,past
S-181218-03550,pt151,64.38603696,Female,PP-MS,prog-MS,7.036276523,20.70263692,glatiramer acetate (Copaxone),W,validation,4.45,42,0.777406053,7.13169851,0,-0.494425709,11.54997093,-1.427023917,1,86,1,0,20,-22.82139022,NA,*04:02,*11:04,256.5507259,past
S-181218-03551,pt151,65.51676934,Female,PP-MS,prog-MS,8.167008898,21.37797268,glatiramer acetate (Copaxone),W,validation,4.4,42,0.771844113,7.079184395,NA,-0.394050699,19.04716333,-0.957355793,2.5,87,1,0,34.1,-16.23596826,NA,*04:02,*11:04,381.8175951,past
S-181218-03552,pt151,66.091718,Female,PP-MS,prog-MS,8.741957563,21.02802218,glatiramer acetate (Copaxone) & Losartan,W,validation,4.05,49,0.782699849,7.686162303,NA,-0.953686738,18.63385586,-1.447895517,2.5,85,1,0,34.2,-11.56574351,NA,*04:02,*11:04,335.1466926,past
S-181218-03553,pt152,45.83436003,Female,RR-MS,RR-MS,0.706365503,NA,Untreated,AA,training,4.8,44,0.796514203,9.14835858,2.772588722,-0.943187424,11.36818448,-1.812684401,1.5,95,NA,0,NA,-18.92678688,NA,*11:02,*15:03,1279.556071,NA
S-181218-03554,pt153,54.83093771,Female,PP-MS,prog-MS,4.287474333,20.83333333,Untreated,W,training,6.7,45,0.759215637,6.293419279,0.693147181,-0.3220298,39.09844689,0.134053895,5.5,76,NA,2,54.644444,3.161103393,NA,*07:01,*11:04,29.0940549,NA
S-181218-03555,pt153,56.76386037,Female,PP-MS,prog-MS,6.220396988,19.9704142,Untreated,W,training,39.65,52,0.751516003,7.792348924,NA,-0.546801485,51.22978715,0.569350311,6,61,NA,5,NA,17.33418869,NA,*07:01,*11:04,-34.96779863,NA
S-181218-03556,pt153,57.76043806,Female,PP-MS,prog-MS,7.216974675,20.13477975,Untreated,W,training,37.05,45,0.756024629,7.042286172,NA,-0.264442437,52.98187259,0.896215448,6.5,62,13,6,139.344438,16.52142623,NA,*07:01,*11:04,-29.10391523,NA
S-181218-03557,pt153,58.75701574,Female,PP-MS,prog-MS,8.213552361,20.58678501,Untreated,W,training,27.1,42,0.75273402,9.003193194,NA,-0.04917539,52.83525303,1.069190563,6.5,61,13,6,NA,14.41939835,NA,*07:01,*11:04,-40.00771111,NA
S-181218-03558,pt154,27.94798084,Female,RR-MS,RR-MS,0.227241615,35.4296875,Untreated,W,training,6.55,52,0.750947673,9.03025631,1.386294361,-0.536544969,15.50458917,-1.259001096,2,89,NA,2,23.427776,-18.4841758,NA,*03:01,*03:01,1039.69097,no
S-181218-03559,pt155,40.97741273,Male,RR-MS,RR-MS,0.254620123,21.46915048,Untreated,W,training,4.75,47,0.767587047,9.413526084,NA,-0.577028119,8.115908519,-1.672866796,1,93,NA,0,7.75,-25.50512209,NA,*03:01,*11:01,422.4644502,past
S-181218-03560,pt155,45.82340862,Male,RR-MS,RR-MS,5.100616016,21.13885586,interferon beta-1a (Rebif),W,training,5.1,49,0.68772529,10.28106746,0,0.760296566,12.16502408,-0.343239761,1.5,85,1,0,13.8,-33.6037823,62.76580938,*03:01,*11:01,413.451048,past
S-181218-03561,pt155,47.2991102,Male,RR-MS,RR-MS,6.576317591,22.3279165,teriflunomide (Aubagio),W,training,4.55,46,0.676944532,6.329720906,NA,1.110736552,24.56640535,0.588290855,2.5,75,3,2,41.7,-24.38567165,57.1648181,*03:01,*11:01,475.6933481,past
S-181218-03562,pt156,36.88980151,Male,PP-MS,prog-MS,10.09993155,26.57589059,Untreated,NA,training,8.4,38,0.772851913,9.305559639,NA,-0.204395283,40.7238253,0.316272637,6,70,NA,4,88.255552,3.717932217,NA,*03:01,*03:01,563.6796074,past
S-181218-03563,pt157,47.61396304,Female,RR-MS,RR-MS,0.640657084,44.66616276,Untreated,AA,training,9.2,52,NA,NA,1.791759469,NA,13.82934838,NA,1.5,92,NA,2,29.96666602,NA,NA,*03:01,*15:01,10833.12129,NA
S-181218-03564,pt158,58.90759754,Female,SP-MS,prog-MS,42.41204654,18.17777778,Untreated,W,validation,9,NA,0.720073271,10.81709469,0,NA,46.10397178,NA,6.5,71,NA,5,60.277776,NA,NA,*04:01,*13:02,107.4611716,past
S-181218-03565,pt158,60.02737851,Female,SP-MS,prog-MS,43.53182752,17.60006835,Untreated,W,validation,8.8,NA,0.695487609,10.83010478,0,NA,NA,NA,6.5,65,NA,5,NA,NA,64.70272677,*04:01,*13:02,35.14128824,past
S-181218-03566,pt158,60.14510609,Female,SP-MS,prog-MS,43.6495551,17.51111111,Untreated,W,validation,8.8,NA,0.682945765,10.80707798,0,NA,NA,NA,6.5,57,NA,5,NA,NA,59.75590433,*04:01,*13:02,85.63770582,past
S-181218-03567,pt158,60.26557153,Female,SP-MS,prog-MS,43.77002053,18.17777778,Untreated,W,validation,8.55,NA,0.701349062,10.25614945,0,NA,NA,NA,6.5,59,NA,5,NA,NA,58.77541279,*04:01,*13:02,551.1143252,past
S-181218-03568,pt158,61.00752909,Female,SP-MS,prog-MS,44.5119781,17.91111111,Untreated,W,validation,11.15,35,NA,NA,0,NA,55.45813694,NA,6.5,59,NA,5,153.377776,NA,52.84757566,*04:01,*13:02,69.78246937,past
S-181218-03569,pt158,64.61601643,Female,SP-MS,prog-MS,48.12046543,17.86666667,Untreated,W,validation,17.3,22,0.688922057,10.867177,NA,2.141638663,59.01836975,3.224246962,6.5,50,20,5,241.99444,0.701949266,54.97904484,*04:01,*13:02,462.2705944,past
S-181218-03570,pt158,65.44010951,Female,SP-MS,prog-MS,48.94455852,17.77777778,Untreated,W,validation,15.1,36,0.690841414,10.75956108,NA,1.379550182,59.76587683,2.623626766,6.5,45,18,5,227.511108,8.371993631,55.13346562,*04:01,*13:02,-126.8727202,past
S-181218-03571,pt159,69.7467488,Male,PP-MS,prog-MS,1.193702943,NA,Untreated,AA,validation,7.45,37,NA,NA,0,NA,23.15180761,NA,3.5,90,NA,1,NA,NA,NA,*04:01,*12:01,-232.3874943,NA
S-181218-03572,pt160,29.79055441,Female,PP-MS,prog-MS,3.323750856,32.34681737,Untreated,AA,validation,10.5,46,0.756816762,9.052867513,NA,-0.330698609,35.16748505,-0.075341336,4.5,76,NA,3,46.05,-0.691114112,NA,*11:04,*13:02,794.6993814,no
S-181218-03573,pt161,47.99178645,Female,SP-MS,prog-MS,20.28473648,21.71925011,Untreated,W,training,6.05,NA,0.776212527,8.585038738,0,NA,33.04059871,NA,5.5,78,NA,5,71.077776,NA,NA,*01:01,*15:01,1471.024515,past
S-181218-03574,pt161,49.23203285,Female,SP-MS,prog-MS,21.52498289,23.5546875,Untreated,W,training,6.5,43,NA,NA,NA,NA,48.59428902,NA,6.5,68,NA,5,124.22222,NA,NA,*01:01,*15:01,1978.369517,past
S-181218-03575,pt161,49.34702259,Female,SP-MS,prog-MS,21.63997262,23.5546875,Untreated,W,training,6.5,43,0.776419439,10.00133995,0,-0.528581256,48.59428902,0.449114508,6.5,68,NA,5,124.22222,14.53318456,NA,*01:01,*15:01,1640.197769,past
S-181218-03576,pt161,49.46748802,Female,SP-MS,prog-MS,21.76043806,24.67553277,Untreated,W,training,5.75,NA,NA,NA,0,NA,NA,NA,6.5,67,NA,5,NA,NA,47.1584589,*01:01,*15:01,1417.60474,past
S-181218-03577,pt161,50.2477755,Female,SP-MS,prog-MS,22.54072553,24.50403667,Untreated,W,training,6.1,39,NA,NA,1.098612289,NA,48.32681065,NA,6.5,57,NA,5,150.53333,NA,50.84010771,*01:01,*15:01,1339.465632,past
S-181218-03582,pt162,53.84531143,Female,SP-MS,prog-MS,26.30527036,26.12456747,natalizumab (Tysabri),W,validation,6.85,NA,0.803470269,8.563313127,0,NA,36.35184566,NA,5,77,NA,2,29.788888,NA,NA,*13:01,*15:01,127.0528084,past
S-181218-03583,pt162,54.75701574,Female,SP-MS,prog-MS,27.21697467,23.61606553,Untreated,W,validation,6.6,59,0.787905019,7.623641947,0,-1.567230563,38.85229159,-0.922777571,6,72,NA,2,56.755554,14.22590334,NA,*13:01,*15:01,218.3209479,past
S-181218-03584,pt162,54.89390828,Female,SP-MS,prog-MS,27.35386721,25.08650519,rituximab,W,validation,7.2,NA,0.788957253,9.301825062,NA,NA,NA,NA,6,67,5,2,63.277776,NA,NA,*13:01,*15:01,218.8666332,past
S-181218-03585,pt162,54.99247091,Female,SP-MS,prog-MS,27.45242984,25.08650519,rituximab,W,validation,5.7,NA,0.788176142,6.807934944,0,NA,NA,NA,6,67,5,2,63.277776,NA,NA,*13:01,*15:01,197.4560223,past
S-181218-03586,pt162,55.67693361,Female,SP-MS,prog-MS,28.13689254,25.47477324,rituximab,W,validation,8.45,56,0.74731675,11.24405206,0,-0.678861507,38.76286829,-0.182425675,6,69,NA,2,85.2,6.066855501,73.86547144,*13:01,*15:01,156.6778613,past
S-181218-03587,pt162,60.3394935,Female,SP-MS,prog-MS,32.79945243,27.57292261,Untreated,W,validation,5.35,60,0.758164274,7.411556288,NA,-1.082467139,34.93757688,-0.717565307,4,68,9,2,90.9000001,5.907772286,NA,*13:01,*15:01,-1.445385701,past
S-181218-03588,pt163,49.42094456,Male,PP-MS,prog-MS,12.32306639,29.58579882,Untreated,AA,training,10.8,35,0.729629129,12.10713038,0.693147181,0.731518239,35.7495411,0.845318968,6,86,NA,4,36.999996,-9.757853335,NA,*01:02,*09:01,161.0301464,current
S-181218-03589,pt163,52.06570842,Male,PP-MS,prog-MS,14.96783025,27.20082116,Untreated,AA,training,134.05,31,0.72564097,12.05144602,NA,1.011334541,55.30257717,2.085358019,6.5,66,15,7,NA,7.253432235,NA,*01:02,*09:01,199.6261431,current
S-181218-03590,pt163,52.98562628,Male,PP-MS,prog-MS,15.88774812,28.31783601,Untreated,AA,training,179.9,38,0.713665087,11.89051222,NA,0.863735305,70.5636227,2.746294246,7.5,59,17,7,211.822218,23.85521606,NA,*01:02,*09:01,335.4135702,current
S-181218-03591,pt164,54.40657084,Female,PP-MS,prog-MS,8.553045859,19.12818168,Untreated,W,training,6.85,50,0.78395651,6.96979067,0,-1.028326137,35.88810875,-0.623289529,4.5,71,NA,2,91.494444,6.366506791,NA,*15:01,*15:01,-39.08523333,past
S-181218-03592,pt164,56.49555099,Female,PP-MS,prog-MS,10.64202601,20.04267642,Untreated,W,training,5.75,56,0.784306631,7.06646697,NA,-1.346409102,31.79023415,-1.100729292,4,70,NA,2,84.588888,5.157983286,NA,*15:01,*15:01,19.558138,past
S-181218-03593,pt164,57.49212868,Female,PP-MS,prog-MS,11.6386037,19.16628563,Untreated,W,training,5.65,59,0.78709049,7.580189418,NA,-1.552530952,32.27014449,-1.248898159,4,72,6,2,62.822222,7.510230268,NA,*15:01,*15:01,-101.7376629,past
S-181218-03594,pt164,58.52703628,Female,PP-MS,prog-MS,12.67351129,20.11888432,Untreated,W,training,6.15,61,0.783957422,7.549082711,NA,-1.599910689,31.65429491,-1.320295205,4,72,6,2,80.683332,7.324761161,NA,*15:01,*15:01,299.6898715,past
S-181218-03595,pt164,60.32854209,Female,PP-MS,prog-MS,14.47501711,20.15698826,Untreated,W,training,7.15,52,0.784975959,7.74586823,NA,-1.150645362,39.76783171,-0.526370154,5,61,11,2,102.566666,11.35733354,43.72374514,*15:01,*15:01,455.9816199,past
S-181218-03596,pt164,60.98015058,Female,PP-MS,prog-MS,15.1266256,20.04267642,Untreated,W,training,6.95,52,0.783618909,7.67971364,NA,-1.126155003,39.71284695,-0.508660799,5,61,8,2,103.16111,11.07988718,43.18293072,*15:01,*15:01,323.2805953,past
S-181218-03598,pt165,30.50513347,Male,RR-MS,RR-MS,0.31211499,25.56734694,Untreated,W,training,3.75,46,NA,NA,0,NA,10.64748252,NA,1.5,93,NA,0,21.5,NA,NA,*11:01,*15:01,1151.331303,past
S-181218-03599,pt165,35.39493498,Male,RR-MS,RR-MS,5.201916496,25.99183673,interferon beta-1a (Avonex),W,training,4.95,50,0.759445908,7.631916513,0,-0.585989125,10.32757184,-1.566659728,1,90,1,0,22.2,-23.21206022,NA,*11:01,*15:01,-63.68912925,past
S-181218-03600,pt166,55.50171116,Female,PP-MS,prog-MS,1.637234771,20.30820388,Untreated,W,training,3.75,49,0.792499641,6.96979067,0,-1.130541257,14.45896907,-1.810866769,2,89,NA,0,41.83333202,-14.13414756,NA,*03:01,*03:01,20.58780662,NA
S-181218-03601,pt166,57.5523614,Female,PP-MS,prog-MS,3.68788501,19.89697857,Untreated,W,training,4.95,58,0.788095884,6.878326468,NA,-1.518714323,12.87802017,-2.217663551,1.5,86,NA,2,NA,-12.18907213,NA,*03:01,*03:01,113.4170636,NA
S-181218-03602,pt166,58.54893908,Female,PP-MS,prog-MS,4.684462697,21.08319657,Untreated,W,training,4.75,53,0.794438969,6.880384082,NA,-1.373382792,13.52210997,-2.062676055,1.5,86,3,1,36.9,-12.86512161,NA,*03:01,*03:01,57.50324322,NA
S-181218-03604,pt166,59.55920602,Female,PP-MS,prog-MS,5.694729637,20.5296329,Untreated,W,training,4.15,47,0.791848117,6.831953566,NA,-1.014861886,14.17510092,-1.728458982,1.5,79,4,1,NA,-15.46880544,NA,*03:01,*03:01,-14.88454897,NA
S-181218-03605,pt167,62.72142368,Male,PP-MS,prog-MS,24.07118412,25.53909213,Untreated,W,training,15.05,34,0.757219869,9.640302952,0,0.285555445,44.81543967,0.937511781,6.5,76,NA,5,91.86111,3.359010639,NA,*13:02,*15:01,431.8416402,past
S-181218-03606,pt167,64.50102669,Male,PP-MS,prog-MS,25.85078713,24.2574092,Untreated,W,training,179.9,33,0.74262635,9.843737548,NA,0.600881951,67.47369215,2.366995198,7.5,51,NA,7,222.633332,23.15295071,NA,*13:02,*15:01,965.8234785,past
S-181218-03608,pt168,23.3100616,Female,RR-MS,RR-MS,0.657084189,20.14080418,Untreated,W,training,3.9,51,NA,NA,0,NA,7.331814958,NA,1,98,NA,0,1.6,NA,NA,*01:02,*13:01,-5.04813903,current
S-181218-03609,pt168,26.84188912,Female,RR-MS,RR-MS,4.188911704,22.80991736,dimethyl fumarate (Tecfidera),W,training,3.45,56,0.793505843,7.790282381,0,-1.512425096,6.915883316,-2.518956468,1,93,0,1,7.7,-18.20833806,78.91836191,*01:02,*13:01,-15.59387642,current
S-181218-03610,pt168,27.95345654,Female,RR-MS,RR-MS,5.300479124,20.83030919,dimethyl fumarate (Tecfidera),W,training,4.8,59,0.791611414,7.989560449,0,-1.634118993,8.017468098,-2.564361661,1,93,0,1,5,-16.00132974,80.2747312,*01:02,*13:01,-59.08217831,current
S-181218-03612,pt169,64.95277207,Male,SP-MS,prog-MS,16.49555099,27.87182381,azathioprine,W,training,5.9,NA,0.703200596,10.05504917,0,NA,43.79777927,NA,6,71,NA,4,74.888888,NA,NA,*01:01,*07:01,583.866325,past
S-181218-03613,pt169,65.99863107,Male,SP-MS,prog-MS,17.54140999,32.05564918,Untreated,W,training,6.9,29,0.707023845,9.946211737,0,1.451234844,48.17381954,2.087687198,6.5,57,NA,4,140.966664,-3.871221317,NA,*01:01,*07:01,455.8669134,past
S-181218-03614,pt169,66.11635866,Male,SP-MS,prog-MS,17.65913758,31.11111111,rituximab,W,training,10.55,NA,0.705238138,10.14690421,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01:01,*07:01,343.1941745,past
S-181218-03615,pt169,66.23682409,Male,SP-MS,prog-MS,17.77960301,31.11111111,rituximab,W,training,10.55,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01:01,*07:01,404.5297267,past
S-181218-03616,pt169,67.05544148,Male,SP-MS,prog-MS,18.5982204,30.92745638,rituximab,W,training,8.85,33,0.650591414,10.07065317,0,2.261814577,49.98993123,2.860788755,6.5,55,14,4,164.555552,-9.418123976,77.9690824,*01:01,*07:01,445.8276773,past
S-181218-03617,pt169,70.52977413,Male,SP-MS,prog-MS,22.07255305,28.72678773,glatiramer acetate (Copaxone),W,training,16,24,0.708626956,10.33374283,NA,1.68210756,55.55612422,2.660877954,6.5,50,17,5,270.227772,1.413918766,53.58420819,*01:01,*07:01,136.0117383,past
S-181218-03619,pt170,49.83983573,Male,SP-MS,prog-MS,23.67967146,31.89130381,Untreated,W,validation,6.05,NA,NA,NA,NA,NA,37.69571243,NA,6,75,NA,4,54.9,NA,NA,*13:03,*15:01,210.762442,past
S-181218-03620,pt170,51.27173169,Male,SP-MS,prog-MS,25.11156742,32.75743505,Untreated,W,validation,6.7,51,0.750347923,8.935903526,0,-0.473760687,43.06575838,0.210813564,6,65,NA,4,85.02222,8.506683612,NA,*13:03,*15:01,141.506262,past
S-181218-03621,pt170,51.46885695,Male,SP-MS,prog-MS,25.30869268,NA,rituximab,W,validation,7.25,47,0.705924275,10.77350395,0,0.535785278,43.28328682,1.068562594,6,65,NA,4,88.933332,-0.446139893,49.43595743,*13:03,*15:01,-24.69944226,past
S-181218-03622,pt170,55.6659822,Male,SP-MS,prog-MS,29.50581793,32.82146683,Untreated,W,validation,6.95,44,0.747656787,9.100637107,NA,-0.061469244,46.10858409,0.713003199,6,59,13,4,148.538884,7.804402349,44.42649931,*13:03,*15:01,50.44369176,past
S-181218-03623,pt170,56.10951403,Male,SP-MS,prog-MS,29.94934976,33.485869,Untreated,W,validation,6.35,42,0.743409872,9.122928915,NA,0.119095293,45.61965443,0.839276984,6,57,14,4,152.538884,5.675289462,39.56647675,*13:03,*15:01,360.5986468,past
S-181218-03624,pt171,53.14168378,Male,SP-MS,prog-MS,26.41204654,21.33194589,Untreated,W,training,17.95,50,0.809669002,7.781555959,0.693147181,-1.492353372,52.53455294,-0.156461135,6.5,54,NA,5,147.733332,27.22800725,NA,*15:01,*15:01,345.7644666,past
S-181218-03625,pt171,54.29158111,Male,SP-MS,prog-MS,27.56194387,21.84372918,Untreated,W,training,61,51,0.807012467,7.761319181,0,-1.496372251,58.676603,0.155986551,6.5,58,NA,6,173.377776,33.40656337,NA,*15:01,*15:01,272.9680291,past
S-181218-03626,pt171,54.40657084,Male,SP-MS,prog-MS,27.67693361,21.81464299,rituximab,W,training,50.5,NA,0.792265673,9.123692565,0,NA,NA,NA,6.5,55,NA,5,NA,NA,63.91438318,*15:01,*15:01,138.8517231,past
S-181218-03627,pt171,54.52703628,Male,SP-MS,prog-MS,27.79739904,22.59997014,rituximab,W,training,47.6,NA,0.794316054,8.886409167,0,NA,NA,NA,6.5,54,NA,5,NA,NA,NA,*15:01,*15:01,111.8457441,past
S-181218-03628,pt171,55.30732375,Male,SP-MS,prog-MS,28.57768652,23.00844028,rituximab,W,training,84.15,49,0.800358859,7.239214974,1.098612289,-1.272374697,62.71986979,0.551722261,6.5,53,21,6,204.344442,35.41511705,NA,*15:01,*15:01,172.7567735,past
S-181218-03629,pt172,36.73374401,Female,RR-MS,RR-MS,11.93429158,27.49433107,Untreated,W,training,3.9,24,0.672276987,10.75329654,2.772588722,2.338106815,32.35911741,2.018206404,3.5,73,NA,2,NA,-27.74194901,72.67614292,*11:01,*15:01,3772.141827,no
S-181218-03630,pt172,37.67282683,Female,RR-MS,RR-MS,12.8733744,26.60617705,daclizumab (Zinbryta),W,training,3.75,33,NA,NA,NA,NA,18.46806573,NA,2,81,NA,0,27.7,NA,NA,*11:01,*15:01,521.7566154,no
S-181218-03631,pt172,37.97946612,Female,RR-MS,RR-MS,13.18001369,25.624658,daclizumab (Zinbryta),W,training,4,30,0.735288051,10.78950463,0,0.889196697,18.63075596,0.097311747,2,77,NA,1,NA,-28.3089328,NA,*11:01,*15:01,419.7753877,no
S-181218-03632,pt172,38.99247091,Female,RR-MS,RR-MS,14.19301848,26.36079729,daclizumab (Zinbryta),W,training,3.5,33,0.740720289,10.77751776,0,0.635280181,21.70664264,0.042546602,2.5,77,2,1,33.4,-22.92655994,NA,*11:01,*15:01,274.8270532,no
S-181218-03633,pt173,62.93771389,Female,SP-MS,prog-MS,29.44284736,22.86236854,Untreated,W,training,14.1,NA,0.745422451,9.488426551,1.098612289,NA,49.18928507,NA,6.5,77,NA,5,42.2,NA,NA,*03,*04,707.0338922,past
S-181218-03634,pt173,63.91512663,Female,SP-MS,prog-MS,30.4202601,26.27194669,Untreated,W,training,11.7,NA,NA,NA,NA,NA,48.21337938,NA,6.5,NA,NA,NA,NA,NA,NA,*03,*04,632.7065568,past
S-181218-03635,pt173,64.02737851,Female,SP-MS,prog-MS,30.53251198,26.27194669,rituximab,W,training,11.7,NA,0.729487564,9.501142572,0,NA,48.21337938,NA,6.5,NA,NA,NA,NA,NA,NA,*03,*04,511.2380621,past
S-181218-03636,pt173,64.15058179,Female,SP-MS,prog-MS,30.65571526,23.62444749,rituximab,W,training,12.75,NA,0.73949955,9.819127204,0,NA,47.81868644,NA,6.5,66,NA,5,NA,NA,NA,*03,*04,364.7214564,past
S-181218-03637,pt173,64.93086927,Female,SP-MS,prog-MS,31.43600274,23.62444749,rituximab,W,training,23.15,NA,0.743073501,9.630694093,0,NA,54.43176991,NA,6.5,68,NA,6,104.62222,NA,NA,*03,*04,401.656641,past
S-181218-03638,pt174,49.9137577,Male,RR-MS,RR-MS,1.911019849,30.65321181,Untreated,W,validation,8.2,37,0.754897006,8.863757192,NA,0.171593394,35.47102959,0.36146813,6,90,NA,5,25,-4.950209217,NA,*04,*07:01,333.6428153,past
S-181218-03639,pt174,54.51060917,Male,RR-MS,RR-MS,6.507871321,30.08355035,Untreated,W,validation,10.05,37,0.738082549,9.09549053,0,0.475039905,45.35983724,1.124398048,6.5,73,12,5,68.944444,2.182199618,60.31196661,*04,*07:01,116.2534843,past
S-181218-03640,pt174,56.27378508,Male,RR-MS,RR-MS,8.271047228,31.27712674,Untreated,W,validation,13.75,44,0.730392597,9.021235863,NA,0.250093491,45.62752871,0.949531601,6.5,68,13,5,80.844444,4.493223293,55.35830575,*04,*07:01,224.789149,past
S-181218-03642,pt175,50.93497604,Female,PP-MS,prog-MS,4.514715948,29.8046875,interferon beta-1a (Rebif),AA,training,13,19,0.677206849,10.08880462,0,2.508942446,40.20790234,2.56503844,6,78,NA,3,62.277776,-21.44497342,NA,*04:01,*07:01,-127.806552,past
S-181218-03643,pt176,56.04106776,Female,SP-MS,prog-MS,28.91718001,24.91211466,Untreated,W,training,7.95,51,0.76409509,7.676473646,0,-0.721852544,42.84282823,-0.008688951,6.5,72,NA,4,NA,10.53733054,NA,*15:01,*15:01,953.0165354,no
S-181218-03644,pt176,56.7063655,Female,SP-MS,prog-MS,29.58247775,25.52708076,Untreated,W,training,9.3,49,0.757537646,7.379632153,0,-0.499590438,43.49193483,0.211067337,6.5,68,NA,5,84,9.16748822,NA,*15:01,*15:01,1101.987355,no
S-181218-03645,pt176,56.82135524,Female,SP-MS,prog-MS,29.69746749,25.52708076,Untreated,W,training,8.15,NA,NA,NA,0,NA,43.49193483,NA,6.5,68,NA,5,84,NA,NA,*15:01,*15:01,1188.307987,no
S-181218-03646,pt176,56.94182067,Female,SP-MS,prog-MS,29.81793292,25.01352082,Untreated,W,training,8.35,NA,0.753190014,7.663407665,0,NA,46.32154466,NA,6.5,63,NA,5,NA,NA,NA,*15:01,*15:01,1143.51505,no
S-181218-03648,pt176,57.68377823,Female,SP-MS,prog-MS,30.55989049,24.89224498,Untreated,W,training,14.5,50,0.753700473,7.276556403,0,-0.482302625,51.14042281,0.618841396,6.5,55,13,5,155.6,16.65893993,NA,*15:01,*15:01,1291.17104,no
S-181218-03652,pt177,62.32717317,Female,PP-MS,prog-MS,38.22039699,16.4453125,Untreated,W,training,4.15,64,0.772838143,7.173191742,0,-1.55512591,21.99410517,-1.779457317,2.5,73,NA,2,68.694442,-2.742237382,NA,*11,*15:01,132.0577576,past
S-181218-03653,pt177,64.14784394,Female,PP-MS,prog-MS,40.04106776,17.1875,Untreated,W,training,4.75,61,0.774775319,7.249215057,NA,-1.434203458,23.01882196,-1.625366836,2.5,70,7,1,NA,-2.815936598,NA,*11,*15:01,42.99299484,past
S-181218-03654,pt177,65.22108145,Female,PP-MS,prog-MS,41.11430527,16.6015625,Untreated,W,training,6.25,64,0.775301986,7.344719054,NA,-1.5995903,26.7433625,-1.572541519,3,71,7,2,118.833332,2.410918446,NA,*11,*15:01,115.6673648,past
S-181218-03655,pt177,66.16016427,Female,PP-MS,prog-MS,42.05338809,16.6796875,Untreated,W,training,5.5,63,0.777230605,7.43543802,NA,-1.582434893,27.09608521,-1.540019066,3,66,7,2,148.6666641,2.607807618,NA,*11,*15:01,259.1699122,past
S-181218-03656,pt177,67.71252567,Female,PP-MS,prog-MS,43.60574949,15.390625,Untreated,W,training,5.7,49,0.757182437,8.025516386,NA,-0.493180066,45.8567136,0.338037249,5.5,52,11,2,217.511106,11.47403748,NA,*11,*15:01,1168.693168,past
S-181218-03657,pt177,68.26830938,Female,PP-MS,prog-MS,44.1615332,16.06618289,pioglitazone,W,training,5.9,59,0.751697784,8.195057691,NA,-0.913807194,45.43701909,-0.036263703,5.5,52,11,2,213.955552,14.8751683,61.28326809,*11,*15:01,1544.976067,past
S-181218-03660,pt178,52.14510609,Female,PP-MS,prog-MS,5.152635181,24.67702134,Untreated,W,validation,6.5,26,0.741922133,8.419800845,0,0.977315939,38.42976088,1.189248946,6,77,NA,4,51.166666,-9.310371329,NA,*03,*03,545.3666823,NA
S-181218-03661,pt178,54.04243669,Female,PP-MS,prog-MS,7.049965777,26.05603135,Untreated,W,validation,7.95,21,0.730152812,8.615408239,NA,1.449517758,41.48733742,1.742435443,6,62,10,4,NA,-10.54210604,NA,*03,*03,567.2381633,NA
S-181218-03662,pt178,55.01984942,Female,PP-MS,prog-MS,8.027378508,26.38263899,Untreated,W,validation,13.1,22,0.72931768,8.718990525,NA,1.412628451,45.31655742,1.908396044,6,63,10,4,112.488888,-6.377796865,NA,*03,*03,526.7269034,NA
S-181218-03663,pt179,57.34428474,Female,SP-MS,prog-MS,18.68583162,32.93524817,Untreated,W,validation,12.2,NA,0.754498725,8.009363077,0,NA,47.83631661,NA,6.5,65,NA,6,96.644444,NA,NA,*07:01,*15:01,75.49466194,past
S-181218-03664,pt179,58.29705681,Female,SP-MS,prog-MS,19.6386037,32.33798966,Untreated,W,validation,11,NA,0.716173325,8.34664209,NA,NA,48.15014694,NA,6.5,53,NA,5,153.488888,NA,NA,*07:01,*15:01,-12.29476989,past
S-181218-03665,pt179,58.41204654,Female,SP-MS,prog-MS,19.75359343,32.33798966,rituximab,W,validation,11,NA,0.716173325,8.34664209,NA,NA,48.15014694,NA,6.5,53,NA,5,153.488888,NA,NA,*07:01,*15:01,-4.644641596,past
S-181218-03666,pt179,58.55167693,Female,SP-MS,prog-MS,19.89322382,32.29239452,rituximab,W,validation,10.4,NA,NA,NA,0,NA,49.82392651,NA,6.5,60,NA,5,NA,NA,NA,*07:01,*15:01,-52.06017682,past
S-181218-03667,pt179,59.31279945,Female,SP-MS,prog-MS,20.65434634,30.43587805,rituximab,W,validation,11.45,44,0.751425176,8.212297138,0,-0.129476465,49.23029811,0.816490377,6.5,57,13,5,142.088888,11.54386947,NA,*07:01,*15:01,211.5946464,past
S-181218-03668,pt179,62.63655031,Female,SP-MS,prog-MS,23.97809719,29.30713026,Untreated,W,validation,44.1,38,0.722830694,7.955425089,NA,0.698325773,56.83696231,1.901778141,6.5,42,14,6,203.57222,11.63107628,NA,*07:01,*15:01,-64.67167666,past
S-181218-03672,pt180,60.40793977,Female,PP-MS,prog-MS,8.878850103,23.7259365,Untreated,W,training,7.3,41,0.700661471,9.589598388,0,0.942526267,43.77330132,1.434834979,6,68,NA,4,53.188888,-3.650814037,NA,*04:02,*15:01,259.8138262,no
S-181218-03673,pt180,62.26694045,Female,PP-MS,prog-MS,10.73785079,24.49751167,Untreated,W,training,10.7,30,0.689470386,9.847869129,NA,1.716057213,52.32381049,2.523144573,6.5,52,15,5,151.677776,-2.126781385,NA,*04:02,*15:01,73.75361878,no
S-181218-03674,pt180,63.22518823,Female,PP-MS,prog-MS,11.69609856,25.07619305,Untreated,W,training,16.6,33,0.688423717,9.855399642,NA,1.579063993,55.41141988,2.56702929,6.5,52,15,5,155.611108,2.205225081,NA,*04:02,*15:01,405.8710105,no
S-181218-03671,pt180,64.26009582,Female,PP-MS,prog-MS,12.73100616,25.61629567,Untreated,W,training,13.1,35,0.685747927,9.840174946,NA,1.523431867,54.55286993,2.476232729,6.5,51,15,5,156.82222,1.85201732,NA,*04:02,*15:01,452.7769152,no
S-181218-03675,pt180,65.67830253,Female,PP-MS,prog-MS,14.14921287,24.88329926,Untreated,W,training,12.4,27,NA,NA,NA,NA,57.38106178,NA,6.5,42,14,5,206.266664,NA,NA,*04:02,*15:01,654.7227214,no
S-181218-03676,pt180,66.23682409,Female,PP-MS,prog-MS,14.70773443,25.61629567,hydroxychloroquine,W,training,35.45,22,0.673882039,9.92544472,NA,2.413062295,65.92467737,3.806966789,6.5,38,14,6,246.866664,5.142742371,61.64265216,*04:02,*15:01,808.816784,no
S-181218-03677,pt181,50.97604381,Female,RR-MS,RR-MS,14.15195072,19.10525691,glatiramer acetate (Copaxone),W,validation,3.5,41,NA,NA,0,NA,2.174906407,NA,0,94,NA,1,8.5,NA,NA,*01:01,*11,321.8000883,past
S-181218-03679,pt182,46.15195072,Male,PP-MS,prog-MS,1.859000684,23.65220722,Untreated,W,training,4.6,53,0.765002362,9.342771159,0,-0.842147338,23.36458679,-1.111113931,3,84,NA,0,17.25,-7.848196321,NA,*04:01,*15:01,167.2659653,past
S-181218-03680,pt182,47.95345654,Male,PP-MS,prog-MS,3.660506502,25.28009193,Untreated,W,training,4.8,54,0.75345917,9.65515439,NA,-0.68579083,22.30594401,-1.034434058,2.5,73,4,2,NA,-10.32712531,NA,*04:01,*15:01,187.7051913,past
S-181218-03681,pt182,48.95003422,Male,PP-MS,prog-MS,4.657084189,25.45526681,Untreated,W,training,4.55,53,0.752313833,9.766693701,NA,-0.613160469,22.70954367,-0.952776538,2.5,73,3,2,38.0000001,-10.58327368,NA,*04:01,*15:01,177.4558933,past
S-181218-03682,pt182,50.04243669,Male,PP-MS,prog-MS,5.749486653,24.19483546,Untreated,W,training,6.85,48,0.747564442,9.653037037,NA,-0.267645659,25.54256775,-0.517370835,2.5,71,4,2,NA,-10.88878169,NA,*04:01,*15:01,387.9979828,past
S-181218-03683,pt182,51.65229295,Male,PP-MS,prog-MS,7.359342916,21.92511398,ocrelizumab (Ocrevus),W,training,12.25,45,0.653546862,9.258749511,NA,1.584949479,45.37834082,2.056074246,6,58,12,4,115.883332,-7.881315622,64.75133004,*04:01,*15:01,456.5272062,past
S-181218-03684,pt183,46.02874743,Female,RR-MS,RR-MS,20.7063655,22.28254008,Untreated,W,validation,3.9,50,0.776258579,6.794586581,0,-0.889403405,12.41473918,-1.713770581,2,95,NA,0,20.97222,-18.36878684,NA,*11:01,*15:01,95.61314272,no
S-181218-03685,pt184,64.70910335,Female,RR-MS,RR-MS,0.38329911,40.625,Untreated,W,training,4.65,50,NA,NA,0,NA,9.122127532,NA,1,93,NA,0,7.2,NA,NA,*04,*07:01,-25.34220153,past
S-181218-03686,pt184,67.8329911,Female,RR-MS,RR-MS,3.507186858,31.77869227,Untreated,W,training,5.35,42,0.7641241,8.935771939,0,-0.254729458,19.57445247,-0.813414047,2,80,3,0,42,-16.97422309,NA,*04,*07:01,131.4147522,past
S-181218-03687,pt185,62.4366872,Male,PP-MS,prog-MS,14.89664613,24.9691358,Untreated,W,training,101.4,45,0.773575362,7.561641746,0,-0.581176346,60.63479667,1.024120655,6.5,62,NA,6,199.499988,27.05144706,NA,*07:01,*16:01,17.84633214,past
S-181218-03688,pt185,62.87474333,Male,PP-MS,prog-MS,15.33470226,22.77777778,Untreated,W,training,120.1,43,0.776913255,8.14786713,0,-0.537493036,63.78114516,1.222533622,6.5,56,NA,7,NA,29.8009921,NA,*07:01,*16:01,247.0738464,past
S-181218-03689,pt185,64.23819302,Male,PP-MS,prog-MS,16.69815195,24.50617284,Untreated,W,training,136.5,44,0.723943553,7.871311203,NA,0.366477856,64.35489278,2.01006813,7,60,17,7,NA,22.16339371,NA,*07:01,*16:01,378.0115716,past
S-181218-03690,pt185,65.25393566,Male,PP-MS,prog-MS,17.71389459,26.38888889,Untreated,W,training,179.9,34,0.719446232,7.777792626,NA,0.967247298,68.11583951,2.707232732,7.5,56,18,7,183.011108,20.46716721,NA,*07:01,*16:01,221.9124656,past
S-181218-03691,pt185,66.32717317,Male,PP-MS,prog-MS,18.7871321,25.52469136,Untreated,W,training,179.9,41,0.721850954,8.112527763,NA,0.560124701,69.33602831,2.428577202,7.5,50,18,8,NA,25.38551105,NA,*07:01,*16:01,357.8337562,past
S-181218-03693,pt186,64.48733744,Male,PP-MS,prog-MS,13.06502396,29.974665,Untreated,W,validation,12.3,42,NA,NA,NA,NA,43.11289875,NA,6,74,NA,4,NA,NA,NA,*03,*15:01,2806.852504,past
S-181218-03694,pt186,65.7522245,Male,PP-MS,prog-MS,14.32991102,29.11999023,Untreated,W,validation,20.05,45,0.756502119,8.181720455,NA,-0.273059585,47.05407801,0.584188498,6,61,13,5,NA,10.67190672,NA,*03,*15:01,1963.385554,past
S-181218-03695,pt186,66.7871321,Male,PP-MS,prog-MS,15.36481862,28.69265285,Untreated,W,validation,18.9,44,0.748313465,8.557374981,NA,-0.073320156,47.77934508,0.788974282,6,65,13,4,114.02222,9.582812754,NA,*03,*15:01,668.1961653,past
S-181218-03696,pt186,67.68788501,Male,PP-MS,prog-MS,16.26557153,30.67671927,Untreated,W,validation,20.3,47,0.752324417,8.262816938,NA,-0.301587061,48.24485254,0.621494898,6,63,13,5,NA,12.12181457,NA,*03,*15:01,457.377729,past
S-181218-03697,pt187,65.80698152,Female,RR-MS,RR-MS,17.62354552,NA,Untreated,AA,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*05:05,*13:03,-144.5673411,past
S-181218-03701,pt188,47.61122519,Male,RR-MS,RR-MS,0.227241615,39.26454882,Untreated,W,validation,3.7,52,0.790867609,7.010311867,0,-1.25697057,10.64304374,-2.113096085,1.5,95,NA,0,5.45,-16.80163454,NA,*13:03,*15:01,525.6017235,past
S-181218-03702,pt188,49.7522245,Male,RR-MS,RR-MS,2.368240931,39.72648469,interferon beta-1a (Rebif),W,validation,4.1,53,0.78962506,7.087573706,0,-1.286507319,10.73105276,-2.133339063,1.5,89,2,1,14.477776,-16.44532432,NA,*13:03,*15:01,338.5993181,past
S-181218-03703,pt188,50.58179329,Male,RR-MS,RR-MS,3.197809719,37.29362245,fingolimod (Gilenya),W,validation,4.5,51,0.786094609,7.936660155,0.693147181,-1.118872637,16.56813676,-1.692630757,2,80,2,1,27.877776,-12.1309734,NA,*13:03,*15:01,426.0168369,past
S-181218-03704,pt188,51.40588638,Male,RR-MS,RR-MS,4.021902806,38.52545143,natalizumab (Tysabri),W,validation,4.2,50,0.779326963,7.940583827,0,-0.944777802,16.11359146,-1.570014192,2,84,2,1,22.833332,-14.16693348,NA,*13:03,*15:01,1021.293486,past
S-181218-03705,pt188,53.09240246,Male,RR-MS,RR-MS,5.708418891,39.01818303,natalizumab (Tysabri),W,validation,4.05,52,0.777304746,8.426830751,0,-1.012204804,24.88611201,-1.175481938,3.5,79,6,2,58.95555412,-4.781930332,60.20485646,*13:03,*15:01,254.3045296,past
S-181218-03706,pt188,53.62354552,Male,RR-MS,RR-MS,6.239561944,38.89500013,natalizumab (Tysabri) & Hydroxychloroquine,W,validation,4.45,52,0.773428917,8.436416881,NA,-0.942258638,25.14793146,-1.103365464,3,75,5,2,54.71110812,-5.155476655,56.47425123,*13:03,*15:01,75.35250913,past
S-181218-03709,pt189,39.44421629,Female,RR-MS,RR-MS,7.838466804,26.81359045,Untreated,W,training,3.35,52,0.787705467,7.441906728,0,-1.199904145,6.912243858,-2.257076321,1,98,NA,0,8,-21.05080527,NA,*11:01,*16:01,301.4461867,current
S-181218-03714,pt190,65.80150582,Male,PP-MS,prog-MS,10.0698152,30.64000119,Untreated,W,training,11,48,0.76277737,6.91770561,NA,-0.542189757,39.35107372,-0.037573432,6,70,NA,3,64.37222,5.413583976,NA,*08:01,*12,-79.50324564,past
S-181218-03715,pt190,67.6605065,Male,PP-MS,prog-MS,11.92881588,30.96539162,Untreated,W,training,5.6,43,0.765587495,8.267962305,NA,-0.333099736,40.99482937,0.222281092,5.5,63,7,2,128.30555,5.158041184,NA,*08:01,*12,-24.05692187,past
S-181218-03716,pt190,68.61875428,Male,PP-MS,prog-MS,12.88706366,30.81608887,Untreated,W,training,5.7,43,0.763593967,8.07059354,NA,-0.29712301,40.87511892,0.246294317,5.5,72,6,2,84.916664,4.711531111,NA,*08:01,*12,-30.11217399,past
S-181218-03717,pt190,69.67282683,Male,PP-MS,prog-MS,13.94113621,30.21887784,Untreated,W,training,5.65,38,0.764955252,8.051659557,NA,-0.061886118,40.85635141,0.442589346,5.5,59,6,2,109.505552,2.555956398,NA,*08:01,*12,159.5672279,past
S-181218-03718,pt191,46.57905544,Male,RR-MS,RR-MS,20.08761123,26.45016603,Untreated,W,training,3.45,46,NA,NA,1.098612289,NA,20.36913871,NA,2.5,82,NA,2,53.65,NA,65.24466262,*10:01:01,*12,976.1354052,no
S-181218-03721,pt192,45.45927447,Male,SP-MS,prog-MS,11.26078029,23.41198376,Untreated,W,validation,6.2,NA,0.763217964,8.517793011,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*11:04,NA,-125.2385338,past
S-181218-03722,pt193,65.14442163,Female,PP-MS,prog-MS,7.603011636,26.16490057,Untreated,W,validation,13.1,49,0.761110932,8.349247801,0,-0.564076682,48.43401485,0.411108367,6.5,77,NA,5,74,14.69533805,NA,*04:01,NA,268.5041921,past
S-181218-03723,pt193,66.98425736,Female,PP-MS,prog-MS,9.442847365,27.072144,Untreated,W,validation,22.45,43,0.750564458,7.497207223,NA,-0.061982556,50.75099953,0.951280875,6.5,68,12,6,NA,12.45148053,NA,*04:01,NA,264.8249292,past
S-181218-03724,pt193,67.92334018,Female,PP-MS,prog-MS,10.38193018,26.45521846,Untreated,W,validation,23.85,47,0.747826901,7.498869734,NA,-0.220421459,50.9650093,0.82942465,6.5,67,14,6,81.8,14.10469223,NA,*04:01,NA,136.903122,past
S-181218-03726,pt193,68.90075291,Female,PP-MS,prog-MS,11.35934292,26.23748004,Untreated,W,validation,22.15,49,0.74680116,7.519692404,NA,-0.305831626,51.28460413,0.774236408,6.5,65,14,6,NA,15.20012226,NA,*04:01,NA,522.4541171,past
S-181218-03728,pt193,70.29979466,Female,PP-MS,prog-MS,12.75838467,25.83829293,Untreated,W,validation,18.25,36,0.73489309,7.546446274,NA,0.58456005,51.89904293,1.552476239,6.5,58,17,5,128.888888,7.726563759,72.07031777,*04:01,NA,569.9734103,past
S-181218-03729,pt193,70.81724846,Female,PP-MS,prog-MS,13.27583847,25.94716214,Untreated,W,validation,25.1,43,0.73900855,7.61085279,NA,0.14656417,50.19575827,1.097609707,6.5,58,17,6,138.427776,10.00187592,70.7304782,*04:01,NA,571.437913,past
S-181218-03730,pt194,36.50376454,Female,RR-MS,RR-MS,18.12731006,32.19591837,Untreated,AA,training,4.4,62,NA,NA,1.098612289,NA,18.7111739,NA,2,81,NA,2,31.9,NA,NA,*15:03,*15:03,185.3966367,past
S-181218-03731,pt194,40.39425051,Female,RR-MS,RR-MS,22.01779603,29.32244898,Untreated,AA,training,5.15,51,NA,NA,0,NA,27.5746545,NA,3,70,9,2,80.138886,NA,51.75522705,*15:03,*15:03,310.1782048,past
S-181218-03732,pt194,42.32991102,Female,RR-MS,RR-MS,23.95345654,34.1877551,pioglitazone,AA,training,4.8,59,0.790400787,9.496946866,NA,-1.612271095,41.11722928,-0.844086005,5.5,59,12,2,150.733328,16.89997301,49.58252295,*15:03,*15:03,212.1990106,past
S-181218-03733,pt195,37.19370294,Male,RR-MS,RR-MS,0.843258042,32.88354721,Untreated,W,validation,4.6,76,0.798563284,7.289610521,1.098612289,-2.642910248,3.393329351,-3.648061089,0,100,NA,0,NA,-11.46197206,NA,*11,*15:01,229.7656823,current
S-181218-03734,pt196,44.05749487,Female,RR-MS,RR-MS,5.14715948,17.4568538,Untreated,AA,validation,6.45,32,NA,NA,NA,NA,26.21627556,NA,2.5,72,NA,2,70.905552,NA,NA,*03:01,*07:01:01,55.85390526,no
S-181218-03735,pt196,49.7303217,Female,RR-MS,RR-MS,10.81998631,18.57729961,alemtuzumab (Lemtrada),AA,validation,15.55,32,0.731275318,9.155356064,NA,0.857692065,46.6819244,1.513254826,6,61,13,4,171.711108,0.028412377,56.86443988,*03:01,*07:01:01,251.9738944,no
S-181218-03739,pt197,53.94934976,Female,SP-MS,prog-MS,2.069815195,25.5805205,Untreated,AA,validation,8.25,NA,0.757863061,10.71654883,0.693147181,NA,NA,NA,6.5,62,NA,5,NA,NA,NA,*13:02:01,*13,2359.131408,past
S-181218-03740,pt198,46.46680356,Female,PP-MS,prog-MS,8.202600958,23.93898977,Untreated,W,training,14.75,43,0.783141894,8.090402297,0,-0.649899805,49.9592672,0.417567478,6.5,55,NA,5,205.799998,17.00017674,NA,*03:01,*13:02,187.904604,past
S-181218-03744,pt199,43.51813826,Female,PP-MS,prog-MS,16.24093087,19.97547565,Untreated,W,training,5.2,52,0.807076133,8.204671829,0.693147181,-1.549481952,18.49215857,-1.954790935,2.5,86,NA,1,25.2,-6.295451663,NA,*11:04,NA,31.79563387,past
S-181218-03745,pt199,45.35797399,Female,PP-MS,prog-MS,18.0807666,19.85680946,Untreated,W,training,4.75,58,0.810656266,6.177944114,NA,-1.925856177,22.35963217,-2.071541539,3,79,5,2,NA,0.990869836,NA,*11:04,NA,31.16407193,past
S-181218-03746,pt200,57.14715948,Female,PP-MS,prog-MS,31.64134155,24.15478289,Untreated,W,training,8,33,0.741301717,9.249945627,0,0.624787288,48.73345923,1.423438171,6,62,NA,4,192.3222121,4.195570314,NA,*03:01,*04:01,-162.8168724,past
S-181218-03747,pt200,58.98699521,Female,PP-MS,prog-MS,33.48117728,25.11616728,Untreated,W,training,6.95,40,0.744981815,9.457903328,NA,0.194648283,47.42683768,0.995556093,6,51,14,4,NA,6.796176564,NA,*03:01,*04:01,-89.42144596,past
S-181218-03748,pt200,60.04106776,Female,PP-MS,prog-MS,34.53524983,25.15622496,Untreated,W,training,7.8,38,0.740566701,9.460164802,NA,0.378248268,47.89373982,1.173523146,6,62,15,4,196.099988,5.595322566,NA,*03:01,*04:01,-141.0760426,past
S-181218-03749,pt200,61.13347023,Female,PP-MS,prog-MS,35.62765229,25.55680179,Untreated,W,training,9.2,35,0.739077421,9.243968553,NA,0.561007158,49.24823185,1.39642383,6,54,15,4,NA,5.289698664,NA,*03:01,*04:01,-118.4438973,past
S-181218-03750,pt201,30.2587269,Female,RR-MS,RR-MS,0.147843943,25.20920136,Untreated,W,training,4.45,40,0.803069233,7.795234929,0,-0.85364155,9.588582587,-1.829100152,1,94,NA,1,4.25,-21.51979124,NA,*04,NA,9667.919946,NA
S-181218-03751,pt202,53.68651608,Male,PP-MS,prog-MS,24.93086927,29.85894323,Untreated,W,training,5.7,46,0.761635891,9.073489189,NA,-0.417668285,42.95927458,0.252375073,6.5,56,NA,4,NA,7.890676633,NA,*01,*11:04,-84.66570667,past
S-181218-03752,pt202,55.41136208,Male,PP-MS,prog-MS,26.65571526,28.29334541,Untreated,W,training,6.15,36,0.760827418,8.739536423,NA,0.116529393,46.09182989,0.861404091,6.5,51,13,4,NA,6.170772633,NA,*01,*11:04,-72.5119025,past
S-181218-03753,pt203,50.02600958,Male,PP-MS,prog-MS,11.81382615,33.25259516,Untreated,W,validation,34.65,66,0.801458463,10.20385137,0,-2.175551498,53.1264904,-0.698926333,6.5,57,NA,6,154.2000001,34.02587043,NA,*03:01,*15:01,-62.70616367,no
S-181218-03754,pt203,51.86584531,Male,PP-MS,prog-MS,13.65366188,40.1384083,Untreated,W,validation,52.1,66,0.777667613,8.494333897,NA,-1.74620368,57.327023,-0.122905849,6.5,54,17,6,NA,34.32636209,NA,*03:01,*15:01,-30.83180509,no
S-181218-03755,pt203,52.8788501,Male,PP-MS,prog-MS,14.66666667,35.19031142,Untreated,W,validation,90.9,65,0.774272475,8.529516941,NA,-1.632971695,60.82280226,0.151795153,6.5,61,16,6,156.13333,36.79358278,NA,*03:01,*15:01,-8.33394883,no
S-181218-03756,pt204,48.77207392,Male,SP-MS,prog-MS,20.5284052,25.46736993,Untreated,W,training,22.15,NA,0.781470504,10.11285667,0,NA,47.99006008,NA,6,60,NA,4,NA,NA,61.64006259,*13:03,NA,36.92979632,no
S-181218-03757,pt204,49.39904175,Male,SP-MS,prog-MS,21.15537303,26.37246029,Untreated,W,training,17.1,29,0.795007603,9.011401509,0,-0.136587135,49.29361846,0.813783526,6,56,NA,4,134.15,11.67178058,NA,*13:03,NA,105.9570674,no
S-181218-03758,pt204,49.51403149,Male,SP-MS,prog-MS,21.27036277,25.5904924,rituximab,W,training,NA,NA,0.775392157,10.1793374,0,NA,NA,NA,6,56,NA,4,NA,NA,67.1580126,*13:03,NA,893.1569972,no
S-181218-03759,pt204,49.63449692,Male,SP-MS,prog-MS,21.3908282,24.78425752,rituximab,W,training,NA,NA,0.772825913,10.09092102,0,NA,NA,NA,6,56,NA,4,NA,NA,68.15001963,*13:03,NA,11.80377625,no
S-181218-03760,pt204,50.41478439,Male,SP-MS,prog-MS,22.17111567,25.32174744,rituximab,W,training,15.9,17,0.791862222,9.136263169,0,0.543705639,51.64195122,1.504998016,6,47,13,4,236.249996,7.840578804,NA,*13:03,NA,134.8817442,no
S-181218-03761,pt205,64.85147159,Female,PP-MS,prog-MS,6.223134839,31.85400638,Untreated,W,validation,4.8,50,0.733643674,8.421342866,0,-0.120342338,18.09906904,-0.77658517,2,80,NA,2,36.805552,-19.67033072,NA,*03:01,*11,-57.13664686,past
S-181218-03762,pt205,66.72963723,Female,PP-MS,prog-MS,8.101300479,31.57252768,Untreated,W,validation,5.65,50,0.728361011,8.539932678,NA,-0.025007374,23.78059217,-0.404503226,3,74,9,2,NA,-14.85479607,NA,*03:01,*11,-99.24479048,past
S-181218-03763,pt205,67.72621492,Female,PP-MS,prog-MS,9.097878166,31.43178833,Untreated,W,validation,7,59,0.725240202,8.583355394,NA,-0.436333497,26.24417101,-0.622749853,3,71,11,4,82.888888,-8.654878869,NA,*03:01,*11,-105.5303967,past
S-181218-03764,pt205,68.75838467,Female,PP-MS,prog-MS,10.13004791,31.6194408,Untreated,W,validation,5.75,57,0.727750541,8.726156679,NA,-0.377715517,25.32862858,-0.620671442,3,67,10,2,NA,-10.10288592,NA,*03:01,*11,-281.1172127,past
S-181218-03766,pt206,52.55578371,Male,PP-MS,prog-MS,5.242984257,30.14634203,Untreated,W,validation,14.15,50,0.785103662,8.828054537,NA,-1.049028516,46.99059485,-0.06977154,6,64,NA,4,117.777772,17.65704585,NA,*04:01,*07:01,217.7771608,past
S-181218-03767,pt206,54.37645448,Male,PP-MS,prog-MS,7.063655031,31.68442071,Untreated,W,validation,30.3,25,0.776912352,8.065579427,NA,0.397816505,53.82946454,1.495140991,6.5,59,13,5,NA,11.35329647,NA,*04:01,*07:01,116.6208344,past
S-181218-03768,pt206,55.40862423,Male,PP-MS,prog-MS,8.095824778,30.91538137,Untreated,W,validation,59.75,23,0.772654939,8.051340933,NA,0.578570497,56.51773137,1.784941746,6.5,60,14,6,157.599996,12.39965914,NA,*04:01,*07:01,26.5393498,past
S-181218-03769,pt206,56.48459959,Male,PP-MS,prog-MS,9.171800137,27.80846245,Untreated,W,validation,55.2,43,0.767249595,8.192293731,NA,-0.36309526,56.53957453,0.996422518,6.5,58,16,6,NA,20.97525488,NA,*04:01,*07:01,476.2480538,past
S-181218-03770,pt206,57.69472964,Male,PP-MS,prog-MS,10.38193018,26.02429118,Untreated,W,validation,179.9,27,0.708978052,7.68017564,NA,1.519889207,68.46920005,3.188825056,7,46,18,7,312.566652,15.80052769,61.29320731,*04:01,*07:01,762.1488399,past
S-181218-03771,pt206,58.19028063,Male,PP-MS,prog-MS,10.87748118,26.54723793,pioglitazone,W,validation,179.9,29,0.759397566,8.648922962,NA,0.506058744,65.51982181,2.187014378,7,47,21,7,312.488876,22.06042023,62.27818034,*04:01,*07:01,537.0894082,past
S-181218-03772,pt207,61.09240246,Male,PP-MS,prog-MS,7.871321013,29.33848436,Untreated,W,validation,11.75,44,0.733042995,9.78992684,0,0.202262388,48.04475075,1.03371341,6,69,NA,4,96.1111101,7.344925846,NA,*03:01,*03:01,256.1073069,current
S-181218-03773,pt207,62.91307324,Male,PP-MS,prog-MS,9.691991786,28.49864226,Untreated,W,validation,179.9,34,0.725830449,9.295416544,NA,0.852032851,65.8151902,2.492321643,7,58,17,7,NA,19.21308444,NA,*03:01,*03:01,1665.927586,current
S-181218-03775,pt208,50.17932923,Female,PP-MS,prog-MS,24.37508556,18.48637835,Untreated,W,training,3.65,58,NA,NA,NA,NA,12.41033206,NA,2,90,NA,0,14.36111,NA,NA,*15:01,*15:01,48.23409981,past
S-181218-03776,pt209,18.00958248,Female,RR-MS,RR-MS,0.180698152,25.91463415,Untreated,AA,training,3.4,62,0.828930887,8.006700845,0,-2.463496864,10.82314437,-3.115579092,2,95,NA,0,NA,-5.661883603,NA,*12,*15:03,924.9198979,no
S-181218-03777,pt210,61.15811088,Female,SP-MS,prog-MS,23.59206023,21.58557137,Untreated,W,training,32.1,NA,0.767984005,9.16440114,0,NA,50.80186444,NA,6.5,68,NA,6,96.144442,NA,NA,*05,*07,-66.53505563,past
S-181218-03778,pt210,62.13004791,Female,SP-MS,prog-MS,24.56399726,21.97999211,Untreated,W,training,29.75,44,0.752731946,9.192481854,NA,-0.153059433,51.55114293,0.916050064,6.5,63,NA,6,128.733328,14.07893348,NA,*05,*07,91.18799284,past
S-181218-03779,pt210,62.36550308,Female,SP-MS,prog-MS,24.79945243,22.41026928,Untreated,W,training,38.75,NA,0.763506329,8.948845729,NA,NA,NA,NA,6.5,65,NA,5,NA,NA,NA,*05,*07,132.1436165,past
S-181218-03780,pt210,63.05270363,Female,SP-MS,prog-MS,25.48665298,24.27480369,Untreated,W,training,34.95,44,0.758321887,9.245514447,0,-0.25393977,55.42371728,1.03057964,7,63,NA,6,125.611108,18.86786848,NA,*05,*07,241.8217102,past
S-181218-03781,pt210,66.65845311,Female,SP-MS,prog-MS,29.09240246,36.71698519,Untreated,W,training,47.8,45,0.760137748,9.07932011,NA,-0.338670918,60.06650453,1.198254802,7,54,19,6,NA,24.28032296,NA,*05,*07,307.5412474,past
S-181218-03782,pt210,68.07118412,Female,SP-MS,prog-MS,30.50513347,40.03673095,Untreated,W,training,62.6,47,0.773092776,9.419060403,NA,-0.676388703,57.20263047,0.767801092,6.5,59,17,6,182.333332,24.48415562,43.5959093,*05,*07,294.4170096,past
S-181218-03783,pt211,46.71868583,Female,PP-MS,prog-MS,28.21629021,23.02040816,interferon beta-1a (Rebif),W,training,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04,*15:01,-96.7256617,past
S-181218-03784,pt211,48.7118412,Female,PP-MS,prog-MS,30.20944559,23.73877551,Untreated,W,training,4.15,51,0.792361826,6.763884909,NA,-1.231975614,32.25559573,-0.980841648,4.5,70,6,2,NA,4.583872271,NA,*04,*15:01,-148.8795975,past
S-181218-03785,pt211,49.65092402,Female,PP-MS,prog-MS,31.14852841,23.24897959,Untreated,W,training,4.15,48,0.794257393,7.064759028,NA,-1.110302254,31.421785,-0.921685016,4.5,74,6,2,74.34999601,2.64482456,NA,*04,*15:01,-96.77362299,past
S-181218-03786,pt211,50.66666667,Female,PP-MS,prog-MS,32.16427105,22.6679639,Untreated,W,training,3.95,51,0.793681363,7.063048163,NA,-1.255788984,31.28057571,-1.05094507,4.5,69,6,2,82.649998,3.825164334,NA,*04,*15:01,181.622713,past
S-181218-03787,pt211,52.04654346,Female,PP-MS,prog-MS,33.54414784,21.74693878,Untreated,W,training,4.15,44,0.784511127,7.317876199,NA,-0.726570763,40.94909537,-0.110019209,5.5,55,10,2,139.499996,8.686456278,55.01023252,*04,*15:01,25.42661498,past
S-181218-03788,pt211,52.65982204,Female,PP-MS,prog-MS,34.15742642,23.15102041,Untreated,W,training,4.3,50,0.783386949,8.333510709,NA,-1.018047405,40.64042535,-0.370311084,5.5,58,10,2,138.622218,11.02545509,51.59834395,*04,*15:01,232.5241291,past
S-181218-03794,pt212,31.39767283,Female,RR-MS,RR-MS,0.509240246,NA,Untreated,W,training,4.1,59,0.761120485,7.457032089,0,-1.083856441,2.959421518,-2.363013431,0,97,NA,0,2,-26.05776316,NA,*07,*07,71.28588443,NA
S-181218-03795,pt213,59.67419576,Female,SP-MS,prog-MS,21.47296372,23.17176871,fingolimod (Gilenya),AA,training,6.35,NA,0.714766,10.34338629,0,NA,42.84952997,NA,5,63,NA,2,111.44444,NA,NA,*01:02,*14,5.657243913,no
S-181218-03796,pt213,60.47364819,Female,SP-MS,prog-MS,22.27241615,24.09297052,Untreated,AA,training,6.35,25,0.728984359,10.23469596,0,1.262761609,40.40398432,1.5301245,5,63,NA,2,122.14444,-9.929033544,NA,*01:02,*14,9.558810804,no
S-181218-03797,pt213,60.58863792,Female,SP-MS,prog-MS,22.38740589,25.19742883,Untreated,AA,training,6.35,25,0.698666589,10.42302512,0,1.809899201,NA,NA,5,60,NA,2,NA,NA,66.18993519,*01:02,*14,81.94192423,no
S-181218-03798,pt213,60.72826831,Female,SP-MS,prog-MS,22.52703628,25.19742883,Untreated,AA,training,7.8,18,0.697713983,10.39845815,0,2.190815806,NA,NA,5,58,NA,2,NA,NA,70.30527865,*01:02,*14,38.49250703,no
S-181218-03799,pt213,61.48939083,Female,SP-MS,prog-MS,23.2881588,24.9310495,Untreated,AA,training,6.6,21,0.712136988,10.33139885,0,1.774645054,38.28280814,1.850300368,5,54,7,2,126.755552,-16.69997458,64.30548996,*01:02,*14,104.0864709,no
S-181218-03801,pt214,54.38193018,Male,PP-MS,prog-MS,0.728268309,31.66395353,Untreated,W,training,5.5,41,NA,NA,0,NA,13.79078529,NA,1.5,90,NA,1,11.4,NA,NA,*01,*03,114.9038409,current
S-181218-03804,pt215,60,Male,PP-MS,prog-MS,5.415468857,28.44399811,Untreated,W,validation,5.2,44,0.752348779,10.02020335,0.693147181,-0.146144509,26.59512021,-0.361363801,3,74,NA,2,48.344444,-10.93990192,NA,*13,*15:01,242.1909749,past
S-181218-03805,pt215,61.85900068,Male,PP-MS,prog-MS,7.274469541,27.52835539,Untreated,W,validation,4.3,57,0.754872698,9.01833205,NA,-0.867182642,28.72200193,-0.856634861,3,70,5,2,NA,-2.263369501,NA,*13,*15:01,321.3246597,past
S-181218-03803,pt215,62.89117043,Male,PP-MS,prog-MS,8.306639288,26.87854442,Untreated,W,validation,4.15,56,0.754402042,8.898092346,NA,-0.806728089,26.94313297,-0.897407717,3,68,5,2,94.388888,-4.591385846,NA,*13,*15:01,224.1326858,past
S-181218-03806,pt215,63.94798084,Male,PP-MS,prog-MS,9.363449692,27.70557656,Untreated,W,validation,4.3,44,0.750906174,8.826147399,NA,-0.12011016,27.54327832,-0.290779168,3,70,3,2,NA,-10.22823047,NA,*13,*15:01,268.7469484,past
S-181218-03807,pt216,43.52087611,Female,SP-MS,prog-MS,26.93497604,19.90817264,Untreated,W,training,56.35,NA,0.72553849,9.236982303,0,NA,62.21916839,NA,6.5,52,NA,6,201.305544,NA,61.49830106,*11,*15:01,21.00608357,past
S-181218-03808,pt216,44.32032854,Female,SP-MS,prog-MS,27.73442847,17.80933968,Untreated,W,training,67.5,34,0.739746208,8.176391597,0,0.600898454,60.87733354,2.027831216,6.5,53,NA,6,206.005544,16.55644219,NA,*11,*15:01,87.67025569,past
S-181218-03809,pt216,44.43531828,Female,SP-MS,prog-MS,27.84941821,17.80933968,rituximab,W,training,NA,NA,0.729746091,10.22575219,0,NA,NA,NA,7,53,NA,5,NA,NA,55.39630328,*11,*15:01,78.2687039,past
S-181218-03810,pt216,44.55578371,Female,SP-MS,prog-MS,27.96988364,18.29268293,rituximab,W,training,NA,NA,0.726546078,9.388402872,0,NA,NA,NA,7,51,NA,5,NA,NA,56.34715687,*11,*15:01,161.5140566,past
S-181218-03812,pt217,59.92881588,Female,PP-MS,prog-MS,15.50992471,20.4237159,Untreated,W,validation,5.65,38,0.773125246,9.601841773,0,-0.209328059,30.23555991,-0.227159361,4.5,78,NA,2,32.45,-6.725525615,NA,*13:03,NA,-96.56781339,past
S-181218-03813,pt217,61.71115674,Female,PP-MS,prog-MS,17.29226557,20.00457247,Untreated,W,validation,5.45,35,0.767611166,9.399803037,NA,0.046065441,34.64410276,0.213685816,4.5,62,9,2,NA,-4.636885329,NA,*13:03,NA,76.05227347,past
S-181218-03814,pt217,62.65023956,Female,PP-MS,prog-MS,18.23134839,20.69044353,Untreated,W,validation,5.4,27,0.768529462,9.487441665,NA,0.445179058,37.23771338,0.681726898,5,70,8,2,53.2000001,-5.668679056,NA,*13:03,NA,16.12229265,past
S-181218-03815,pt217,63.68514716,Female,PP-MS,prog-MS,19.26625599,21.33821064,Untreated,W,validation,5.6,33,0.760939495,9.401539077,NA,0.270388974,41.50873842,0.754766699,6,63,10,4,NA,0.190076149,NA,*13:03,NA,-115.0860039,past
S-181218-03816,pt217,65.60164271,Female,PP-MS,prog-MS,21.18275154,20.95717116,ocrelizumab (Ocrevus),W,validation,5.3,30,0.765248457,9.571783928,NA,0.348508368,43.86881366,0.941627013,6,61,9,4,155.199996,1.840542951,NA,*13:03,NA,-8.483847574,past
S-181218-03818,pt218,59.88227242,Male,SP-MS,prog-MS,25.54962355,27.64565993,Untreated,W,training,71.8,NA,0.744836591,8.803574418,0,NA,49.15473864,NA,6.5,64,NA,6,126.366664,NA,NA,*08,*11:04,370.4533158,past
S-181218-03819,pt218,60.66255989,Male,SP-MS,prog-MS,26.32991102,29.00037618,Untreated,W,training,78.55,48,0.759227072,8.122371243,0,-0.478118372,52.96312736,0.71607169,6.5,56,NA,6,169.366664,18.44363623,NA,*08,*11:04,271.3650716,past
S-181218-03817,pt218,60.77754962,Male,SP-MS,prog-MS,26.44490075,27.91836735,Untreated,W,training,78.55,48,0.733989489,8.969669104,0,-0.022661707,NA,NA,6.5,54,NA,5,NA,NA,60.99093314,*08,*11:04,356.4012497,past
S-181218-03820,pt218,60.91718001,Male,SP-MS,prog-MS,26.58453114,27.82040816,Untreated,W,training,172.85,49,0.757454604,8.277157772,0,-0.498091799,NA,NA,6.5,54,16,5,NA,NA,NA,*08,*11:04,431.1408212,past
S-181218-03821,pt218,61.65913758,Male,SP-MS,prog-MS,27.32648871,27.00373456,Untreated,W,training,106.15,51,0.744846998,8.53503311,0,-0.3744868,57.38534509,1.030358671,6.5,57,19,6,192.066664,21.92450209,50.21848808,*08,*11:04,423.36455,past
S-181218-03822,pt219,28.47364819,Female,RR-MS,RR-MS,0.109514031,20.50460224,Untreated,W,validation,4.2,55,0.807533086,7.110696123,1.098612289,-1.713610682,10.09524944,-2.524182809,1.5,96,NA,0,6.35,-13.20147453,NA,*03:01,*13:03,3289.884875,NA
S-181218-03823,pt220,70.43394935,Male,PP-MS,prog-MS,27.90965092,25.0284055,Untreated,W,validation,7.5,32,0.75446349,8.507142856,0.693147181,0.439220634,41.24164823,0.882608526,6,65,NA,4,142.199996,-1.610620029,NA,*01:02,*07:01,-264.5827351,NA
S-181218-03824,pt220,72.27378508,Male,PP-MS,prog-MS,29.74948665,24.61810377,Untreated,W,validation,7.45,37,0.723345148,8.164225652,NA,0.74100228,42.00318275,1.174827572,6,61,7,4,NA,-3.590361294,NA,*01:02,*07:01,-227.1007631,NA
S-181218-03825,pt220,73.27036277,Male,PP-MS,prog-MS,30.74606434,25.2493372,Untreated,W,validation,7.5,36,0.723408542,9.176266392,NA,0.791818959,43.20064996,1.279012865,6,68,7,4,101.311108,-2.854494497,NA,*01:02,*07:01,-220.4105983,NA
S-181218-03827,pt221,47.80561259,Female,SP-MS,prog-MS,17.63997262,19.68782518,Untreated,W,training,8.65,NA,0.771382805,10.1552963,0,NA,47.53396144,NA,6,60,NA,4,142.099996,NA,NA,*08:01,NA,140.6908804,no
S-181218-03828,pt221,48.64339493,Female,SP-MS,prog-MS,18.47775496,18.92138913,Untreated,W,training,12.7,29,0.771430865,8.053887084,0,0.288896655,50.23094393,1.218773116,6.5,52,NA,4,174.199996,8.744164549,NA,*08:01,NA,181.6619409,no
S-181218-03829,pt221,48.75838467,Female,SP-MS,prog-MS,18.5927447,18.85836582,rituximab,W,training,12.7,29,NA,NA,NA,NA,NA,NA,6.5,50,NA,4,NA,NA,NA,*08:01,NA,397.8618874,no
S-181218-03830,pt221,48.89801506,Female,SP-MS,prog-MS,18.73237509,18.56887336,rituximab,W,training,10.55,28,0.747728552,8.61395686,0,0.768607403,NA,NA,6.5,48,12,4,NA,NA,NA,*08:01,NA,298.5670021,no
S-181218-03831,pt221,49.63997262,Female,SP-MS,prog-MS,19.47433265,19.31328253,rituximab,W,training,12.45,28,0.774446736,8.246433786,0,0.286430684,50.22772459,1.216539718,6.5,50,12,5,181.511108,8.763345207,59.50783874,*08:01,NA,25.51691498,no
S-181218-03832,pt222,43.06639288,Female,SP-MS,prog-MS,12.54757016,37.3898707,Untreated,NA,training,31.45,NA,0.785714615,11.01402841,0,NA,52.44076271,NA,6.5,60,NA,6,153.888888,NA,NA,*07:01,*08:04,-74.31160702,past
S-181218-03833,pt223,33.30869268,Female,RR-MS,RR-MS,0.725530459,21.29529475,Untreated,AA,validation,4.6,45,0.808571431,8.769817872,3.044522438,-1.212742089,8.323547748,-2.195273934,1,95,NA,0,5.388888,-19.52288612,NA,*04:01,*15:03,3914.867254,no
S-181218-03834,pt224,42.44490075,Male,RR-MS,RR-MS,0.281998631,26.97142857,Untreated,AA,training,4.2,48,0.731308637,8.188689124,0.693147181,0.025718992,21.06655432,-0.501519142,4,93,NA,0,10,-18.02961396,64.30206627,*11:02,*15:03,560.9990467,NA
S-181218-03836,pt225,47.63039014,Male,PP-MS,prog-MS,18.08350445,22.81909039,Untreated,W,training,14.05,23,0.747102207,9.065545787,0,1.039714581,48.75811908,1.772647209,6.5,68,NA,5,115.3,0.451180076,NA,*07:01,*15:01,85.5017256,past
S-181218-03837,pt225,49.56605065,Male,PP-MS,prog-MS,20.01916496,20.74755019,Untreated,W,training,26.85,23,0.747946577,8.967249183,NA,1.024476437,58.10375291,2.240411785,6.5,43,21,6,220.544444,9.935231725,NA,*07:01,*15:01,230.0798418,past
S-181218-03838,pt225,50.48323066,Male,PP-MS,prog-MS,20.93634497,NA,Untreated,W,training,179.9,28,0.747568385,8.995288991,NA,0.771497899,70.28236135,2.654485568,7,41,22,7,219.6,24.41180609,NA,*07:01,*15:01,256.0807432,past
S-181218-03839,pt225,51.49897331,Male,PP-MS,prog-MS,21.95208761,21.67321012,Untreated,W,training,179.9,30,0.743741681,9.089076284,NA,0.736636045,69.99146356,2.610294185,7,37,22,7,240.1,24.43758082,NA,*07:01,*15:01,486.6774721,past
S-181218-03840,pt225,52.01368925,Male,PP-MS,prog-MS,22.46680356,19.59845511,not untreated,W,training,179.9,34,0.72473473,9.247925132,NA,0.871807031,73.43331625,2.900619489,7.5,40,22,8,301.155552,26.65158896,NA,*07:01,*15:01,170.384935,past
S-181218-03841,pt225,53.0349076,Male,PP-MS,prog-MS,23.4880219,17.9705704,ocrelizumab (Ocrevus),W,training,112.7,29,0.695592089,9.742555598,NA,1.657541029,69.24788499,3.344293403,7,40,18,7,311.96666,15.32883305,63.15035549,*07:01,*15:01,133.3256559,past
S-181218-03842,pt226,65.10882957,Female,SP-MS,prog-MS,37.5687885,27.54820937,Untreated,W,training,11,NA,0.780252038,8.529516941,0,NA,47.20158085,NA,6,62,NA,4,88.9,NA,NA,*07:01,*11:04,-66.53387209,past
S-181218-03843,pt226,65.96577687,Female,SP-MS,prog-MS,38.4257358,27.58494031,Untreated,W,training,10.75,50,0.77993719,8.386400901,0,-0.955790424,47.60567498,0.040040882,6,62,NA,4,111.9,17.42518473,NA,*07:01,*11:04,-75.53986804,past
S-181218-03844,pt226,66.06160164,Female,SP-MS,prog-MS,38.52156057,27.62492564,rituximab,W,training,10.75,50,0.765349093,9.42682178,0,-0.692522503,NA,NA,6,54,NA,4,NA,NA,56.78976538,*07:01,*11:04,-64.54701085,past
S-181218-03845,pt226,66.20123203,Female,SP-MS,prog-MS,38.66119097,28.21980964,rituximab,W,training,NA,NA,0.777031398,8.965079015,0,NA,NA,NA,6,54,13,4,NA,NA,55.9088027,*07:01,*11:04,-68.18042866,past
S-181218-03846,pt226,66.9431896,Female,SP-MS,prog-MS,39.40314853,27.76859504,rituximab,W,training,10.7,46,0.776425506,8.777555453,0,-0.684572953,49.47345022,0.363511797,6,54,13,4,135.844444,16.82931815,50.96123723,*07:01,*11:04,-46.77663281,past
S-181218-03847,pt226,69.76591376,Female,SP-MS,prog-MS,42.22587269,29.09090909,Untreated,W,training,11.3,37,0.771578389,8.889583992,NA,-0.129451562,48.15219461,0.761076312,6,52,13,4,182.527776,10.46553976,50.11252138,*07:01,*11:04,359.0774043,past
S-181218-03848,pt227,54.80355921,Female,PP-MS,prog-MS,12.60232717,26.46966143,Untreated,W,validation,8.3,36,0.727901216,9.839322295,NA,0.710740739,47.65956105,1.440296504,6,58,NA,4,138.488886,2.340901946,NA,*01:03,*04:01,246.1099752,past
S-181218-03849,pt227,56.62696783,Female,PP-MS,prog-MS,14.4257358,26.71475088,Untreated,W,validation,5.65,39,0.733311071,9.655282571,NA,0.457228163,46.89076043,1.18818031,6,58,7,4,NA,3.874918255,NA,*01:03,*04:01,147.7345414,past
S-181218-03850,pt227,57.62354552,Female,PP-MS,prog-MS,15.42231348,27.34498092,Untreated,W,validation,8.35,37,0.728293935,9.65155865,NA,0.651692697,50.84484628,1.554565248,6.5,58,10,4,152.377776,6.062558325,NA,*01:03,*04:01,113.9111617,past
S-181218-03851,pt227,58.63928816,Female,PP-MS,prog-MS,16.43805613,25.62935471,Untreated,W,validation,6.05,39,0.727350789,9.781828264,NA,0.564791957,43.90856345,1.125037475,6,57,10,4,NA,-0.084349483,NA,*01:03,*04:01,40.82161439,past
S-181218-03852,pt227,59.55920602,Female,PP-MS,prog-MS,17.35797399,24.01876685,Untreated,W,validation,9.85,35,0.705250384,9.9171932,NA,1.171475659,47.34450824,1.810450276,6,57,14,4,151.488888,-2.159300936,70.08215245,*01:03,*04:01,291.7497631,past
S-181218-03855,pt228,28.27652293,Female,RR-MS,RR-MS,0.668035592,22.00310342,Untreated,W,training,3.8,62,0.80123931,7.777792626,1.609437912,-1.963753552,7.30654873,-2.877334443,1,98,NA,0,2,-13.71796749,NA,*07:01,*15:01,85.37940601,past
S-181218-03856,pt229,30.68856947,Female,RR-MS,RR-MS,10.58726899,19.08248244,Untreated,AA,training,18.3,57,0.768569437,7.212294469,NA,-1.114364436,39.47398827,-0.511055574,6.5,78,NA,5,NA,10.73392724,NA,*01:02,*12,-28.52418016,no
S-181218-03858,pt230,50.32443532,Male,SP-MS,prog-MS,17.68377823,27.38212547,Untreated,W,validation,11.75,34,0.76839995,8.835064935,0,0.083791179,56.86047925,1.387663787,6.5,54,NA,5,265.8222101,17.23680414,NA,*01:01,*08,548.2864753,current
S-181218-03859,pt230,51.18138261,Male,SP-MS,prog-MS,18.54072553,30.46296296,Untreated,W,validation,25.75,34,0.767944707,8.572060093,0,0.092006841,59.18040568,1.513841282,6.5,49,NA,6,252.5999961,19.48210245,NA,*01:01,*08,42.74636943,current
S-181218-03860,pt230,51.27994524,Male,SP-MS,prog-MS,18.63928816,31.51020408,rituximab,W,validation,25.75,34,0.757088113,8.763584409,0,0.287933214,NA,NA,6.5,50,16,5,257.099996,NA,44.09834122,*01:01,*08,118.9515709,current
S-181218-03861,pt231,55.26625599,Female,SP-MS,prog-MS,33.68377823,23.53509816,Untreated,W,training,4.7,NA,0.791487718,8.688453801,0,NA,45.29655122,NA,6,67,NA,1,93.344444,NA,NA,*03,NA,-99.40602934,past
S-181218-03862,pt231,56.18069815,Female,SP-MS,prog-MS,34.5982204,23.34014891,Untreated,W,training,4.65,45,0.789629306,7.770223204,0,-0.870898059,41.63419856,-0.195818889,6,61,11,2,99.544444,10.68257665,NA,*03,NA,-4.693767472,past
S-181218-03863,pt231,56.29842574,Female,SP-MS,prog-MS,34.71594798,23.49446395,rituximab,W,training,4.65,45,0.755721663,8.976262256,0,-0.258974881,NA,NA,5.5,59,11,2,NA,NA,60.01953397,*03,NA,19.68198639,past
S-181218-03864,pt231,56.42984257,Female,SP-MS,prog-MS,34.84736482,23.57162147,rituximab,W,training,4.95,49,0.754946177,10.42257892,0,-0.452822813,NA,NA,5.5,56,11,2,NA,NA,59.71009431,*03,NA,17.33396506,past
S-181218-03865,pt231,56.53114305,Female,SP-MS,prog-MS,34.9486653,23.45588519,rituximab,W,training,4.95,49,0.79239458,7.919356191,0,-1.128645246,40.90280762,-0.449562489,5.5,54,11,2,NA,12.29246831,NA,*03,NA,166.2954571,past
S-181218-03866,pt232,50.75975359,Male,PP-MS,prog-MS,8.624229979,26.73484295,Untreated,W,training,29.3,19,0.765077868,7.216709487,0,0.923155041,51.57647405,1.819821995,6.5,65,NA,6,81.94444402,4.32831993,NA,*04:01,*11,159.0903815,past
S-181218-03867,pt232,52.73374401,Male,PP-MS,prog-MS,10.5982204,27.2899927,Untreated,W,training,27.95,28,0.779257339,7.23417718,NA,0.199614874,54.49802342,1.363313805,6.5,53,16,6,NA,13.82224758,NA,*04:01,*11,374.1838042,past
S-181218-03868,pt232,53.74948665,Male,PP-MS,prog-MS,11.61396304,22.87801315,Untreated,W,training,21.35,27,0.776882021,7.210818453,NA,0.294442409,55.90665007,1.515262398,6.5,51,15,6,135.816664,14.36949505,NA,*04:01,*11,334.7838268,past
S-181218-03869,pt232,54.82272416,Male,PP-MS,prog-MS,12.68720055,28.54638422,Untreated,W,training,20.65,27,0.775467423,7.085901464,NA,0.319971324,55.48366335,1.514920369,6.5,51,15,6,NA,13.71461287,NA,*04:01,*11,328.9137143,past
S-181218-03870,pt232,55.97262149,Male,PP-MS,prog-MS,13.83709788,26.29656684,Untreated,W,training,30.6,21,0.75736409,9.143345503,NA,0.958442288,57.5751761,2.157859386,6.5,49,15,6,199.283332,10.00648533,74.24317793,*04:01,*11,467.0534197,past
S-181218-03872,pt233,61.53593429,Female,PP-MS,prog-MS,10.75975359,21.75546853,Untreated,W,training,6.05,NA,0.767419003,9.886036159,NA,NA,38.39360448,NA,5.5,69,NA,2,111.566664,NA,NA,*13,*15:01,224.9027241,past
S-181218-03873,pt233,63.39493498,Female,PP-MS,prog-MS,12.61875428,22.80571992,Untreated,W,training,6.3,32,0.754545723,9.731512288,NA,0.437736594,37.47492838,0.687683298,5.5,64,6,2,NA,-5.3638594,NA,*13,*15:01,35.42143076,past
S-181218-03874,pt233,64.39151266,Female,PP-MS,prog-MS,13.61533196,22.97008547,Untreated,W,training,6.35,32,0.754656261,9.808132372,NA,0.435741741,38.20864298,0.723737329,5.5,66,8,2,96.727776,-4.612024273,NA,*13,*15:01,44.6549109,past
S-181218-03875,pt233,65.38809035,Female,PP-MS,prog-MS,14.61190965,22.47698882,Untreated,W,training,5.8,33,0.749504718,9.836866865,NA,0.476749678,38.15118813,0.755170639,5.5,64,8,2,NA,-5.041980452,NA,*13,*15:01,340.3738543,past
S-181218-03876,pt234,53.7412731,Female,SP-MS,prog-MS,25.13347023,20.7266436,Untreated,W,training,8.45,NA,0.707223786,9.28377669,0,NA,47.81903999,NA,6.5,57,NA,5,131.477776,NA,NA,*07:01,*15:01,9.157393204,no
S-181218-03877,pt234,54.5982204,Female,SP-MS,prog-MS,25.99041752,23.59893109,Untreated,W,training,12.6,23,0.726831528,9.416785274,0,1.40553471,50.85441949,2.187198565,6.5,52,16,5,155.42222,-0.775497804,NA,*07:01,*15:01,528.6610306,no
S-181218-03878,pt234,54.71321013,Female,SP-MS,prog-MS,26.10540726,23.34919691,Untreated,W,training,12.6,23,0.694669391,9.494466128,0,1.985957156,NA,NA,6.5,49,20,5,NA,NA,67.72962931,*07:01,*15:01,380.1801934,no
S-181218-03879,pt234,54.85284052,Female,SP-MS,prog-MS,26.24503765,23.34919691,Untreated,W,training,13.25,25,0.732360086,9.456887901,0,1.201840665,NA,NA,6.5,49,20,5,NA,NA,NA,*07:01,*15:01,418.2900149,no
S-181218-03880,pt234,58.05338809,Female,SP-MS,prog-MS,29.44558522,22.80991736,Untreated,W,training,13.3,22,0.715165529,9.416622566,NA,1.668028958,54.66168463,2.603081072,6.5,44,17,5,233.13333,0.647364125,57.96257947,*07:01,*15:01,620.906135,no
S-181218-03881,pt235,30.39288159,Female,RR-MS,RR-MS,0.558521561,25.54563492,Untreated,W,validation,3.75,61,0.820844822,6.532334292,0.693147181,-2.265608834,10.33522097,-2.974726794,1.5,92,NA,0,17.888888,-7.947350594,NA,*01:01,*15:01,92.51417797,no
S-181218-03882,pt236,31.00889802,Male,PP-MS,prog-MS,4.618754278,24.17756639,Untreated,W,training,11.9,51,0.768686864,9.255409335,0,-0.804719199,49.29310345,0.253488828,6.5,62,NA,5,NA,17.7403366,NA,*13:03,*15:01,799.5497827,past
S-181218-03884,pt237,54.28884326,Female,SP-MS,prog-MS,32.56673511,35.32123736,Untreated,AA,validation,44.5,NA,0.763672674,9.677088709,0,NA,56.5664479,NA,6.5,56,NA,6,172.5111081,NA,NA,*11:02,*15:01,1454.784843,NA
S-181218-03885,pt238,34.39835729,Female,RR-MS,RR-MS,1.360711841,21.68367347,Untreated,AA,training,3,70,NA,NA,NA,NA,9.611449539,NA,1.5,91,NA,0,11.25,NA,NA,*07:01,*11:01,254.0851248,past
S-181218-03886,pt239,65.07049966,Male,SP-MS,prog-MS,23.37029432,28.93455922,Untreated,W,training,4.8,NA,0.647796133,10.7217464,0,NA,21.74096,NA,2.5,69,NA,2,61.81110801,NA,NA,*13,*13,-85.68826366,past
S-181218-03887,pt239,65.908282,Male,SP-MS,prog-MS,24.20807666,27.39431317,Untreated,W,training,3.95,35,0.698314174,10.75489837,0,1.296651793,23.46404733,0.68750968,2.5,68,4,2,60.56110801,-27.17681676,NA,*13,*13,-209.6646775,past
S-181218-03888,pt239,66.02327173,Male,SP-MS,prog-MS,24.32306639,27.10746172,rituximab,W,training,3.95,35,0.64575658,10.78634559,NA,2.245146206,NA,NA,2.5,69,3,2,NA,NA,66.32357781,*13,*13,-49.08707894,past
S-181218-03889,pt239,66.16290212,Male,SP-MS,prog-MS,24.46269678,27.39875163,rituximab,W,training,NA,NA,0.689095321,10.7229149,NA,NA,NA,NA,2.5,69,4,2,NA,NA,NA,*13,*13,158.5051159,past
S-181218-03890,pt240,43.15674196,Male,RR-MS,RR-MS,1.399041752,35.11123879,Untreated,W,training,3.55,44,0.796212407,8.65608519,1.098612289,-0.937740983,11.53998525,-1.799283424,1.5,89,NA,0,51.077776,-18.80445962,NA,*03,*03,12277.21674,past
S-181218-03893,pt241,41.45379877,Male,PP-MS,prog-MS,23.44695414,24.62712452,Untreated,W,validation,74.5,NA,0.779493401,7.977281987,0,NA,52.71353127,NA,6.5,62,NA,6,159.144444,NA,NA,*04:02,*07:01,-61.12886606,current
S-181218-03894,pt241,42.48323066,Male,PP-MS,prog-MS,24.47638604,25.62035295,Untreated,W,validation,179.9,52,0.78645117,7.841885929,0,-1.177268145,61.96334653,0.592575095,6.5,55,19,7,168.711108,33.79468013,NA,*04:02,*07:01,-44.2411385,current
S-181218-03895,pt241,42.5982204,Male,PP-MS,prog-MS,24.59137577,25.69134163,rituximab,W,validation,NA,NA,0.764565716,10.53966748,0,NA,NA,NA,7,55,19,NA,NA,NA,77.36321026,*04:02,*07:01,-104.1177146,current
S-181218-03896,pt241,42.71868583,Male,PP-MS,prog-MS,24.7118412,25.69134163,rituximab,W,validation,NA,NA,0.770057561,10.20540532,0,NA,NA,NA,7,55,19,NA,NA,NA,75.08590015,*04:02,*07:01,-99.11056134,current
S-181218-03897,pt242,54.4476386,Male,SP-MS,prog-MS,15.40862423,29.3523545,Untreated,W,training,9.8,NA,0.74025431,9.795345394,0,NA,43.75934072,NA,6,60,NA,4,103.416666,NA,NA,*15:01,*15:01,125.5599136,current
S-181218-03898,pt242,55.53456537,Male,SP-MS,prog-MS,16.49555099,27.99538092,Untreated,W,training,10.55,15,0.726352709,9.86026685,0,1.829861729,45.65273908,2.275556909,6,53,12,4,134.605554,-9.831612029,NA,*15:01,*15:01,130.1001858,current
S-181218-03899,pt242,55.6495551,Male,SP-MS,prog-MS,16.61054073,28.82313511,rituximab,W,training,NA,NA,0.720599525,10.0992188,0,NA,NA,NA,6,53,12,4,NA,NA,NA,*15:01,*15:01,168.780574,current
S-181218-03900,pt242,55.77002053,Male,SP-MS,prog-MS,16.73100616,28.82313511,rituximab,W,training,NA,NA,0.75254878,9.899981413,0,NA,NA,NA,6,53,12,4,NA,NA,NA,*15:01,*15:01,267.111158,current
S-181218-03901,pt242,58.50787132,Male,SP-MS,prog-MS,19.46885695,27.49021588,Untreated,W,training,15.4,10,0.668939621,9.203819155,NA,3.125785768,51.25550686,3.650354219,6,56,14,4,160.038886,-16.00055147,67.81473533,*15:01,*15:01,82.92292417,current
S-181218-03903,pt243,60.22997947,Male,PP-MS,prog-MS,4.350444901,26.72056233,Untreated,W,training,6.15,39,0.688304898,9.641733102,0,1.269443876,40.21386877,1.525952434,6,68,NA,4,89.066664,-10.1798484,NA,*07:01,*15:01,403.6870064,past
S-181218-05730,pt243,62.30253251,Male,PP-MS,prog-MS,6.422997947,25.22706796,Untreated,W,training,24.55,34,0.675822468,9.23190615,NA,1.754515004,53.55494565,2.618697378,6.5,58,14,6,NA,-1.244982944,NA,*07:01,*15:01,560.7184968,past
S-181218-05731,pt243,63.29637235,Male,PP-MS,prog-MS,7.416837782,26.35102041,Untreated,W,training,49.35,30,0.693399025,9.417191927,NA,1.645157998,58.42478349,2.777397006,6.5,52,14,6,168.599996,4.618214546,NA,*07:01,*15:01,498.5267787,past
S-181218-03902,pt243,64.32854209,Male,PP-MS,prog-MS,8.449007529,25.8114788,Untreated,W,training,88.7,27,0.584145625,8.900685319,NA,3.772710361,62.55112969,4.773647762,6.5,52,16,6,NA,-10.58135864,62.02794223,*07:01,*15:01,809.6520307,past
S-181218-05732,pt243,65.28952772,Male,PP-MS,prog-MS,9.409993155,30.4,Untreated,W,training,179.9,31,0.675506524,9.830056274,NA,1.916098978,71.7838115,3.691504195,7.5,47,17,7,211.04444,15.51611229,61.01806891,*07:01,*15:01,770.6820384,past
S-181218-05734,pt244,65.68377823,Male,PP-MS,prog-MS,18.37097878,28.59969996,Untreated,W,validation,11.1,36,0.70286951,8.720134035,0,1.162481991,48.13591866,1.843602045,6,62,NA,4,103.7777761,-1.286195272,NA,*07:01,*13,712.3168266,past
S-181218-05735,pt245,32.03285421,Female,SP-MS,prog-MS,6.409308693,27.44059917,Untreated,AA,training,5,36,0.728297412,9.961331842,0,0.703590684,32.77392311,0.668896916,3.5,72,NA,2,110.96666,-12.47978747,NA,*07:01,*08:04,739.2070422,past
S-181218-05736,pt246,60.46269678,Female,PP-MS,prog-MS,10.0807666,23.20580957,Untreated,W,validation,10.75,52,0.781335149,8.877381955,0,-1.084940529,44.21868175,-0.242414741,6,68,NA,4,94.82222001,15.21134454,NA,*08:01,*15:01,67.33459126,no
S-181218-05737,pt247,58.86105407,Male,PP-MS,prog-MS,15.48528405,21.41006835,Untreated,AA,training,3.9,41,0.760983443,8.8149246,0,-0.146090032,26.39699524,-0.371505496,3,75,NA,2,74.566664,-11.13852175,NA,*08:04,*15:01,215.291123,past
S-181218-05738,pt247,61.48665298,Male,PP-MS,prog-MS,18.11088296,22.95510204,Untreated,AA,training,4.65,37,0.761789195,8.886132618,NA,0.047211697,27.79389689,-0.137583361,3,70,5,2,NA,-11.49750337,NA,*08:04,*15:01,-62.86446259,past
S-181218-05739,pt247,62.54072553,Male,PP-MS,prog-MS,19.16495551,23.49480969,Untreated,AA,training,4.65,43,0.759597361,9.008958312,NA,-0.224997211,28.01651308,-0.354399925,3,69,5,2,94.799998,-8.80223951,NA,*08:04,*15:01,-68.32219256,past
S-181218-05740,pt247,63.55646817,Male,PP-MS,prog-MS,20.18069815,24.11764706,Untreated,AA,training,5,42,0.73811039,9.013960458,NA,0.214733786,32.83067747,0.261879769,4,70,5,2,119.07222,-7.98243312,60.96658519,*08:04,*15:01,554.9990024,past
S-181218-05741,pt248,65.22108145,Female,PP-MS,prog-MS,11.4661191,33.59144574,Untreated,W,training,111.5,16,0.733417033,10.5767891,0,1.650412816,66.19528867,3.181354684,6.5,51,NA,7,214.699992,12.34098685,NA,*04:01,*07:01,4079.502674,past
S-181218-05743,pt249,58.72689938,Male,PP-MS,prog-MS,20.41067762,28.51682642,Untreated,W,validation,6.1,58,NA,NA,NA,NA,44.46913292,NA,6,61,NA,4,144.63333,NA,NA,*03,*13,292.5951191,no
S-181218-05745,pt250,39.96167009,Female,HD,HD,NA,28.69227252,Untreated,AA,HD,3.6,36,0.812486499,6.901737207,NA,-0.815749769,2.541455166,-2.159681534,0,100,NA,0,0,-28.91111395,NA,*01:01,*08:04,-48.22540225,no
S-181218-05746,pt250,44.61875428,Female,HD,HD,NA,28.59171598,Untreated,AA,HD,4.05,43,0.81646252,7.708859601,NA,-1.251229226,13.93562628,-1.938980498,1.5,92,0,0,18.2,-16.2759888,66.86764035,*01:01,*08:04,-23.63438021,no
S-181218-05747,pt251,38.38740589,Female,SP-MS,prog-MS,9.544147844,22.56326531,Untreated,AA,validation,7.7,40,0.77860928,8.562740006,NA,-0.412218589,49.88376005,0.612994724,6.5,62,NA,4,162.899996,14.76565903,NA,*07:01,*15:01,790.0060405,past
S-181218-05748,pt251,39.26351814,Female,SP-MS,prog-MS,10.4202601,22.95159546,Untreated,AA,validation,11.8,41,0.782701911,8.924390132,0.693147181,-0.538038064,51.68376626,0.600042086,6.5,55,16,5,190.299996,17.70856404,NA,*07:01,*15:01,648.1558438,past
S-181218-05749,pt251,39.37850787,Female,SP-MS,prog-MS,10.53524983,23.66143862,Untreated,AA,validation,11.8,41,0.773561875,9.457434797,0,-0.373090006,NA,NA,6.5,49,17,5,189.799996,NA,67.07237387,*07:01,*15:01,691.619163,past
S-181218-05750,pt251,39.51813826,Female,SP-MS,prog-MS,10.67488022,NA,Untreated,AA,validation,NA,NA,NA,NA,0,NA,NA,NA,6.5,53,17,5,191.299996,NA,45.83490831,*07:01,*15:01,825.6125767,past
S-181218-05751,pt251,42.37097878,Female,SP-MS,prog-MS,13.52772074,22.46530612,Untreated,AA,validation,38.6,36,0.760855053,9.546526853,0,0.116030671,59.33486553,1.541928846,6.5,46,17,6,233.06666,19.41833849,63.24824292,*07:01,*15:01,699.6716962,past
S-181218-05752,pt252,35.50992471,Male,HD,HD,NA,28.33869105,Untreated,W,HD,5.8,38,0.799060662,7.910590612,NA,-0.67737835,4.669331853,-1.934235741,0,100,NA,0,NA,-28.0401534,NA,*07:01,*15:01,65.01978015,NA
S-181218-05753,pt253,56.15331964,Male,PP-MS,prog-MS,5.544147844,24.29387755,Untreated,W,training,6.8,35,0.766757798,9.770812936,0,0.06146597,47.64538627,0.895112392,6,63,9,4,138.14444,8.224505317,NA,*11:04,*15:01,406.1808659,past
S-181218-05754,pt253,58.0698152,Male,PP-MS,prog-MS,7.460643395,25.24081633,Untreated,W,training,15.3,34,0.759136172,9.797682494,NA,0.25097238,52.24654912,1.290611669,6.5,59,14,4,NA,11.1042602,NA,*11:04,*15:01,627.0867478,past
S-181218-05755,pt253,59.06639288,Male,PP-MS,prog-MS,8.457221081,25.63265306,Untreated,W,training,48,31,0.761281878,9.811043262,NA,0.368131541,56.59605329,1.612503478,6.5,54,15,6,194.577772,14.38953274,NA,*11:04,*15:01,366.0524313,past
S-181218-05756,pt253,60.09856263,Male,PP-MS,prog-MS,9.489390828,NA,Untreated,W,training,179.9,28,0.75462866,9.734180933,NA,0.644082793,65.0643957,2.279338168,7,54,19,7,NA,20.35123337,45.23660796,*11:04,*15:01,228.658429,past
S-181218-05757,pt254,48.06570842,Female,PP-MS,prog-MS,9.620807666,30.84627667,Untreated,W,training,7.9,28,0.777738905,9.967822928,NA,0.227017692,51.76603874,1.245816909,6.5,57,15,5,150.122216,10.84134558,NA,*03:01,*15:01,345.1297461,current
S-181218-05758,pt254,50.02053388,Female,PP-MS,prog-MS,11.57563313,27.32617216,Untreated,W,training,11.7,24,0.775055294,10.30541307,NA,0.483291125,55.03224624,1.62866228,6.5,55,15,5,NA,11.77965751,NA,*03:01,*15:01,783.5609063,current
S-181218-05759,pt254,50.9596167,Female,PP-MS,prog-MS,12.51471595,24.6407316,Untreated,W,training,16.75,19,0.773934218,10.53278931,NA,0.763326596,56.49478895,1.938690978,6.5,47,16,5,183.011108,10.69845886,NA,*03:01,*15:01,585.5053449,current
S-181218-05760,pt254,51.97535934,Female,PP-MS,prog-MS,13.53045859,NA,Untreated,W,training,28.2,12,0.762876312,10.54151835,NA,1.32661115,61.25246351,2.655672983,6.5,49,18,6,NA,10.33945941,NA,*03:01,*15:01,595.3581115,current
S-181218-05761,pt254,52.99110198,Female,PP-MS,prog-MS,14.54620123,22.82624474,Untreated,W,training,42.4,11,NA,NA,NA,NA,67.2234577,NA,6.5,28,19,6,314.28888,NA,NA,*03:01,*15:01,332.8429458,current
S-181218-05763,pt255,37.51129363,Female,SP-MS,prog-MS,7.802874743,32.7727778,interferon beta-1a (Avonex),W,training,5.2,NA,NA,NA,NA,NA,34.90816842,NA,4.5,71,NA,2,NA,NA,NA,*11:03,*13:01,1643.85741,NA
S-181218-05762,pt255,38.01232033,Female,SP-MS,prog-MS,8.303901437,31.15923841,daclizumab (Zenapax),W,training,5.6,NA,NA,NA,NA,NA,34.79681739,NA,5,72,NA,2,NA,NA,NA,*11:03,*13:01,760.4402269,NA
S-181218-05764,pt256,51.91238877,Female,SP-MS,prog-MS,7.865845311,20.08809584,interferon beta-1a (Avonex),W,training,NA,NA,NA,NA,2.397895273,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*04:02,*07:01,NA,NA
S-181218-05765,pt257,46.15468857,Female,RR-MS,RR-MS,17.16084873,30.62139195,daclizumab (Zinbryta),W,training,4.6,59,0.765657815,8.925321417,0,-1.165740558,12.99861279,-1.915473446,1.5,90,NA,0,15.8,-15.27476606,NA,*11,*13:02,181.5393517,past
S-181218-05766,pt257,47.18959617,Female,RR-MS,RR-MS,18.19575633,32.1990749,daclizumab (Zinbryta),W,training,4.8,61,0.763749719,9.007734472,0,-1.235227074,12.46013342,-2.001430039,1.5,89,0,0,22.40000002,-15.18205494,NA,*11,*13:02,122.3756528,past
S-181218-05767,pt257,51.86310746,Female,RR-MS,RR-MS,22.86926762,32.12736204,glatiramer acetate (Copaxone),W,training,5.95,62,0.754262748,9.306740866,NA,-1.115978698,23.47100005,-1.335266049,3,77,2,2,50.33888804,-5.254397614,62.93929869,*11,*13:02,92.12232983,past
S-181218-05768,pt258,41.05954825,Male,RR-MS,RR-MS,1.144421629,31.68975069,Untreated,W,training,4.05,NA,0.770711292,9.090880932,0,NA,7.395642208,NA,1,98,NA,0,NA,NA,NA,*01:01,*13:01,1261.412177,no
S-181218-05769,pt258,41.58521561,Male,RR-MS,RR-MS,1.67008898,NA,daclizumab (Zenapax),W,training,3.85,NA,0.781580368,10.22026716,0.693147181,NA,10.07167137,NA,1.5,96,NA,0,NA,NA,NA,*01:01,*13:01,1331.412806,no
S-181218-05770,pt258,49.36618754,Male,RR-MS,RR-MS,9.451060917,NA,daclizumab (Zinbryta),W,training,3.6,59,0.803553214,8.201934351,0,-1.849629821,9.518507523,-2.667898357,1.5,96,NA,0,10.8,-12.54266758,79.0297643,*01:01,*13:01,119.5488967,no
S-181218-05771,pt258,50.34086242,Male,RR-MS,RR-MS,10.4257358,NA,daclizumab (Zinbryta),W,training,3.8,61,0.73654606,7.288927695,0,-0.744289103,10.64897066,-1.682877624,1.5,94,1,0,10.8,-21.45272142,NA,*01:01,*13:01,159.9986059,no
S-181218-05772,pt259,29.17180014,Female,RR-MS,RR-MS,1.42642026,32.24206349,IV steroids,W,training,3.45,NA,0.764385493,9.825093485,3.044522438,NA,10.63102701,NA,1.5,91,NA,0,NA,NA,NA,*03:01,*15:01,5834.794761,past
S-181218-05774,pt259,29.29226557,Female,RR-MS,RR-MS,1.546885695,31.78146259,daclizumab (Zenapax),W,training,3.5,NA,0.765534807,9.804661198,2.48490665,NA,10.26289348,NA,1.5,92,NA,0,NA,NA,NA,*03:01,*15:01,3767.013214,past
S-181218-05773,pt259,29.76591376,Female,RR-MS,RR-MS,2.020533881,33.43349259,daclizumab (Zenapax),W,training,3.4,NA,0.750582723,9.63541201,0.693147181,NA,7.601127312,NA,1,96,NA,0,NA,NA,NA,*03:01,*15:01,1263.455235,past
S-181218-05775,pt259,40.98015058,Female,RR-MS,RR-MS,13.2347707,28.81364974,natalizumab (Tysabri),W,training,3.1,45,0.740024207,9.845752502,0,0.024313378,12.13114862,-0.962146995,1.5,90,1,0,10.1,-26.95225157,NA,*03:01,*15:01,-68.58923963,past
S-181218-05776,pt259,42.14921287,Female,RR-MS,RR-MS,14.40383299,29.26754526,natalizumab (Tysabri),W,training,3.45,49,NA,NA,0,NA,18.28859964,NA,2.5,82,2,2,25.4,NA,65.9734309,*03:01,*15:01,-107.2105149,past
S-181218-05777,pt259,43.58658453,Female,RR-MS,RR-MS,15.84120465,28.98510815,natalizumab (Tysabri),W,training,4.4,29,NA,NA,1.386294361,NA,35.01123639,NA,4,60,4,2,75.744444,NA,NA,*03:01,*15:01,1417.477612,past
S-181218-05779,pt260,28.678987,Male,RR-MS,RR-MS,0.45174538,31.2953779,Untreated,W,training,3.25,NA,0.734232018,9.822982238,1.945910149,NA,9.647099625,NA,1.5,89,NA,0,13.2,NA,NA,*11:01,*15:01,14895.43989,current
S-181218-05781,pt260,28.8678987,Male,RR-MS,RR-MS,0.640657084,30.56536402,daclizumab (Zenapax),W,training,3.85,NA,0.7290912,9.772125234,0,NA,6.732104109,NA,1,99,NA,0,NA,NA,NA,*11:01,*15:01,11494.21386,current
S-181218-05780,pt260,29.25119781,Male,RR-MS,RR-MS,1.023956194,30.47014481,daclizumab (Zenapax),W,training,3.9,NA,0.72759287,9.794230567,0,NA,7.205566676,NA,1,98,NA,0,3.2,NA,NA,*11:01,*15:01,2714.779301,current
S-181218-05782,pt260,36.28473648,Male,RR-MS,RR-MS,8.057494867,29.83535013,daclizumab (Zinbryta),W,training,3.95,34,0.730686871,9.902687232,0,0.764390157,6.93858008,-0.608545296,1,95,NA,0,2.444444,-38.86741101,84.31501757,*11:01,*15:01,877.8265618,current
S-181218-05784,pt260,37.29774127,Male,RR-MS,RR-MS,9.070499658,27.89922634,daclizumab (Zinbryta),W,training,4,38,0.727056665,9.845964366,0,0.622060679,2.793488881,-0.941033203,0,97,0,0,1,-41.71963249,NA,*11:01,*15:01,539.6154531,current
S-181218-05785,pt260,41.95756331,Male,RR-MS,RR-MS,13.7303217,30.47014481,natalizumab (Tysabri),W,training,4.1,39,0.730455623,9.895404976,NA,0.508759755,10.31950242,-0.649063023,1.5,96,0,0,4,-33.16443417,70.65077624,*11:01,*15:01,896.2731539,current
S-181218-05786,pt261,54.61738535,Female,RR-MS,RR-MS,20.30663929,NA,daclizumab (Zinbryta),W,validation,4.95,41,0.725899289,9.099520537,NA,0.487065361,34.95264233,0.599355088,5,80,NA,0,47.4,-8.3342302,NA,*03:01,*07:01,186.2467754,past
S-181218-05787,pt261,55.63312799,Female,RR-MS,RR-MS,21.32238193,NA,daclizumab (Zinbryta),W,validation,4.8,47,0.714099398,9.039196116,NA,0.388250776,36.70147506,0.606416359,5,76,4,0,54.666666,-5.687801367,NA,*03:01,*07:01,64.90524442,past
S-181218-05788,pt261,59.02532512,Female,RR-MS,RR-MS,24.71457906,26.42930595,daclizumab (Zinbryta),W,validation,5.6,48,0.706072781,9.074176947,NA,0.48114449,38.52657705,0.778158052,5,65,6,1,90.133332,-4.706512421,46.36843042,*03:01,*07:01,-62.72266154,past
S-181218-05789,pt262,35.40041068,Male,RR-MS,RR-MS,5.092402464,NA,Untreated,W,training,3.35,NA,NA,NA,0.693147181,NA,10.58821022,NA,1.5,93,NA,0,NA,NA,NA,*11,*15:01,933.0825222,NA
S-181218-05791,pt262,35.63312799,Male,RR-MS,RR-MS,5.325119781,NA,daclizumab (Zenapax),W,training,3,NA,0.722053993,9.396404915,0,NA,11.52434959,NA,1.5,89,NA,0,NA,NA,NA,*11,*15:01,724.0443716,NA
S-181218-05790,pt262,35.95619439,Male,RR-MS,RR-MS,5.648186174,NA,daclizumab (Zenapax),W,training,3.6,NA,0.714514283,9.21473072,0.693147181,NA,10.55615372,NA,1.5,NA,NA,NA,NA,NA,NA,*11,*15:01,783.8180292,NA
S-181218-05792,pt262,43.77823409,Male,RR-MS,RR-MS,13.47022587,29.06122449,daclizumab (Zinbryta),W,training,2.95,60,0.750489627,9.1461218,0,-0.943964608,11.65033157,-1.798828409,1.5,NA,NA,NA,NA,-18.63758013,71.31221032,*11,*15:01,103.7899575,NA
S-181218-05793,pt262,44.84873374,Male,RR-MS,RR-MS,14.54072553,29.37758264,daclizumab (Zinbryta),W,training,3.25,68,0.764828139,7.677863501,0,-1.618414214,11.75561706,-2.358980589,1.5,NA,2,NA,NA,-12.40583733,NA,*11,*15:01,208.1685033,NA
S-181218-05795,pt263,46.20123203,Female,RR-MS,RR-MS,21.24298426,NA,Untreated,W,validation,NA,NA,NA,NA,1.098612289,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01,*04:08,NA,NA
S-181218-05796,pt264,32.84873374,Male,RR-MS,RR-MS,18.54893908,22.38702135,bone marrow transplant,AA,validation,4.85,44,0.741266724,10.24508947,0.693147181,0.053850705,41.69517136,0.582772751,4.5,50,3,2,131.555552,2.343464737,66.85129414,*01:02:01,*07:01:01,284.103289,no
S-181218-05797,pt264,33.42368241,Male,RR-MS,RR-MS,19.12388775,24.83086899,bone marrow transplant,AA,validation,5.1,37,NA,NA,NA,NA,39.52805137,NA,4.5,55,2,2,109.477776,NA,71.40625559,*01:02:01,*07:01:01,129.5253239,no
S-181218-05798,pt265,46.48049281,Male,RR-MS,RR-MS,15.34565366,37.29068808,daclizumab (Zinbryta),W,validation,3.65,43,0.761952247,9.789534672,NA,-0.267495279,13.67965632,-1.12722316,1.5,87,NA,0,NA,-22.75305912,71.6135722,*07:01,*11:04,106.7896846,past
S-181218-05799,pt265,47.53182752,Male,RR-MS,RR-MS,16.39698836,38.40223744,daclizumab (Zinbryta),W,validation,3.6,48,0.704309712,9.211839248,NA,0.512962177,13.76839127,-0.468200807,1.5,86,4,0,NA,-29.75371861,NA,*07:01,*11:04,150.2863687,past
S-181218-05800,pt266,24.03011636,Male,RR-MS,RR-MS,1.089664613,NA,interferon beta-1b (Betaseron),W,training,3.6,NA,NA,NA,1.386294361,NA,14.66201325,NA,2,NA,NA,NA,NA,NA,NA,*03,*13:05,NA,NA
S-181218-05801,pt267,54.01779603,Female,RR-MS,RR-MS,1.125256674,24.03098808,Untreated,W,training,4.45,NA,0.755985916,9.257987025,1.098612289,NA,12.87668282,NA,2,96,NA,0,8.2,NA,NA,*03:01,*04:01,646.3871836,no
S-181218-05803,pt267,54.22587269,Female,RR-MS,RR-MS,1.333333333,NA,daclizumab (Zenapax),W,training,4.3,NA,0.749266018,8.988071438,0.693147181,NA,12.54370133,NA,2,91,NA,0,NA,NA,NA,*03:01,*04:01,327.1826913,no
S-181218-05802,pt267,54.59000684,Female,RR-MS,RR-MS,1.697467488,NA,daclizumab (Zenapax),W,training,6,NA,0.787288379,7.874739125,0.693147181,NA,13.5164751,NA,2,90,NA,0,NA,NA,NA,*03:01,*04:01,-44.20141487,no
S-181218-05804,pt267,61.52772074,Female,RR-MS,RR-MS,8.635181383,27.71891199,daclizumab (Zinbryta),W,training,8.15,NA,0.771701025,7.37337431,0,NA,14.85775235,NA,1.5,87,NA,0,20.116666,NA,NA,*03:01,*04:01,-60.64584923,no
S-181218-05805,pt267,61.96851472,Female,RR-MS,RR-MS,9.075975359,NA,Untreated,W,training,4.1,61,0.767198896,9.867134723,0,-1.297473552,12.26925065,-2.06344238,1.5,88,NA,0,NA,-14.80751313,75.18507789,*03:01,*04:01,88.16381125,no
S-181218-05806,pt267,64.61327858,Female,RR-MS,RR-MS,11.72073922,22.68271482,dimethyl fumarate (Tecfidera),W,training,3.85,66,0.762505714,7.937731775,0,-1.47258049,11.4515692,-2.252324215,1.5,88,2,0,NA,-14.03458622,72.72547002,*03:01,*04:01,-108.6989674,no
S-181218-05807,pt267,65.91649555,Female,RR-MS,RR-MS,13.02395619,20.66030493,dimethyl fumarate (Tecfidera),W,training,3.95,55,0.732806458,7.22620901,NA,-0.365036979,29.16380177,-0.412839168,4,67,4,1,79.049998,-6.382880006,73.96867933,*03:01,*04:01,-70.38167682,no
S-181218-05808,pt267,66.43394935,Female,RR-MS,RR-MS,13.54140999,23.19823107,dimethyl fumarate (Tecfidera) & Montelukast,W,training,3.6,62,0.767000081,7.961718816,NA,-1.345846321,29.67741585,-1.208896262,4,67,2,1,66.777776,3.040052881,76.41618866,*03:01,*04:01,5.008041714,no
S-181218-05809,pt268,45.43737166,Female,SP-MS,prog-MS,22.70225873,20.11545771,daclizumab (Zinbryta),W,validation,3.8,42,0.742102126,9.761923988,0,0.142695875,22.93900673,-0.30714758,3,83,NA,1,NA,-17.21973742,65.31658625,*14:01,*15:01,135.4696702,past
S-181218-05810,pt268,46.43394935,Female,SP-MS,prog-MS,23.69883641,20.62283737,daclizumab (Zinbryta),W,validation,3.75,39,0.733201422,9.609988595,0,0.459206973,24.23884602,0.025102047,3,74,6,1,NA,-18.79497095,NA,*14:01,*15:01,80.12522735,past
S-181218-05811,pt268,49.72758385,Female,SP-MS,prog-MS,26.99247091,20.90419501,daclizumab (Zinbryta),W,validation,4.3,43,0.711245877,8.722905701,NA,0.647590534,30.55741247,0.507966835,3.5,59,8,2,NA,-14.18761292,65.69526438,*14:01,*15:01,80.27536107,past
S-181218-05812,pt269,46.5982204,Male,RR-MS,RR-MS,10.46132786,NA,daclizumab (Zinbryta),W,validation,3.65,65,0.713355912,9.679406061,0,-0.533624954,11.44836231,-1.465119409,1.5,92,NA,0,NA,-22.56692702,80.21676422,*04:08,*15:02,37.21242477,no
S-181218-05813,pt269,47.59206023,Male,RR-MS,RR-MS,11.45516769,27.26252363,daclizumab (Zinbryta),W,validation,3.9,61,0.717867523,8.687948112,0,-0.407201983,12.06694075,-1.327299625,1.5,89,3,0,NA,-23.09672932,NA,*04:08,*15:02,93.84979608,no
S-181218-05814,pt270,42.80629706,Female,RR-MS,RR-MS,9.869952088,23.14528701,daclizumab (Zinbryta),W,training,3.85,63,0.74002174,9.905784912,0,-0.910935345,7.307213859,-1.994449965,1,96,NA,0,NA,-23.28072377,67.87634352,*03:02,*13:01,40.07327357,past
S-181218-05815,pt270,43.78370979,Female,RR-MS,RR-MS,10.84736482,23.28224137,daclizumab (Zinbryta),W,training,3.65,64,NA,NA,0,NA,10.05944959,NA,1.5,96,0,0,NA,NA,72.55057192,*03:02,*13:01,66.4852056,past
S-181218-05816,pt271,43.2936345,Female,RR-MS,RR-MS,11.40314853,22.06704988,daclizumab (Zinbryta),W,training,3.1,73,0.787275361,9.791438049,0,-2.283317576,9.479625793,-3.033570424,1.5,93,NA,0,NA,-8.642085937,53.82379376,*01:01,*11:04,293.7745613,no
S-181218-05817,pt271,44.32854209,Female,RR-MS,RR-MS,12.43805613,23.57162147,daclizumab (Zinbryta),W,training,3.55,75,0.790610314,8.996528148,NA,-2.447424152,10.51795409,-3.117793736,1.5,90,2,0,NA,-6.113072607,56.57602323,*01:01,*11:04,243.9399009,no
S-181218-05818,pt272,44.42710472,Male,RR-MS,RR-MS,13.52772074,25.11492699,daclizumab (Zinbryta),W,training,3.95,52,0.725130711,9.462343452,0,-0.070632389,11.72793806,-1.062497294,1.5,90,NA,0,NA,-26.49300898,64.29985711,*01:03,*03:01,2.100608847,current
S-181218-05819,pt272,45.38261465,Male,RR-MS,RR-MS,14.48323066,23.32341806,daclizumab (Zinbryta),W,training,3.7,55,0.746379577,8.812843434,0,-0.609987833,13.42647526,-1.427441708,1.5,87,1,0,NA,-19.89516118,NA,*01:03,*03:01,-8.495444503,current
S-181218-05820,pt273,51.70431211,Female,RR-MS,RR-MS,13.61806982,NA,daclizumab (Zinbryta),W,training,5.2,45,0.740338372,8.641179171,0,0.018643717,16.92588015,-0.720361289,2,86,NA,0,NA,-22.10601888,69.93651258,*07:01,*15:01,-83.66828391,no
S-181218-05821,pt273,52.81587953,Female,RR-MS,RR-MS,14.72963723,33.705045,daclizumab (Zinbryta),W,training,5.3,51,0.72986455,9.738907677,0,-0.104102121,19.01711078,-0.715762048,2,75,4,2,NA,-18.89980927,69.32390498,*07:01,*15:01,-32.52538371,no
S-181218-05822,pt274,57.53045859,Female,RR-MS,RR-MS,10.81724846,34.92767916,daclizumab (Zinbryta),W,training,4.45,60,0.77403494,8.693161274,0,-1.368881278,10.42717972,-2.218039327,1.5,96,NA,0,NA,-16.00094199,66.94946767,*11:01,*15:01,-130.9607863,no
S-181218-05823,pt274,58.46954141,Female,RR-MS,RR-MS,11.75633128,33.48822304,daclizumab (Zinbryta),W,training,4.4,56,0.780524421,8.050703381,0,-1.278152457,13.88980257,-1.963913425,1.5,88,1,0,NA,-13.36246708,NA,*11:01,*15:01,-88.87590812,no
S-181218-05824,pt275,37.52224504,Female,RR-MS,RR-MS,4.999315537,19.91111111,Untreated,W,training,4.8,56,NA,NA,0,NA,16.06455114,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,1855.473512,NA
S-181218-05825,pt276,61.63723477,Male,PP-MS,prog-MS,1.642710472,24.78425752,glatiramer acetate (Copaxone),W,training,5.5,37,NA,NA,NA,NA,17.7271674,NA,2,93,NA,0,11.777776,NA,NA,*13:03,*15:01,257.1678575,current
S-181218-05826,pt276,68.22724162,Male,PP-MS,prog-MS,8.232717317,27.59114933,glatiramer acetate (Copaxone),W,training,5.1,33,0.712744786,10.00034199,0,1.140147438,27.91240221,0.78500126,3.5,71,5,2,67.333332,-21.30683269,49.4221502,*13:03,*15:01,251.6736843,current
S-181218-05827,pt276,69.30047912,Male,PP-MS,prog-MS,9.305954825,28.51682642,glatiramer acetate (Copaxone) & Hydroxychloroquine,W,training,5.55,42,0.731684528,9.995747631,NA,0.330699791,34.33181438,0.436310998,4.5,69,6,2,88.92222002,-7.534689632,52.92226471,*13:03,*15:01,89.01047114,current
S-181218-05828,pt277,53.78234086,Male,SP-MS,prog-MS,25.98494182,31.97565063,daclizumab (Zinbryta),W,training,5.1,44,0.685087813,9.872822138,0,1.067698166,16.83243056,0.154527777,2,87,NA,0,NA,-31.72870124,58.42707065,*07,*07,186.361904,current
S-181218-05829,pt277,54.74058864,Male,SP-MS,prog-MS,26.9431896,32.65962176,daclizumab (Zinbryta),W,training,5.5,48,0.679283103,9.372374184,0,0.964611445,18.30629529,0.143868044,2,81,4,2,NA,-29.31843387,NA,*07,*07,61.13596499,current
S-181218-05830,pt277,58.34360027,Male,SP-MS,prog-MS,30.54620123,31.80465784,daclizumab (Zinbryta),W,training,4.35,46,0.680612818,9.825417897,NA,1.044535866,25.24574202,0.567708445,3,75,8,2,67.133332,-23.10499179,55.76260159,*07,*07,376.5305035,current
S-181218-05831,pt277,58.70773443,Male,SP-MS,prog-MS,30.91033539,32.14664341,daclizumab (Zinbryta),W,training,4.15,45,0.684924434,10.00518637,NA,1.018685892,27.68095112,0.671247604,3.5,75,8,2,74.433332,-20.43497084,56.86016881,*07,*07,644.9174573,current
S-181218-05832,pt278,42.04243669,Female,RR-MS,RR-MS,4.761122519,NA,Untreated,W,validation,4.2,NA,NA,NA,2.564949357,NA,11.93010291,NA,1.5,94,NA,0,10,NA,NA,*13,*15:01,4149.29892,current
S-181218-05834,pt278,42.19028063,Female,RR-MS,RR-MS,4.908966461,37.39409555,daclizumab (Zenapax),W,validation,4.35,NA,0.776532932,9.773549695,1.791759469,NA,13.300737,NA,1.5,87,NA,0,13,NA,NA,*13,*15:01,3612.517372,current
S-181218-05833,pt278,42.49965777,Female,RR-MS,RR-MS,5.2183436,NA,daclizumab (Zenapax),W,validation,4.45,NA,0.769862663,9.736310733,0,NA,14.66736512,NA,1.5,77,NA,1,25.45,NA,NA,*13,*15:01,1272.704669,current
S-181218-05835,pt278,43.88227242,Female,RR-MS,RR-MS,6.600958248,35.20969661,interferon beta-1a (Avonex),W,validation,NA,NA,0.785692701,9.531771484,0,NA,NA,NA,NA,71,NA,2,52.255554,NA,NA,*13,*15:01,NA,current
S-181218-05836,pt279,33.27310062,Female,RR-MS,RR-MS,5.065023956,25.01274611,Untreated,W,training,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*08:01,*11:04,5.412751828,no
S-181218-05837,pt280,42.53251198,Male,RR-MS,RR-MS,3.181382615,25.28010986,Untreated,W,training,4.55,53,0.735920797,8.990316948,1.098612289,-0.317319243,20.41815971,-0.822516742,2.5,88,NA,1,43.57222,-15.56197279,NA,*04:08,*13:01,607.0998051,past
S-181218-05838,pt280,43.58658453,Male,RR-MS,RR-MS,4.235455168,25.59220998,daclizumab (Zinbryta),W,training,5.1,51,0.73991478,9.23931648,0.693147181,-0.285476234,18.41222171,-0.898957719,2.5,86,NA,2,41.233332,-17.85716122,NA,*04:08,*13:01,986.5561202,past
S-181218-05839,pt280,44.58316222,Male,RR-MS,RR-MS,5.232032854,25.96673013,daclizumab (Zinbryta),W,training,4.75,44,NA,NA,NA,NA,23.08079357,NA,3,82,NA,2,50.366664,NA,NA,*04:08,*13:01,616.3563588,past
S-181218-05840,pt280,45.54140999,Male,RR-MS,RR-MS,6.19028063,25.99794014,daclizumab (Zinbryta),W,training,4.7,46,0.743644574,9.338645632,NA,-0.092983261,21.82382876,-0.562119741,3,82,4,2,71.4944401,-16.194091,NA,*04:08,*13:01,873.7711141,past
S-181218-05841,pt281,26.57905544,Female,RR-MS,RR-MS,8.501026694,22.5,interferon beta-1a (Rebif),W,training,5.5,74,0.783062897,9.024251729,1.386294361,-2.259256975,12.14903665,-2.87613589,1.5,94,NA,0,9.4,-6.191232916,NA,*13:01,*15:01,239.3078115,NA
S-181218-05842,pt281,27.61396304,Female,RR-MS,RR-MS,9.535934292,22.8125,daclizumab (Zinbryta),W,training,4.75,82,0.762473073,9.013108202,0,-2.303363199,11.70788827,-2.935804951,1.5,93,NA,0,15.4,-6.231736241,NA,*13:01,*15:01,108.1060603,NA
S-181218-05843,pt281,28.45722108,Female,RR-MS,RR-MS,10.37919233,22.2265625,daclizumab (Zinbryta),W,training,5.05,72,0.761421598,9.949034367,1.098612289,-1.764780121,10.93445445,-2.523940368,1.5,95,NA,0,NA,-11.89746476,57.30389179,*13:01,*15:01,293.4421489,NA
S-181218-05846,pt282,27.89048597,Female,RR-MS,RR-MS,7.206023272,NA,Untreated,W,validation,3.75,NA,0.779351889,9.867756743,2.772588722,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*13:01,*15:01,3490.072287,NA
S-181218-05847,pt282,28.04654346,Female,RR-MS,RR-MS,7.362080767,21.953125,daclizumab (Zenapax),W,validation,3.55,NA,0.75905281,10.04368418,1.791759469,NA,8.651387723,NA,1,98,NA,0,NA,NA,NA,*13:01,*15:01,4834.976638,NA
S-181218-05845,pt282,28.41341547,Female,RR-MS,RR-MS,7.728952772,22.8515625,daclizumab (Zenapax),W,validation,3.75,NA,0.806177723,9.901786106,0,NA,10.6616889,NA,1.5,94,NA,0,NA,NA,NA,*13:01,*15:01,1539.662429,NA
S-181218-05848,pt283,41.3744011,Female,RR-MS,RR-MS,19.87679671,NA,Untreated,W,training,4.1,NA,0.731074306,10.16442773,0.693147181,NA,12.25905234,NA,2,93,NA,0,NA,NA,NA,*04:01,*15:01,543.3822959,current
S-181218-05850,pt283,41.52224504,Female,RR-MS,RR-MS,20.02464066,NA,daclizumab (Zenapax),W,training,4.1,NA,0.730060434,10.25262919,0.693147181,NA,12.17192892,NA,2,92,NA,0,NA,NA,NA,*04:01,*15:01,377.856353,current
S-181218-05849,pt283,41.89459274,Female,RR-MS,RR-MS,20.39698836,NA,daclizumab (Zenapax),W,training,4.45,NA,0.722373505,10.29021147,0,NA,11.15936974,NA,1.5,85,NA,0,NA,NA,NA,*04:01,*15:01,199.1980567,current
S-181218-05851,pt284,37.32238193,Female,RR-MS,RR-MS,3.351129363,40.39503237,apl,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,1.5,96,NA,0,NA,NA,NA,*07:01,*07:01,NA,past
S-181218-05852,pt284,56.00273785,Female,RR-MS,RR-MS,22.03148528,29.33609543,dimethyl fumarate (Tecfidera),W,validation,6.3,19,0.686239512,9.658801111,0,2.345932123,37.07975481,2.267498596,4.5,64,5,2,112.655552,-23.09239388,79.29884499,*07:01,*07:01,89.45886263,past
S-181218-05853,pt284,57.09787817,Female,RR-MS,RR-MS,23.1266256,NA,dimethyl fumarate (Tecfidera),W,validation,5.6,27,NA,NA,NA,NA,44.38905192,NA,5.5,53,8,2,165.055552,NA,72.17400428,*07:01,*07:01,121.1188188,past
S-181218-05854,pt285,51.56468172,Female,RR-MS,RR-MS,19.69883641,35.03963569,natalizumab (Tysabri),AA,validation,6.05,48,0.730781828,9.642122788,0,0.035226189,17.5583962,-0.673932596,1.5,73,1,1,40.43888805,-21.62413203,64.92904104,*03:01,*15:01,-167.4713292,past
S-181218-05855,pt285,52.7118412,Female,RR-MS,RR-MS,20.84599589,32.92741548,natalizumab (Tysabri),AA,validation,6.15,49,0.732096966,9.601706556,NA,-0.04046853,27.72684483,-0.214556158,3,69,6,2,64.70000001,-10.76809983,62.99934232,*03:01,*15:01,-129.6357595,past
S-181218-05857,pt286,35.38672142,Male,SP-MS,prog-MS,9.152635181,25.34252988,interferon beta-1b (Betaseron),W,training,14.1,NA,NA,NA,NA,NA,47.9577018,NA,6,73,NA,4,NA,NA,NA,*15:01,*15:01,NA,NA
S-181218-05856,pt286,35.51813826,Male,SP-MS,prog-MS,9.284052019,25.31131987,interferon beta-1b (Betaseron),W,training,6.75,NA,NA,NA,NA,NA,38.5444954,NA,6,82,NA,4,NA,NA,NA,*15:01,*15:01,NA,NA
S-181218-05858,pt287,53.08966461,Female,SP-MS,prog-MS,28.42436687,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07,*07,63.47969283,NA
S-181218-05859,pt287,53.25941136,Female,SP-MS,prog-MS,28.59411362,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07,*07,162.9861161,NA
S-181218-05860,pt288,34.70225873,Female,RR-MS,RR-MS,0.164271047,26.85646671,interferon beta-1b (Betaseron),W,validation,NA,NA,NA,NA,2.63905733,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07,*10:01,NA,NA
S-181218-05861,pt289,36.29295003,Female,SP-MS,prog-MS,0.5229295,39.10572472,Untreated,W,training,12.5,NA,0.774604941,9.193906066,2.564949357,NA,47.09180086,NA,6.5,66,NA,4,NA,NA,NA,*13:01,*15:01,2358.159493,NA
S-181218-05862,pt289,36.42984257,Female,SP-MS,prog-MS,0.65982204,38.35296774,daclizumab (Zenapax),W,training,7.9,NA,0.788454299,9.072341874,1.945910149,NA,33.35479773,NA,4,67,NA,2,NA,NA,NA,*13:01,*15:01,3426.753201,NA
S-181218-05863,pt290,36.0164271,Male,RR-MS,RR-MS,0.878850103,30.05259204,Untreated,W,training,3.9,NA,0.723388042,9.709599359,1.098612289,NA,9.54063062,NA,1.5,95,NA,0,NA,NA,NA,*07:01,*15:01,374.7809452,NA
S-181218-05864,pt290,36.55578371,Male,RR-MS,RR-MS,1.418206708,NA,daclizumab (Zenapax),W,training,3.5,NA,0.762662091,9.267571005,0,NA,2.04264606,NA,0,100,NA,0,0,NA,NA,*07:01,*15:01,286.1960484,NA
S-181218-05865,pt291,40.89527721,Male,SP-MS,prog-MS,10.20123203,NA,Untreated,W,training,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01,*11,2609.156314,past
S-181218-05867,pt291,43.18412047,Male,SP-MS,prog-MS,12.49007529,NA,Untreated,W,training,5.6,NA,0.695165289,9.857234168,0.693147181,NA,30.41009145,NA,3,64,NA,2,NA,NA,NA,*01,*11,3316.77433,past
S-181218-05868,pt291,43.32648871,Male,SP-MS,prog-MS,12.63244353,NA,daclizumab (Zenapax),W,training,5.45,NA,0.692860022,9.847023016,0.693147181,NA,29.10884873,NA,3,64,NA,2,NA,NA,NA,*01,*11,1196.164631,past
S-181218-05866,pt291,43.76728268,Male,SP-MS,prog-MS,13.07323751,NA,daclizumab (Zenapax),W,training,5.35,NA,0.681549681,9.722445177,0,NA,36.3079035,NA,4.5,69,NA,2,NA,NA,NA,*01,*11,306.3998362,past
S-181218-05869,pt291,53.90554415,Male,SP-MS,prog-MS,23.21149897,29.86532505,natalizumab (Tysabri),W,training,179.9,29,NA,NA,NA,NA,60.02804281,NA,7,60,16,NA,NA,NA,NA,*01,*11,119.2886281,past
S-181218-05871,pt291,56.64339493,Male,SP-MS,prog-MS,25.94934976,33.39934024,dimethyl fumarate (Tecfidera),W,training,18.05,26,0.722770633,9.732461955,NA,1.32293851,55.36124065,2.349672774,6.5,51,18,5,198.761108,4.481597489,53.8628967,*01,*11,129.0420808,past
S-181218-05872,pt292,28.56399726,Male,RR-MS,RR-MS,1.152635181,20.44839453,Untreated,W,training,4.2,NA,0.814063524,8.561592779,1.098612289,NA,23.08792961,NA,2.5,80,NA,0,NA,NA,NA,*03:01,*11:01,2953.252933,past
S-181218-05875,pt292,28.60232717,Male,RR-MS,RR-MS,1.190965092,20.44839453,Untreated,W,training,4.2,NA,0.814063524,8.561592779,1.098612289,NA,23.08792961,NA,2.5,80,NA,0,NA,NA,NA,*03:01,*11:01,3067.768748,past
S-181218-05874,pt292,28.72279261,Male,RR-MS,RR-MS,1.311430527,20.81593104,daclizumab (Zenapax),W,training,3.75,NA,0.774061393,8.711607996,0.693147181,NA,21.47911149,NA,2.5,80,NA,1,NA,NA,NA,*03:01,*11:01,2572.271217,past
S-181218-05873,pt292,29.10061602,Male,RR-MS,RR-MS,1.689253936,20.88275586,daclizumab (Zenapax),W,training,4.15,NA,0.773250383,8.874727766,0,NA,18.49386262,NA,2,85,NA,0,NA,NA,NA,*03:01,*11:01,2117.255545,past
S-181218-05876,pt293,34.66392882,Male,RR-MS,RR-MS,2.088980151,NA,Untreated,W,training,3.05,NA,0.756919625,8.61667647,NA,NA,6.562029593,NA,1,95,NA,1,3,NA,NA,*04,*04,1847.22105,NA
S-181218-05878,pt293,34.83915127,Male,RR-MS,RR-MS,2.264202601,26.12850413,daclizumab (Zenapax),W,training,3,NA,0.760602315,8.662850764,0.693147181,NA,10.40671177,NA,2,91,NA,1,NA,NA,NA,*04,*04,872.2939633,NA
S-181218-05877,pt293,35.22245038,Male,RR-MS,RR-MS,2.647501711,27.097464,daclizumab (Zenapax),W,training,2.95,NA,0.760954521,8.404472321,0,NA,6.431525653,NA,1,96,NA,0,NA,NA,NA,*04,*04,307.2435638,NA
S-181218-05879,pt294,44.65160849,Female,RR-MS,RR-MS,0.410677618,29.79238754,Untreated,W,validation,NA,NA,NA,NA,0.693147181,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*07:01,*15:01,925.2108922,past
S-181218-05881,pt294,45.36071184,Female,RR-MS,RR-MS,1.119780972,30.62283737,Untreated,W,validation,4.1,NA,0.794443205,8.386172929,0,NA,12.34347174,NA,1.5,88,NA,0,NA,NA,NA,*07:01,*15:01,-1.611925393,past
S-181218-05882,pt294,45.45379877,Female,RR-MS,RR-MS,1.212867899,30.83044983,daclizumab (Zenapax),W,validation,4.75,NA,NA,NA,0,NA,11.91085738,NA,1.5,90,NA,0,NA,NA,NA,*07:01,*15:01,285.2311688,past
S-181218-05880,pt294,45.86721424,Female,RR-MS,RR-MS,1.626283368,31.28027682,daclizumab (Zenapax),W,validation,4.5,NA,0.790537322,8.706490362,0,NA,11.85837529,NA,1.5,89,NA,0,NA,NA,NA,*07:01,*15:01,21.45715749,past
S-181218-05883,pt294,57.24845996,Female,RR-MS,RR-MS,13.00752909,32.41503395,natalizumab (Tysabri),W,validation,4.9,53,0.78628813,9.220092663,0.693147181,-1.226286536,18.19882477,-1.698855396,2,78,5,0,45.933332,-9.524576217,NA,*07:01,*15:01,103.6593193,past
S-181218-05884,pt295,36.95550992,Female,RR-MS,RR-MS,0.167008898,26.65709,Untreated,W,training,4.1,NA,0.708369984,10.5322562,2.708050201,NA,11.73858349,NA,1.5,85,NA,1,16.7,NA,NA,*04:03,*15:01,1950.119407,no
S-181218-05888,pt295,37.14442163,Female,RR-MS,RR-MS,0.355920602,NA,daclizumab (Zenapax),W,training,4,NA,0.699348172,10.53478592,1.609437912,NA,8.499497157,NA,1,92,NA,0,10.2,NA,NA,*04:03,*15:01,1544.590341,no
S-181218-05885,pt295,37.52772074,Female,RR-MS,RR-MS,0.739219713,26.38937174,daclizumab (Zenapax),W,training,3.8,NA,0.697673909,10.57510461,1.098612289,NA,7.743253755,NA,1,92,NA,1,6.5,NA,NA,*04:03,*15:01,398.5941852,no
S-181218-05886,pt295,47.62765229,Female,RR-MS,RR-MS,10.83915127,29.90795464,dimethyl fumarate (Tecfidera),W,training,4.55,38,0.768440024,10.29785801,0,-0.12477497,14.60298926,-0.960066939,1.5,84,1,1,17,-23.12614607,NA,*04:03,*15:01,-45.7860798,no
S-181218-05887,pt295,48.62422998,Female,RR-MS,RR-MS,11.83572895,31.93496435,dimethyl fumarate (Tecfidera),W,training,4.5,37,0.740748222,9.999842641,0,0.426933138,15.97638228,-0.426808665,1.5,80,1,1,23,-26.76427079,NA,*04:03,*15:01,83.85592759,no
S-181218-05889,pt296,52.38329911,Female,RR-MS,RR-MS,0.049281314,26.04516254,Untreated,W,training,6.85,NA,0.706587694,9.547883464,1.791759469,NA,21.57533416,NA,3.5,83,NA,2,NA,NA,NA,*01:01,*04:05,-346.1819809,NA
S-181218-05890,pt296,52.55304586,Female,RR-MS,RR-MS,0.219028063,NA,daclizumab (Zenapax),W,training,7.1,NA,NA,NA,1.098612289,NA,21.99277968,NA,3.5,83,NA,2,NA,NA,NA,*01:01,*04:05,-347.7073419,NA
S-181218-05892,pt297,44.26009582,Female,SP-MS,prog-MS,26.71594798,21.97352766,Untreated,W,validation,12.7,58,0.750276615,6.52649486,0.693147181,-0.836198959,46.41093506,0.078893123,6,66,14,4,NA,15.14411902,43.15637938,*03:01,*15:01,-36.00923364,past
S-181218-05898,pt298,44.36960986,Female,HD,HD,NA,20.3125,Untreated,W,HD,NA,NA,NA,NA,NA,NA,4.82,NA,NA,NA,NA,NA,NA,NA,NA,*01,*13,-16.67985817,no
S-181218-05899,pt298,45.3853525,Female,HD,HD,NA,20.3125,Untreated,W,HD,NA,NA,NA,NA,NA,NA,4.82,NA,NA,NA,NA,NA,NA,NA,NA,*01,*13,64.8885101,no
S-181218-05900,pt299,56.81861739,Female,PP-MS,prog-MS,16.67624914,28.22030041,Untreated,W,training,7.1,43,0.7888273,8.91449171,NA,-0.752502976,44.15703833,0.033184151,6,64,10,4,122.84444,12.12995812,NA,*11,*15:01,246.5556466,past
S-181218-05901,pt299,58.73511294,Female,PP-MS,prog-MS,18.5927447,24.82406078,Untreated,W,training,6.05,42,0.788025336,8.959183074,NA,-0.686069386,43.1706378,0.038172964,5.5,58,12,2,NA,10.54009879,NA,*11,*15:01,158.9544949,past
S-181218-05902,pt299,59.75085558,Female,PP-MS,prog-MS,19.60848734,24.85907356,Untreated,W,training,5.4,43,0.780036993,8.93485034,NA,-0.593866394,42.27812686,0.069598648,5.5,61,8,2,99.9,8.810049074,NA,*11,*15:01,22.01492218,past
S-181218-05903,pt299,60.72553046,Female,PP-MS,prog-MS,20.58316222,26.53968699,Untreated,W,training,5.2,37,0.778200247,9.069698042,NA,-0.24895466,46.46963984,0.574350706,5.5,50,10,2,224.038886,9.868508091,NA,*11,*15:01,-6.652772006,past
S-181218-05904,pt300,33.68377823,Male,HD,HD,NA,25.84592517,Untreated,W,HD,3.7,69,0.779537722,4.890349128,NA,-1.9358353,2.328749753,-3.109876527,0,100,NA,0,0,-18.13590662,NA,*11:04,*13,-65.44762375,past
S-181218-05905,pt300,34.70225873,Male,HD,HD,NA,26.76570899,Untreated,W,HD,4,71,0.774631829,9.069813137,NA,-1.951221286,2.605351184,-3.108556031,0,100,0,0,0,-18.53300363,NA,*11:04,*13,-90.41601448,past
S-181218-05906,pt300,35.94524298,Male,HD,HD,NA,27.16428197,Untreated,W,HD,3.45,79,0.778836171,5.075173815,NA,-2.442781934,1.710378843,-3.566777217,0,100,0,0,0,-14.96281609,NA,*11:04,*13,-29.88247645,past
S-181218-05907,pt301,60.05749487,Female,PP-MS,prog-MS,5.678302533,23.61799816,Untreated,W,training,4.8,NA,0.79622969,7.592366129,0.693147181,NA,22.22597962,NA,3,80,4,1,57.483332,NA,NA,*07:01,*16:01,223.583379,past
S-181218-05908,pt301,62.10814511,Female,PP-MS,prog-MS,7.728952772,24.53627181,Untreated,W,training,5.5,59,0.78995953,7.783640596,NA,-1.604307835,21.06419419,-1.868514312,3,83,4,2,64.233332,-3.225397472,NA,*07:01,*16:01,296.3823015,past
S-181218-05909,pt301,63.12388775,Female,PP-MS,prog-MS,8.744695414,24.75665748,Untreated,W,training,4.95,59,0.769896158,9.382948237,NA,-1.242228927,20.74529659,-1.581287131,3,83,5,2,54.4055541,-6.833289465,62.45709477,*07:01,*16:01,444.4698907,past
S-181218-05910,pt301,64.19712526,Female,PP-MS,prog-MS,9.817932923,24.24242424,Untreated,W,training,5.05,61,0.748719171,7.056175284,NA,-0.963974345,24.30448751,-1.164944368,3,78,5,2,61.9333321,-5.801662949,60.01481997,*07:01,*16:01,612.7227272,past
S-181218-05911,pt301,65.23203285,Female,PP-MS,prog-MS,10.85284052,25.52800735,Untreated,W,training,5.85,55,0.746696183,7.622663951,NA,-0.615701546,27.64595514,-0.701082296,3.5,76,8,2,80.783332,-5.623779987,60.2935065,*07:01,*16:01,368.2888701,past
S-181218-05914,pt302,54.52156057,Female,SP-MS,prog-MS,21.77412731,25.91087241,Untreated,W,validation,6.55,24,0.704652345,10.32433376,0,1.753836421,48.45396828,2.355841455,6,58,10,4,NA,-6.339796309,53.15480752,*08:01,*15:01,101.0016742,NA
S-181218-05915,pt303,56.22176591,Male,HD,HD,NA,34.49690696,Untreated,W,HD,4.95,32,0.749029066,9.332292483,NA,0.537294392,17.60029988,-0.250764097,1,90,NA,0,NA,-34.28718858,NA,*04:01:01,*13,65.4517495,past
S-181218-05916,pt303,57.29500342,Male,HD,HD,NA,34.66436848,Untreated,W,HD,4.8,35,0.755412506,7.526717561,NA,0.26621176,17.66632483,-0.474687969,1,90,0,0,NA,-31.75874663,NA,*04:01:01,*13,37.67393874,past
S-181218-05917,pt303,59.2881588,Male,HD,HD,NA,NA,Untreated,W,HD,5.35,29,0.759650812,7.403061091,NA,0.501488473,18.02164798,-0.2591242,1,NA,0,NA,NA,-33.54059241,NA,*04:01:01,*13,-182.2004204,past
S-181218-05918,pt303,60.78302533,Male,HD,HD,NA,35.11231512,Untreated,W,HD,5.65,33,0.721493486,7.061334367,NA,0.982261728,21.12583541,0.303646636,2,88,0,0,54.188888,-30.46187316,55.16889578,*04:01:01,*13,-78.82360018,past
S-181218-05919,pt304,65.92197125,Male,PP-MS,prog-MS,15.71526352,24.47268794,natalizumab (Tysabri),W,training,10.95,28,0.727642991,9.369478593,NA,1.131086751,53.88386525,2.112828649,6,52,13,4,135.0999962,4.746934369,NA,*08:01,*15:01,2757.176225,past
S-181218-05920,pt304,67.89596167,Male,PP-MS,prog-MS,17.68925394,24.00738689,Untreated,W,training,12.5,28,0.728812512,10.23802936,NA,1.109980683,57.0859274,2.259776631,6.5,48,14,5,NA,8.140716436,NA,*08:01,*15:01,3592.446723,past
S-181218-05921,pt304,68.8733744,Male,PP-MS,prog-MS,18.66666667,24.39446367,Untreated,W,training,13,26,0.719972474,9.49031784,NA,1.37343622,58.2607093,2.541105716,6.5,53,14,5,163.1111082,6.922363123,NA,*08:01,*15:01,1594.453066,past
S-181218-05922,pt304,69.79329227,Male,PP-MS,prog-MS,19.58658453,23.23250037,Untreated,W,training,9.95,28,NA,NA,NA,NA,56.76081154,NA,6.5,39,18,5,236.9888841,NA,46.05760877,*08:01,*15:01,930.236654,past
S-181218-05923,pt305,50.39288159,Female,PP-MS,prog-MS,2.932238193,28.85053044,glatiramer acetate (Copaxone),W,validation,15.9,40,0.786754395,9.203617826,1.386294361,-0.559211544,50.96610806,0.545385642,6.5,58,NA,5,NA,17.1832381,55.11474559,*03:01,*15:01,486.8231175,past
S-181218-05924,pt306,57.54140999,Male,PP-MS,prog-MS,18.65845311,29.50919416,Untreated,W,training,5.6,45,0.784886873,7.767263997,NA,-0.785312498,19.30171787,-1.272363005,2.5,84,4,0,83.49444,-12.42733246,NA,*11,*15:01,163.877736,past
S-181218-05925,pt306,59.49623546,Male,PP-MS,prog-MS,20.61327858,29.37398594,Untreated,W,training,4.65,47,0.779086591,7.898411093,NA,-0.784557658,23.83913255,-1.038420937,3,72,5,2,NA,-7.896774473,NA,*11,*15:01,136.5370744,past
S-181218-05926,pt306,60.58863792,Male,PP-MS,prog-MS,21.70568104,29.71200649,Untreated,W,training,4.75,49,0.77893777,7.896552702,NA,-0.885793392,24.03983237,-1.112993308,3,77,4,2,63.888886,-6.776485703,NA,*11,*15:01,129.1757103,past
S-181218-05927,pt306,61.60438056,Male,PP-MS,prog-MS,22.72142368,27.21065441,Untreated,W,training,5.45,45,0.758774167,7.921898411,NA,-0.314062696,39.73585693,0.173509737,5.5,61,7,2,157.999996,3.726143128,73.2829863,*11,*15:01,159.9618431,past
S-181218-05929,pt307,54.30800821,Female,SP-MS,prog-MS,28.88706366,25.64891762,Untreated,W,training,24.15,47,0.761455591,9.119868469,0,-0.466375189,54.47019884,0.803411073,6.5,59,NA,6,201.305552,19.84403687,NA,*01,*15:01,36.5315119,past
S-181218-05930,pt307,55.14579055,Female,SP-MS,prog-MS,29.724846,25.35049661,Untreated,W,training,16.9,42,0.762350806,9.284426915,0,-0.222727243,53.26288129,0.945645275,6.5,52,17,5,215.305552,16.42350913,NA,*01,*15:01,124.8247072,past
S-181218-05931,pt307,55.37577002,Female,SP-MS,prog-MS,29.95482546,25.39792388,rituximab,W,training,17.75,NA,0.737438903,9.450616322,0,NA,53.37641225,NA,6.5,52,17,5,215.305552,NA,48.45553048,*01,*15:01,76.49035145,past
S-181218-05932,pt307,55.49623546,Female,SP-MS,prog-MS,30.0752909,25.39792388,rituximab,W,training,17.75,NA,0.749836141,9.282009659,0,NA,53.37641225,NA,6.5,52,17,5,215.305552,NA,NA,*01,*15:01,44.79588361,past
S-181218-05933,pt308,36.04928131,Male,PP-MS,prog-MS,11.86858316,26.08104915,glatiramer acetate (Copaxone),W,validation,4.9,61,0.775176999,8.103494278,NA,-1.441452481,31.77185262,-1.181373941,4,67,10,2,108.427776,6.002941581,NA,*03:01,*15:01,120.860241,no
S-181218-05934,pt308,38.02327173,Male,PP-MS,prog-MS,13.84257358,25.29887695,Untreated,W,validation,4.85,67,0.778656661,8.111928063,NA,-1.81601353,30.30629239,-1.570823079,4,68,10,2,NA,7.939759011,NA,*03:01,*15:01,152.2785467,no
S-181218-05935,pt308,38.88569473,Male,PP-MS,prog-MS,14.70499658,NA,Untreated,W,validation,4.3,63,0.779475069,7.899153483,NA,-1.622940201,30.19773136,-1.414501778,4,75,11,2,61.85,6.077389403,NA,*03:01,*15:01,115.4875635,no
S-181218-05937,pt309,52.91444216,Female,SP-MS,prog-MS,12.53114305,29.17823977,Untreated,W,training,36.75,54,0.765834928,7.657755271,0,-0.909133195,44.78370021,-0.065937248,6,65,10,4,NA,14.17939249,59.13887404,*01:01:01,*11:01:01,127.9854197,past
S-181218-05938,pt310,55.67145791,Male,PP-MS,prog-MS,10.9650924,25.40494991,Untreated,W,validation,4.7,73,0.734204757,11.78865388,NA,-1.325564993,25.22038122,-1.421065202,3,74,3,2,63.53333201,-1.601210022,NA,*03:01,*13:05,39.24675975,past
S-181218-05939,pt310,57.54962355,Male,PP-MS,prog-MS,12.84325804,26.84061047,Untreated,W,validation,3.55,57,0.673708404,11.1100869,NA,0.597570091,22.49435119,0.051427609,3,75,2,2,NA,-21.79630651,56.99054742,*03:01,*13:05,26.18759107,past
S-181218-05940,pt310,58.62286105,Male,PP-MS,prog-MS,13.91649555,27.49602072,Untreated,W,validation,4,65,0.757297181,10.70369381,NA,-1.326622597,21.37912626,-1.619465355,3,81,3,2,49.48888801,-5.432858092,NA,*03:01,*13:05,51.63910113,past
S-181218-05941,pt310,59.67693361,Male,PP-MS,prog-MS,14.9705681,27.49602072,Untreated,W,validation,5.1,52,0.74138955,7.649692624,NA,-0.364051794,32.03655753,-0.264298952,3.5,59,5,2,114.499996,-3.519073313,59.02256061,*03:01,*13:05,138.1530944,past
S-181218-05943,pt311,50.92128679,Male,PP-MS,prog-MS,1.63449692,27.41868556,Untreated,W,training,5.4,41,0.773279483,7.114769448,0,-0.367993745,23.05435662,-0.729459834,3,85,3,2,27.5,-12.46546696,NA,*04:05,*11:01,-131.1025531,past
S-181218-05944,pt311,52.91444216,Male,PP-MS,prog-MS,3.627652293,25.02389782,Untreated,W,training,5.95,44,0.76563114,6.997595983,NA,-0.385848123,33.32620709,-0.216264038,3.5,74,6,2,NA,-2.031433748,NA,*04:05,*11:01,-74.14412544,past
S-181218-05945,pt312,59.97535934,Male,PP-MS,prog-MS,24.04106776,22.12666846,Untreated,W,training,8.5,37,0.771187082,7.340835554,NA,-0.122389737,31.91658014,-0.067820149,3.5,74,7,2,120.51666,-5.834221782,NA,*04:01,*13:02,128.7961749,past
S-181218-05946,pt312,61.85352498,Male,PP-MS,prog-MS,25.9192334,22.36555287,Untreated,W,training,9.2,47,0.769794879,6.396929655,NA,-0.616872339,35.27703049,-0.309682208,4,70,7,2,101.527776,2.017930423,NA,*04:01,*13:02,132.3623874,past
S-181218-05947,pt312,62.85010267,Male,PP-MS,prog-MS,26.91581109,22.72387948,Untreated,W,training,12.8,49,0.767140235,6.137727054,NA,-0.672886081,45.98740474,0.194063138,6.5,68,14,5,131.24444,13.23711333,NA,*04:01,*13:02,116.3120123,past
S-181218-05948,pt312,64.84325804,Male,PP-MS,prog-MS,28.90896646,22.93290334,ocrelizumab (Ocrevus),W,training,23.3,46,0.753281596,7.577633833,NA,-0.266900308,49.06243697,0.692621121,6.5,62,14,6,148.14444,12.62431702,65.20400969,*04:01,*13:02,257.7600594,past
S-181218-05949,pt313,28.15331964,Female,PP-MS,prog-MS,4.197125257,17.60975744,Untreated,W,training,179.9,4,0.692880924,10.65657677,0,3.005487175,84.5345133,5.260648246,8.5,37,21,8,NA,18.37120406,56.51638664,*04:04,*16:01,9618.371556,NA
S-181218-05950,pt314,42.58726899,Female,SP-MS,prog-MS,7.099247091,26.9921875,Untreated,W,training,14,50,0.804932357,8.957252944,0,-1.406872264,52.93554031,-0.064161826,6.5,55,17,6,197.54444,26.85251504,NA,*07:01,*15:01,198.6471336,past
S-181218-05951,pt315,63.52087611,Female,PP-MS,prog-MS,23.08008214,20.390625,Untreated,W,training,79.4,26,0.746789371,9.486152272,NA,0.889478051,56.84045455,2.062250189,6.5,55,16,6,186.877776,9.898210079,NA,*04:01,*15:01,238.872045,past
S-181218-05952,pt315,65.66735113,Female,PP-MS,prog-MS,25.22655715,22.0703125,Untreated,W,training,179.9,20,0.741789274,9.555843139,NA,1.291478029,66.01056959,2.870868594,7.5,54,19,8,NA,15.41670211,NA,*04:01,*15:01,194.8226811,past
S-181218-05953,pt315,66.68309377,Female,PP-MS,prog-MS,26.24229979,21.9921875,Untreated,W,training,179.9,35,0.745484412,9.624963418,NA,0.445381714,67.53961333,2.239988658,7.5,54,21,7,237.566664,24.63138004,NA,*04:01,*15:01,204.2229948,past
S-181218-05954,pt316,63.137577,Male,SP-MS,prog-MS,19.06091718,32.98758218,interferon beta-1b (Betaseron),W,validation,5.5,46,0.731858773,10.30948585,0,0.11971229,46.89225459,0.905230134,6,63,10,4,140.4444401,6.94228505,51.13500116,*07:01,*15:01,633.184906,past
S-181218-05955,pt316,65.28405202,Male,SP-MS,prog-MS,21.2073922,33.89335281,dimethyl fumarate (Tecfidera),W,validation,5.1,28,NA,NA,0,NA,46.5002953,NA,6,65,11,2,145.2444401,NA,58.23066515,*07:01,*15:01,590.3244669,past
S-181218-05956,pt316,66.51060917,Male,SP-MS,prog-MS,22.43394935,36.1723886,interferon beta-1b (Betaseron),W,validation,6.4,48,0.671903325,8.672999643,NA,1.097792545,46.84351997,1.722902341,6,60,15,2,162.86666,-1.990978338,NA,*07:01,*15:01,702.7078545,past
S-181218-05957,pt316,67.73716632,Male,SP-MS,prog-MS,23.6605065,36.78597516,interferon beta-1b (Betaseron),W,validation,7.15,47,0.726762433,9.053218616,NA,0.159723991,46.17487784,0.901895552,6,56,15,4,206.1888761,5.861456414,51.21933068,*07:01,*15:01,646.3614454,past
S-181218-05958,pt317,33.11430527,Male,HD,HD,NA,39.48798454,Untreated,AA,HD,NA,NA,0.758005281,4.86753445,NA,NA,7.9148,NA,NA,NA,NA,NA,NA,NA,NA,*03:02,*13:01,-68.67322398,NA
S-181218-05961,pt318,29.43737166,Male,RR-MS,RR-MS,7.030800821,26.90612245,Untreated,W,training,3,61,0.795929959,9.28924397,0,-1.81597622,16.24644257,-2.293734481,2.5,85,1,0,NA,-6.120429714,71.50748176,*11:04,*13:01,870.595446,past
S-181218-05963,pt319,59.43052704,Female,PP-MS,prog-MS,7.121149897,26.08452085,Untreated,W,training,7,41,0.744125624,7.323830566,NA,0.158139023,43.17894652,0.746518826,6,62,10,4,140.766664,2.879922375,NA,*01,*03,183.725497,past
S-181218-05964,pt320,47.4934976,Female,PP-MS,prog-MS,3.137577002,26.0261749,Untreated,W,validation,6.15,63,0.761862565,9.250522162,NA,-1.305091526,20.33194524,-1.655255226,2.5,72,4,2,58.433332,-6.675619608,NA,*04,*07,281.700988,past
S-181218-05965,pt320,51.03901437,Female,PP-MS,prog-MS,6.683093771,25.2082094,natalizumab (Tysabri),W,validation,7.55,60,0.771399941,8.393442384,NA,-1.321328077,39.34336229,-0.691323467,5,61,8,2,124.8666641,12.48328443,58.93869678,*04,*07,88.2886323,past
S-181218-05966,pt320,52.15058179,Female,PP-MS,prog-MS,7.794661191,23.60945866,natalizumab (Tysabri),W,validation,6.5,70,0.774896605,8.274357007,NA,-1.9040389,41.90886233,-1.048045611,5.5,60,9,2,144.2166641,20.34191971,59.95401583,*04,*07,113.1387377,past
S-181218-05967,pt321,56.05749487,Female,PP-MS,prog-MS,8.156057495,20.703125,Untreated,W,training,25.25,27,NA,NA,NA,NA,48.55273981,NA,6.5,67,13,6,102.92222,NA,NA,*01:01,*15:01,242.0637983,no
S-181218-05968,pt321,58.03148528,Female,PP-MS,prog-MS,10.13004791,18.515625,Untreated,W,training,41.65,27,0.758056215,8.379079889,NA,0.634187258,52.58784633,1.629509132,6.5,59,15,6,NA,7.964571474,NA,*01:01,*15:01,188.517818,no
S-181218-05969,pt321,59.00889802,Female,PP-MS,prog-MS,11.10746064,23.75,Untreated,W,training,30.2,28,0.756465574,8.500250471,NA,0.610932442,52.40585554,1.60065082,6.5,59,16,6,136.92222,7.993819053,NA,*01:01,*15:01,264.4057159,no
S-181218-05970,pt321,59.98631075,Female,PP-MS,prog-MS,12.08487337,22.734375,Untreated,W,training,24.55,30,0.747962753,8.775394959,NA,0.660459362,56.74036694,1.865058085,6.5,46,16,6,218.53333,11.87844576,NA,*01:01,*15:01,332.0718345,no
S-181218-05971,pt322,61.63449692,Female,PP-MS,prog-MS,24.17522245,26.30433923,Untreated,W,training,25.3,29,0.770763101,9.605216279,NA,0.300947633,55.09328756,1.478895168,6.5,55,14,4,214.711104,13.49704143,NA,*03:01,*15:01,179.9558377,past
S-181218-05972,pt322,63.62765229,Female,PP-MS,prog-MS,26.16837782,29.80228928,Untreated,W,training,136,22,0.7607125,9.580661778,NA,0.846053593,67.5744313,2.577766008,6.5,47,16,7,NA,21.02663897,NA,*03:01,*15:01,480.932467,past
S-181218-05973,pt322,64.60506502,Female,PP-MS,prog-MS,27.14579055,NA,Untreated,W,training,179.9,22,0.760181265,9.644198555,NA,0.855640665,69.4757566,2.683569482,7,55,19,8,260.74444,22.84087876,NA,*03:01,*15:01,228.4706031,past
S-181218-05974,pt322,65.77412731,Female,PP-MS,prog-MS,28.31485284,29.30280957,ocrelizumab (Ocrevus),W,training,168.5,21,0.748722092,9.870654395,NA,1.114402373,71.9161342,3.026038113,7,42,17,7,255.59444,22.93075819,48.70065445,*03:01,*15:01,235.3228742,past
S-181218-05975,pt323,47.2881588,Male,PP-MS,prog-MS,5.212867899,25.21548576,Untreated,W,training,8.15,63,0.796346115,8.116118432,0,-1.927407961,45.76241858,-0.869496141,6.5,58,21,5,176.177768,24.40775209,NA,*03:01,*15:01,729.7269946,current
S-181218-05976,pt323,49.30047912,Male,PP-MS,prog-MS,7.225188227,26.38422206,Untreated,W,training,7.15,60,0.787214642,7.149131599,NA,-1.606732229,46.50263045,-0.562529675,6.5,55,21,5,NA,22.23506111,NA,*03:01,*15:01,449.954954,current
S-181218-05977,pt324,67.96440794,Male,SP-MS,prog-MS,26.40657084,33.79017735,Untreated,W,training,7.85,57,0.674426243,10.88395424,0,0.584615421,NA,NA,NA,NA,NA,NA,NA,NA,47.1665648,*13:01,*13:02,490.851765,current
S-181218-05978,pt324,69.68925394,Male,SP-MS,prog-MS,28.13141684,34.24803883,glatiramer acetate (Copaxone),W,training,8.25,58,0.659639818,10.93688554,0,0.799501784,44.87270586,1.371430723,6.5,69,16,5,160.422216,-1.252226612,50.55890117,*13:01,*13:02,256.868544,current
S-181218-05980,pt325,60.27926078,Female,SP-MS,prog-MS,28.38603696,17.95315678,Untreated,W,validation,10.75,31,0.780177138,8.655040258,0,0.027133272,52.15994799,1.098456411,6.5,44,18,5,263.144436,13.0509329,NA,*15:01,*15:01,-97.0817501,no
S-181218-05981,pt325,63.59479808,Female,SP-MS,prog-MS,31.70157426,18.29694063,Untreated,W,validation,10.4,32,0.745043867,7.967280179,NA,0.609214332,57.58616251,1.865576018,6.5,33,19,5,347.777764,13.18973272,64.95650865,*15:01,*15:01,11.53284062,no
S-181218-05982,pt325,64.15058179,Female,SP-MS,prog-MS,32.25735797,18.64072448,Untreated,W,validation,12.95,26,0.778902094,8.90666441,NA,0.309947368,57.89385299,1.630444106,6.5,38,19,5,333.899988,16.21585652,51.40409248,*15:01,*15:01,28.00342484,no
S-181218-05983,pt326,23.46064339,Female,HD,HD,NA,22.43230252,Untreated,AA,HD,3.45,63,NA,NA,NA,NA,6.980546145,NA,1,98,1,0,NA,NA,NA,*07:01,*11:01,-17.66028672,NA
S-181218-05984,pt327,46.15195072,Female,HD,HD,NA,31.31136138,Untreated,AA,HD,NA,NA,0.780497159,7.947678571,NA,NA,6.8832,NA,1,95,NA,1,NA,NA,NA,*13:01,*15:03,53.50908021,past
S-181218-05987,pt328,32.41889117,Male,HD,HD,NA,38.14357305,Untreated,AA,HD,4.75,40,NA,NA,NA,NA,3.982753227,NA,0,100,0,0,NA,NA,NA,*03,*07,283.7029961,past
S-181218-05988,pt328,35.44695414,Male,HD,HD,NA,38.13528718,Untreated,AA,HD,4.35,32,0.793129358,8.357024439,NA,-0.258573101,13.96156588,-1.105245893,1.5,93,0,0,NA,-24.86025032,77.81074117,*03,*07,-68.14001825,past
S-181218-05989,pt329,51.4661191,Male,SP-MS,prog-MS,25.32785763,22.89307408,Untreated,W,validation,44.35,22,0.726076959,10.09212247,1.386294361,1.471112973,68.77828762,3.163816259,6.5,47,20,6,299.472208,16.552681,61.47181875,*11:01,*13:01,782.3123205,past
S-181218-05990,pt330,69.55509925,Female,SP-MS,prog-MS,28.59685147,35.46655881,Untreated,W,validation,85.2,34,NA,NA,NA,NA,60.2634318,NA,6.5,54,17,6,NA,NA,57.07072872,*04:03,*15:01,-206.231312,past
S-181218-05991,pt331,49.2183436,Female,SP-MS,prog-MS,23.52087611,19.74161707,Untreated,W,training,49.3,60,0.783502798,7.922985959,0,-1.539745462,56.77725583,0.021953117,6.5,54,21,6,205.166662,31.90120283,NA,*15:01,*15:01,37.51011983,past
S-181218-05992,pt331,52.47638604,Female,SP-MS,prog-MS,26.77891855,22.89882421,Untreated,W,training,56.5,54,0.782814343,7.887584032,NA,-1.215556664,58.14928084,0.364352663,6.5,50,20,6,270.188882,30.32841355,60.28818671,*15:01,*15:01,36.40375265,past
S-181218-05993,pt332,62.08350445,Female,SP-MS,prog-MS,34.54072553,26.04182414,Untreated,W,training,25.95,44,0.733792569,8.144098463,0,0.188735004,62.2184889,1.751168606,6.5,46,21,6,177.066664,21.64154188,61.47024148,*03:01,*03:01,102.8092281,past
S-181218-05994,pt332,65.09240246,Female,SP-MS,prog-MS,37.54962355,26.64001589,Untreated,W,training,179.9,36,0.68661674,7.708410667,NA,1.45579187,71.9161342,3.31231338,7,42,18,7,231.299996,19.82969897,NA,*03:01,*03:01,197.1249295,past
S-181218-05995,pt332,65.99315537,Female,SP-MS,prog-MS,38.45037645,28.21869489,Untreated,W,training,179.9,38,0.72718167,8.321907968,NA,0.619804743,73.8174595,2.709052921,7.5,39,21,8,284.09444,29.32483023,58.20748766,*03:01,*03:01,62.23599303,past
S-181218-05998,pt333,63.4770705,Male,SP-MS,prog-MS,32.57768652,27.26251981,Untreated,W,training,18.75,33,0.683439475,9.658481754,0,1.669013424,58.99630312,2.826788128,6.5,38,19,5,NA,4.973040084,49.92146366,*04:01:01,*13:01,104.2582745,past
S-181218-05999,pt333,66.38740589,Male,SP-MS,prog-MS,35.4880219,26.51437163,Untreated,W,training,29.45,22,0.677757486,9.871584004,NA,2.343123024,64.33769022,3.666717367,6.5,37,19,6,NA,4.191058372,61.74451375,*04:01:01,*13:01,-0.59723596,past
S-181218-06000,pt334,54.82272416,Male,RR-MS,RR-MS,0.177960301,23.1856056,Untreated,AA,training,6,28,0.743148424,11.07734645,3.931825633,0.851263885,30.97621651,0.700293439,4,71,4,2,66.688888,-15.61890424,NA,*13:01,*16:01,11224.90324,current
S-181218-06001,pt334,55.51266256,Male,RR-MS,RR-MS,0.8678987,24.57432677,natalizumab (Tysabri),AA,training,4.95,40,NA,NA,NA,NA,19.28728272,NA,2,74,2,2,56.138888,NA,NA,*13:01,*16:01,1442.139515,current
S-181218-06002,pt334,56.7008898,Male,RR-MS,RR-MS,2.056125941,24.1516725,dimethyl fumarate (Tecfidera),AA,training,5.25,30,0.721919207,10.49180186,0,1.130461049,23.96332929,0.573821474,3,72,2,2,62.338888,-25.16791794,NA,*13:01,*16:01,508.2316692,current
S-181218-06003,pt334,58.5982204,Male,RR-MS,RR-MS,3.953456537,24.57432677,ocrelizumab (Ocrevus),AA,training,4.8,29,NA,NA,NA,NA,29.42954944,NA,3,64,4,2,80.383332,NA,70.20070573,*13:01,*16:01,535.5190259,current
S-181218-06004,pt335,51.44969199,Female,PP-MS,prog-MS,5.453798768,22.35447815,Untreated,AA,validation,17.25,52,0.774344762,9.744374581,0.693147181,-0.958786676,49.01068272,0.109772368,6.5,65,14,6,141.666664,18.85740934,NA,*01:01,*13:01,268.3796632,past
S-181218-06005,pt335,53.61533196,Female,PP-MS,prog-MS,7.619438741,24.53186239,Untreated,AA,validation,42.15,43,0.747720537,9.867912187,NA,-0.01065899,50.86756845,1.00031257,6.5,57,14,6,NA,12.10184466,NA,*01:01,*13:01,304.5302794,past
S-181218-06006,pt335,54.43942505,Female,PP-MS,prog-MS,8.443531828,23.22543185,Untreated,AA,validation,49.1,50,0.74708625,9.856448355,NA,-0.362937313,51.50957202,0.737917528,6.5,65,16,6,145.755552,15.94381764,NA,*01:01,*13:01,118.0361423,past
S-181218-06007,pt335,55.39767283,Female,PP-MS,prog-MS,9.401779603,23.73348817,Untreated,AA,validation,179.9,52,0.741930725,9.866408544,NA,-0.37381825,63.1440929,1.327028044,7,50,22,7,218.399994,27.67717703,59.64800102,*01:01,*13:01,175.2551493,past
S-181218-06008,pt336,47.78097194,Female,SP-MS,prog-MS,5.848049281,34.11235303,Untreated,W,training,8.55,29,0.739642549,9.83397669,0,0.862572842,57.60737309,2.079122726,6.5,47,15,5,187.56666,10.90952584,57.68980663,*11:01,*13:03,356.4776251,past
S-181218-06009,pt337,44.85420945,Female,RR-MS,RR-MS,2.904859685,24.50223945,Untreated,W,training,4.75,48,0.753097562,8.803424212,0.693147181,-0.367500561,22.51433918,-0.756813399,2.5,81,0,0,45.244444,-13.0099643,NA,*03,*13:03,289.7627119,past
S-181218-06010,pt337,47.05544148,Female,RR-MS,RR-MS,5.106091718,25.63137491,dimethyl fumarate (Tecfidera),W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*03,*13:03,-107.1107214,past
S-181218-06011,pt338,64.62696783,Male,PP-MS,prog-MS,4.577686516,24.63374291,Untreated,W,training,8.1,30,0.694057781,9.871325866,0,1.633269585,44.52949561,2.052946782,6,70,10,4,87.344444,-9.169083271,NA,*13:01,*13:03,480.9475125,past
S-181218-06012,pt338,66.60095825,Male,PP-MS,prog-MS,6.551676934,25.13586957,Untreated,W,training,24.3,18,0.664806118,9.666308462,NA,2.784696228,53.8668787,3.498604478,6.5,54,17,6,NA,-10.2908451,NA,*13:01,*13:03,549.5867955,past
S-181218-06013,pt338,67.4825462,Male,PP-MS,prog-MS,7.433264887,26.40595463,Untreated,W,training,35.8,13,0.660207302,10.01516309,NA,3.127493647,57.20069933,3.95748192,6.5,54,20,6,142.966664,-10.07087276,NA,*13:01,*13:03,508.6252623,past
S-181218-06015,pt339,53.96303901,Female,SP-MS,prog-MS,22.770705,19.87670068,Untreated,W,validation,6.55,50,0.760339344,7.869019376,NA,-0.602112752,32.73995868,-0.427758986,3.5,76,5,2,63.988888,-0.653212154,49.35146511,*01:01,*15:01,67.84224144,past
S-181218-06016,pt340,44.08213552,Male,RR-MS,RR-MS,0.391512663,23.80013149,Untreated,W,training,2.45,59,0.76765416,8.551594618,0,-1.201768121,8.812089138,-2.160951329,1.5,94,0,0,26.20000012,-19.1340283,NA,*03:01,*15:01,456.7519521,no
S-181218-06021,pt341,55.48528405,Female,PP-MS,prog-MS,14.71321013,33.79066819,teriflunomide (Aubagio),W,training,10.7,56,0.78556511,6.091309882,NA,-1.369120574,41.66538414,-0.612004379,5.5,71,13,4,132.983328,15.2394361,NA,*01:02,*08:01,492.1006362,past
S-181218-06022,pt341,57.41820671,Female,PP-MS,prog-MS,16.64613279,35.61812269,Untreated,W,training,13.7,56,0.778979809,6.165417854,NA,-1.250277211,45.52855826,-0.313706847,6,63,12,4,130.999996,18.02307992,NA,*01:02,*08:01,223.2200891,past
S-181218-06023,pt341,58.49144422,Female,PP-MS,prog-MS,17.71937029,34.52708907,Untreated,W,training,16.75,53,NA,NA,NA,NA,49.33367864,NA,6,64,12,4,135.794442,NA,63.02281668,*01:02,*08:01,295.6462184,past
S-181218-06024,pt342,59.23613963,Male,SP-MS,prog-MS,21.49212868,25.70523917,interferon beta-1a (Avonex),W,training,4.7,46,NA,NA,0,NA,41.3585554,NA,4.5,55,12,2,189.166662,NA,49.57844192,*03:01,*15:01,668.2866598,no
S-181218-06027,pt343,43.17043121,Male,HD,HD,NA,20.88256144,Untreated,AA,HD,5.05,53,0.794288617,6.510258341,NA,-1.370669425,4.67159499,-2.515484907,0,100,0,0,NA,-21.74028384,NA,*07,*11:02,197.8261483,past
S-181218-06028,pt343,44.62422998,Male,HD,HD,NA,22.15999211,Untreated,AA,HD,3.6,47,0.77810031,8.480944059,NA,-0.766758479,2.985442707,-2.09577007,0,100,0,0,NA,-28.91214565,NA,*07,*11:02,185.2258187,past
S-181218-06029,pt343,45.85078713,Male,HD,HD,NA,22.04367755,Untreated,AA,HD,3.75,47,0.665789042,2.564949357,NA,1.260096294,11.75805411,0.054945876,1,98,0,0,NA,-42.35340359,75.26198238,*07,*11:02,140.8278731,past
S-181218-06030,pt343,46.65297741,Male,HD,HD,NA,21.35076134,Untreated,AA,HD,3.5,54,0.791429426,8.611775834,NA,-1.37103102,12.41283923,-2.11774149,1.5,95,0,0,12.9,-15.8970803,71.52231784,*07,*11:02,149.087671,past
S-181218-06032,pt344,27.03627652,Male,HD,HD,NA,26.45659929,Untreated,W,HD,3.7,58,0.776783053,6.715383386,NA,-1.314554349,7.3236524,-2.332063097,0,98,0,0,NA,-24.21406537,NA,*10,*16,65.05522047,current
S-181218-06033,pt345,36.55030801,Male,RR-MS,RR-MS,0.150581793,26.60221741,Untreated,AA,validation,3.1,37,0.760046558,10.37199006,1.098612289,0.078660653,11.54329548,-0.946800383,1.5,85,0,0,19.1,-28.03377577,NA,*03,NA,886.4387918,no
S-181218-06034,pt345,37.04859685,Male,RR-MS,RR-MS,0.648870637,27.78528935,interferon beta-1a (Rebif),AA,validation,2.6,36,NA,NA,NA,NA,15.88144685,NA,2,83,1,0,26.85,NA,NA,*03,NA,243.37014,no
S-181218-06035,pt345,38.6201232,Male,RR-MS,RR-MS,2.220396988,28.35992428,interferon beta-1a (Rebif),AA,validation,3,44,0.763150919,9.721545924,0.693147181,-0.341088164,11.71723273,-1.289840899,1.5,88,0,0,13.5,-24.04699146,NA,*03,NA,43.51629526,no
S-181218-06036,pt345,40.03832991,Male,RR-MS,RR-MS,3.638603696,28.22471606,interferon beta-1a (Rebif),AA,validation,3.55,NA,0.747164895,9.865318286,0,NA,18.69170059,NA,2,75,1,1,29.8,NA,75.66670464,*03,NA,44.02568302,no
S-181218-06038,pt346,56.71731691,Female,HD,HD,NA,25.21735858,Untreated,AA,HD,7.05,34,0.770989194,8.334951631,NA,0.037063708,16.36531175,-0.733738875,1,91,0,0,NA,-29.48366564,NA,*03,*07,-159.1775584,past
S-181218-06039,pt346,57.90554415,Female,HD,HD,NA,21.8299522,Untreated,AA,HD,5.25,39,0.768796689,8.006367568,NA,-0.183172355,15.42037829,-0.967007313,1,91,0,0,NA,-28.42805403,NA,*03,*07,-174.8944387,past
S-181218-06040,pt347,38.32443532,Female,RR-MS,RR-MS,10.85557837,33.41240937,Untreated,NA,training,5,51,NA,NA,0,NA,28.79020875,NA,3,71,7,2,77.95,NA,65.81566546,*04:04:04,*13:01,194.6149874,past
S-181218-06041,pt347,42.32717317,Female,RR-MS,RR-MS,14.85831622,28.96527943,dimethyl fumarate (Tecfidera),NA,training,5.7,53,NA,NA,NA,NA,37.40540319,NA,5,66,10,2,135.816664,NA,65.4335757,*04:04:04,*13:01,64.039046,past
S-181218-06042,pt348,29.32238193,Female,RR-MS,RR-MS,0.328542094,21.54685673,Untreated,W,validation,3.95,68,0.791637543,7.836369761,0.693147181,-2.102237159,7.602765621,-2.97822997,1,98,1,0,3.694444,-12.1638154,NA,*01:03,*15:01,1126.084023,past
S-181218-06043,pt348,30.52977413,Female,RR-MS,RR-MS,1.535934292,20.39813765,glatiramer acetate (Copaxone),W,validation,3.65,65,NA,NA,NA,NA,7.092395498,NA,1,98,1,0,5.638888,NA,NA,*01:03,*15:01,-10.20085668,past
S-181218-06044,pt348,32.50376454,Female,RR-MS,RR-MS,3.509924709,21.71292114,glatiramer acetate (Copaxone),W,validation,3.45,63,0.792672121,2.63905733,NA,-1.861104264,10.48159963,-2.627999172,1.5,95,2,0,9.805554,-11.47534576,62.61631487,*01:03,*15:01,361.6173264,past
S-181218-06047,pt349,25.0349076,Male,HD,HD,NA,22.1570827,Untreated,NA,HD,3.4,47,0.786122223,7.230563153,NA,-0.911528037,9.276581808,-1.893684144,0,97,0,0,NA,-28.23013672,NA,*04:04,*13:02,-65.03204737,no
S-181218-06048,pt350,28.24640657,Male,HD,HD,NA,19.83929876,Untreated,AA,HD,2.3,41,0.763378428,8.626764828,NA,-0.189311757,10.74908553,-1.212348524,1,95,0,0,NA,-30.60320106,NA,*13:04,NA,-24.18662089,past
S-181218-06049,pt351,62.40109514,Female,PP-MS,prog-MS,5.845311431,29.8046875,Untreated,W,training,7.4,40,0.782840952,7.459338895,0,-0.488586568,33.76650935,-0.279776416,4,72,9,2,78.077776,-0.657892453,NA,*08:01,*13:01,134.165373,past
S-181218-06050,pt351,64.3559206,Female,PP-MS,prog-MS,7.800136893,29.6875,Untreated,W,training,7.45,40,0.775593141,7.574045005,NA,-0.357787045,41.34800985,0.219739494,6,59,14,4,154.777776,5.735472287,NA,*08:01,*13:01,39.32253576,past
S-181218-06051,pt351,65.27583847,Female,PP-MS,prog-MS,8.720054757,28.828125,Untreated,W,training,10.45,35,0.77665869,7.491087594,NA,-0.117213076,46.1013542,0.665886949,6,61,15,4,157.388888,8.303529346,NA,*08:01,*13:01,182.0476922,past
S-181218-06052,pt351,66.27241615,Female,PP-MS,prog-MS,9.716632444,30.78125,Untreated,W,training,17.35,37,0.767582777,8.993675787,NA,-0.057343701,52.16298692,1.027773736,6.5,55,18,5,210.74444,13.82133023,52.51479204,*08:01,*13:01,150.9701702,past
S-181218-06053,pt352,74.68309377,Female,PP-MS,prog-MS,13.84531143,24.38652644,interferon beta-1a (Avonex),AA,validation,18.6,28,NA,10.72377386,0,NA,49.1707488,NA,6.5,62,14,5,142.888888,NA,63.5309116,*07,*13,-22.82385416,NA
S-181218-06054,pt353,60.40793977,Female,PP-MS,prog-MS,16.94182067,25.7033168,Untreated,W,training,20.8,51,0.77808399,8.50512061,0,-0.974306899,48.36467042,0.063540471,6.5,64,16,6,124.533332,18.35237716,NA,*03:01,*15:01,-81.2668918,past
S-181218-06055,pt353,62.22861054,Female,PP-MS,prog-MS,18.76249144,26.1661189,Untreated,W,training,49.5,50,0.771564325,8.202208436,NA,-0.804687318,51.29219204,0.356306595,6.5,52,17,6,NA,19.7391356,NA,*03:01,*15:01,15.53597256,past
S-181218-06056,pt353,63.24435318,Female,PP-MS,prog-MS,19.77823409,25.40391156,Untreated,W,training,57.85,49,0.77418266,8.590815331,NA,-0.799979052,52.05679357,0.399569761,6.5,50,17,6,183.82222,20.46096893,NA,*03:01,*15:01,-4.144654035,past
S-181218-06057,pt354,27.78097194,Male,HD,HD,NA,26.06836435,Untreated,AA,HD,3.3,51,0.775396653,9.432042885,NA,-0.925809167,2.057234437,-2.276870963,0,100,0,0,NA,-28.39559475,NA,*14:54:01,*15:03,-50.61447741,NA
S-181218-06058,pt355,64.62422998,Male,PP-MS,prog-MS,21.96030116,26.8503214,Untreated,W,training,10.3,46,0.749012472,7.600402335,NA,-0.189856441,45.5459301,0.576411872,6,64,8,4,112,8.407971414,NA,*04,*11,131.0808965,past
S-181218-06059,pt355,66.50239562,Male,PP-MS,prog-MS,23.8384668,26.29935721,Untreated,W,training,10.75,45,0.73325984,7.907283609,NA,0.146388302,46.42184319,0.903411487,6,60,12,4,112.688888,6.22955836,NA,*04,*11,446.453633,past
S-181218-06064,pt356,43.91238877,Female,SP-MS,prog-MS,24.96098563,25.1486054,dimethyl fumarate (Tecfidera),W,training,15.35,35,0.770187516,9.967963572,0.693147181,-0.000429336,51.21246239,1.026624822,6,60,14,4,174.922216,12.3538161,65.34270859,*11:04:01,*14:54:01,83.93960898,past
S-181218-06066,pt357,40.42710472,Female,RR-MS,RR-MS,0.79945243,16.91815272,Untreated,W,training,3.75,54,0.78969115,8.836519269,0,-1.339660766,8.169798898,-2.309608349,1,96,1,0,12.2,-18.52375142,NA,*11:04,*15:01,2.404587609,past
S-181218-06067,pt357,41.61533196,Female,RR-MS,RR-MS,1.987679671,17.79454351,glatiramer acetate (Copaxone),W,training,4.15,56,NA,NA,NA,NA,8.426207155,NA,1,96,1,0,22.9,NA,NA,*11:04,*15:01,62.40984433,past
S-181218-06068,pt358,37.83436003,Female,RR-MS,RR-MS,0.558521561,37.75682169,Untreated,NA,training,4.65,58,0.792242099,7.268920128,0.693147181,-1.59354008,7.841027444,-2.539406238,1,97,1,0,4.35,-16.54637463,NA,*13:03,*13:03,-75.59293038,past
S-181218-06070,pt359,47.49623546,Male,PP-MS,prog-MS,5.021218344,23.7654321,Untreated,W,training,4.75,30,0.560401714,10.45504237,0,4.045328875,26.90470884,3.169353031,3.5,72,4,1,47.1,-48.70414788,64.99548464,*11:04:01,*13:01,64.83512741,NA
S-181218-06071,pt360,39.87405886,Female,SP-MS,prog-MS,20.72005476,18.84297521,natalizumab (Tysabri),AA,training,179.9,0,NA,NA,0,NA,70.7597113,NA,7,43,20,8,321.0499921,NA,58.61067353,*01:02:01,*14:54:01,346.9318566,no
S-181218-06072,pt360,40.678987,Female,SP-MS,prog-MS,21.52498289,NA,Untreated,AA,training,179.9,36,NA,NA,1.609437912,NA,73.74285509,NA,7.5,43,20,8,337.0499921,NA,68.30019533,*01:02:01,*14:54:01,1828.419413,no
S-181218-06073,pt360,41.56057495,Female,SP-MS,prog-MS,22.40657084,17.26354454,Untreated,AA,training,179.9,32,0.785082459,9.105424202,0,-0.113352626,75.8511075,2.198825186,7.5,43,19,8,335.6999921,38.01821571,63.07745634,*01:02:01,*14:54:01,405.7384536,no
S-181218-06074,pt360,42.23134839,Female,SP-MS,prog-MS,23.07734428,16.74931129,Untreated,AA,training,179.9,30,0.783439649,9.473934649,0,0.020216247,77.0712963,2.373571403,7.5,35,20,9,374.9388801,38.02511297,58.70396377,*01:02:01,*14:54:01,288.100467,no
S-181218-06076,pt361,37.37713895,Female,RR-MS,RR-MS,0.553045859,40.71237359,Untreated,AA,training,4.1,49,0.785798842,9.674703121,0,-1.009613529,11.15694281,-1.87924844,1.5,91,2,0,8.00000001,-18.53463774,58.88631982,*01:02,*15:01,311.3423796,no
S-181218-06077,pt361,39.1211499,Female,RR-MS,RR-MS,2.29705681,36.3994646,glatiramer acetate (Copaxone),AA,training,4.55,49,0.808721404,7.77148876,0,-1.42329156,14.02480536,-2.078679438,1.5,83,2,1,15.25,-11.90907295,65.89848665,*01:02,*15:01,269.9731257,no
S-181218-06078,pt361,40.69267625,Female,RR-MS,RR-MS,3.868583162,NA,glatiramer acetate (Copaxone),AA,training,4.3,49,0.786565298,9.936535407,NA,-1.023445578,14.06169082,-1.741488343,1.5,86,2,0,11.75000001,-15.50424438,67.2187746,*01:02,*15:01,201.3409133,no
S-181218-06083,pt362,37.97946612,Female,HD,HD,NA,24.03326122,Untreated,W,HD,3.55,67,0.783279297,8.111628078,NA,-1.899437144,10.10093759,-2.679716799,1,95,0,0,NA,-13.40913102,NA,*04:01:01,*15:01,26.95017568,no
S-181218-06084,pt362,40.10677618,Female,HD,HD,NA,24.34142562,Untreated,W,HD,3.7,67,NA,NA,NA,NA,11.64957385,NA,1,96,0,0,NA,NA,80.19427238,*04:01:01,*15:01,32.82715622,no
S-181218-06085,pt362,41.18001369,Female,HD,HD,NA,26.77122769,Untreated,W,HD,3.95,66,0.789333952,4.219507705,NA,-1.956743328,16.53039891,-2.397175283,3,94,0,0,31.6,-4.557795667,60.16358753,*04:01:01,*15:01,-32.67424864,no
S-181218-06086,pt363,22.01779603,Male,SP-MS,prog-MS,13.2128679,23.59891529,Untreated,AA,training,11.7,30,0.730826351,9.883182799,0,0.969715937,55.00517273,2.035166137,6.5,39,11,5,212.466664,7.334076197,44.96940419,*07,*13:03,195.352841,current
S-181218-06087,pt364,57.36892539,Male,HD,HD,NA,27.74691358,Untreated,W,HD,4.1,53,0.783719738,7.33171497,NA,-1.179935376,14.10874787,-1.870294662,1,92,0,0,26.6,-18.65180016,NA,*04,*07,-111.0079221,past
S-181218-06088,pt364,58.25051335,Male,HD,HD,NA,25.71500543,Untreated,W,HD,4.4,51,0.783871689,7.222566019,NA,-1.078756128,14.24607011,-1.778388918,1,92,0,0,24.8,-19.43355377,NA,*04,*07,-31.68567822,past
S-181218-06089,pt364,59.45790554,Male,HD,HD,NA,27.11025238,Untreated,W,HD,4.35,54,NA,NA,NA,NA,11.90717678,NA,1,93,1,0,13.2,NA,75.01244458,*04,*07,196.972632,past
S-181218-06090,pt364,60.32032854,Male,HD,HD,NA,27.56309624,Untreated,W,HD,3.55,55,0.758136673,7.688913337,NA,-0.822165351,13.9637857,-1.577737157,2,91,2,0,32.244444,-17.43050658,69.0822852,*04,*07,-43.51898753,past
S-181218-06091,pt365,22.4366872,Female,HD,HD,NA,22.26345083,Untreated,AA,HD,4.7,60,0.798130934,7.411556288,NA,-1.803735958,3.501473759,-2.938803188,0,100,0,0,NA,-18.97658466,NA,*13,*15:03,-52.43589043,past
S-181218-06092,pt366,46.45859001,Male,HD,HD,NA,23.5883686,Untreated,NA,HD,4.3,36,0.763254078,8.035602693,NA,0.072736037,3.41932897,-1.369494336,0,100,0,0,NA,-36.10392521,NA,*07,*10,117.6972523,no
S-181218-06093,pt366,47.34017796,Male,HD,HD,NA,24.30968424,Untreated,NA,HD,5.15,31,0.762205624,8.133293861,NA,0.351460916,4.099939808,-1.100770762,0,100,0,0,NA,-37.95515079,NA,*07,*10,90.97138911,no
S-181218-06094,pt366,48.56673511,Male,HD,HD,NA,24.29059338,Untreated,NA,HD,5.25,35,0.773425121,5.049856007,NA,-0.058857624,14.17541943,-0.92677654,1.5,94,0,0,NA,-25.24035143,NA,*07,*10,103.8347289,no
S-181218-06095,pt367,52.62970568,Female,HD,HD,NA,35.86886974,Untreated,W,HD,4.65,64,0.779497089,8.211482916,NA,-1.675298327,8.218120563,-2.588575627,1,97,0,0,5.055554,-15.42661904,NA,*03:01,*03:01,-104.8373509,past
S-181218-06097,pt368,44.29568789,Female,RR-MS,RR-MS,0.109514031,35.24687153,Untreated,AA,training,4.75,54,NA,NA,NA,NA,12.12215434,NA,1.5,89,4,0,26.14444402,NA,NA,*03,*14,-86.8570764,past
S-181218-06098,pt368,45.2347707,Female,RR-MS,RR-MS,1.048596851,NA,Untreated,AA,training,4.55,53,0.766011964,7.660585462,0,-0.860367385,11.24993716,-1.749315057,1.5,87,2,0,22.94444402,-19.7973416,NA,*03,*14,-197.9730759,past
S-181218-06099,pt368,46.15468857,Female,RR-MS,RR-MS,1.968514716,37.18619444,Untreated,AA,training,4.8,58,0.77075641,7.771910256,0,-1.205792954,14.75067543,-1.858970529,1.5,87,2,0,41.58888804,-13.15888187,NA,*03,*14,-148.5833106,past
S-181218-06100,pt368,46.82546201,Female,RR-MS,RR-MS,2.639288159,NA,interferon beta-1b (Extavia),AA,training,5.65,51,0.768309115,9.363147292,NA,-0.797902052,30.72604014,-0.695493456,4,69,3,1,69.23333202,-0.888651212,62.15029218,*03,*14,-185.5110027,past
S-181218-06101,pt368,47.87953457,Female,RR-MS,RR-MS,3.693360712,34.70902506,interferon beta-1b (Extavia),AA,training,5.3,59,0.778180646,8.053569169,NA,-1.391737114,33.56723668,-1.047367908,4.5,69,6,2,97.17222003,7.346729146,69.76864349,*03,*14,-155.625108,past
S-181218-06102,pt369,52.67077344,Female,HD,HD,NA,27.57544812,Untreated,W,HD,4.1,72,NA,NA,NA,NA,10.19478808,NA,1,96,0,0,NA,NA,NA,*04,*04,-93.68545256,past
S-181218-06103,pt369,54.60643395,Female,HD,HD,NA,27.93424665,Untreated,W,HD,4.6,65,NA,NA,NA,NA,10.63044945,NA,1,96,0,0,NA,NA,72.460009,*04,*04,-31.92279588,past
S-181218-06104,pt370,29.44558522,Female,HD,HD,NA,27.55973828,Untreated,AA,HD,4.65,62,0.790150181,7.007600614,NA,-1.763630676,3.216981669,-2.919800823,0,100,0,0,NA,-19.62537869,NA,*11:02,*15:03,-52.94631085,no
S-181218-06105,pt371,31.76454483,Female,HD,HD,NA,17.8125,Untreated,NA,HD,3.75,62,0.803074065,6.597145702,NA,-1.99686494,8.410605276,-2.848330873,1,95,1,0,NA,-13.12659823,NA,*14:06,*16:02,88.70973967,past
S-181218-06106,pt371,33.77686516,Female,HD,HD,NA,19.765625,Untreated,NA,HD,3.8,53,NA,NA,NA,NA,10.08975159,NA,1,95,0,0,NA,NA,51.74574094,*14:06,*16:02,57.11776166,past
S-181218-06107,pt372,44.99657769,Male,HD,HD,NA,32.48930512,Untreated,AA,HD,3.35,64,0.808104881,6.966967139,NA,-2.191576353,6.693516567,-3.099898793,0,98,0,0,NA,-16.87764919,NA,*12,*15:03,-83.49055805,NA
S-181218-06108,pt372,45.80150582,Male,HD,HD,NA,33.63038714,Untreated,AA,HD,3.7,63,0.794572359,9.690912953,NA,-1.895397407,2.28283289,-3.078327961,0,100,0,0,NA,-19.36260594,NA,*12,*15:03,-3.175686019,NA
S-181218-06109,pt373,60.02190281,Female,PP-MS,prog-MS,6.138261465,20.66317889,Untreated,W,validation,14.25,33,0.782689149,7.696667082,NA,-0.122121865,44.99111752,0.604683437,6.5,65,15,5,122.188888,7.23788234,60.80905779,*01:03,*15:01,329.772803,no
S-181218-06110,pt373,61.07597536,Female,PP-MS,prog-MS,7.192334018,22.05577929,Untreated,W,validation,9.75,36,NA,NA,NA,NA,43.36326359,NA,6.5,65,14,5,122.788888,NA,80.37397194,*01:03,*15:01,148.0614657,no
S-181218-06111,pt373,62.51334702,Female,PP-MS,prog-MS,8.629705681,22.35688208,Untreated,W,validation,9.15,28,0.73796805,6.720220155,NA,0.944752864,47.04261237,1.604806647,6.5,59,16,5,185.699996,-0.401728593,70.32987951,*01:03,*15:01,280.2214297,no
S-181218-06112,pt373,62.97330595,Female,PP-MS,prog-MS,9.089664613,22.35688208,Untreated,W,validation,7.1,32,0.782805702,7.650168701,NA,-0.072264533,46.05396012,0.701142004,6.5,62,16,5,173.599996,7.847838897,60.85950138,*01:03,*15:01,240.7386101,no
S-181218-06114,pt374,56.77481177,Male,HD,HD,NA,26.99780862,Untreated,AA,HD,4.45,30,0.792519832,7.36264527,NA,-0.143651658,13.31485362,-1.042130737,1.5,95,0,0,NA,-25.33067877,NA,*07:01:01,*11:01:02,-45.43720445,NA
S-181218-06115,pt375,43.76454483,Female,RR-MS,RR-MS,13.86721424,20.78971534,glatiramer acetate (Copaxone),W,training,4.05,59,0.652071397,8.943244933,1.098612289,0.884126544,19.45193469,0.135284271,2.5,76,0,0,60.177776,-27.44169862,82.8438556,*13:01,*15:01,-91.84612622,NA
S-181218-06116,pt376,55.91238877,Female,PP-MS,prog-MS,5.612594114,NA,dimethyl fumarate (Tecfidera),AA,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,*01,*15:03,-137.2743644,past
S-181218-06117,pt376,56.64065708,Female,PP-MS,prog-MS,6.340862423,31.09976117,dimethyl fumarate (Tecfidera),AA,training,5.9,46,0.787621929,8.806573821,NA,-0.886632139,29.30632443,-0.842899165,3,66,11,2,84.994444,-1.502374768,59.83981855,*01,*15:03,50.63070626,past
S-181218-06118,pt376,57.67556468,Female,PP-MS,prog-MS,7.375770021,30.31399593,dimethyl fumarate (Tecfidera),AA,training,9.55,46,0.784631531,8.741935464,NA,-0.832665137,31.00554487,-0.710272518,3,64,13,2,86.194444,-0.29337114,58.19545942,*01,*15:03,-37.22006062,past
S-181218-06120,pt377,48.05475702,Male,PP-MS,prog-MS,3.230663929,29.35839745,Untreated,W,validation,4.6,50,0.782031482,8.174984533,0,-0.993585614,13.8994068,-1.724793472,1.5,83,3,1,30.788888,-15.93776556,58.89782164,*03:01,*13:02,246.2320461,past
S-181218-06121,pt377,48.97467488,Male,PP-MS,prog-MS,4.150581793,NA,interferon beta-1b (Extavia),W,validation,6.1,48,0.779766285,8.185628891,0,-0.84878467,17.60504723,-1.412829191,2,81,3,2,42.538888,-13.54744475,61.28050503,*03:01,*13:02,181.7143716,past
S-181218-06122,pt377,49.89459274,Male,PP-MS,prog-MS,5.070499658,28.99550007,Untreated,W,validation,5.85,49,NA,NA,NA,NA,21.82118708,NA,2.5,75,6,2,62.838888,NA,56.3137472,*03:01,*13:02,391.8576322,past
S-181218-06123,pt377,50.87200548,Male,PP-MS,prog-MS,6.047912389,30.37451009,glatiramer acetate (Copaxone),W,validation,5.75,46,0.775155673,8.347353412,NA,-0.661656579,36.55627789,-0.281458884,4.5,64,11,2,114.533332,3.703981729,54.64823745,*03:01,*13:02,324.7054022,past
S-181218-06124,pt378,38.72963723,Female,SP-MS,prog-MS,10.65297741,30.32366608,natalizumab (Tysabri),AA,training,9.5,48,0.707398122,10.16754269,NA,0.457226376,29.72864971,0.305721131,3,66,9,2,88.488888,-13.28717623,53.45240869,*07:01:01,*11:01:01,-128.5131669,no
S-181218-06125,pt378,39.80287474,Female,SP-MS,prog-MS,11.72621492,28.20060888,rituximab,AA,training,38.7,41,NA,NA,0,NA,45.96972349,NA,6,64,13,5,111.877776,NA,51.57846286,*07:01:01,*11:01:01,105.9181644,no
S-181218-06126,pt378,40.78028747,Female,SP-MS,prog-MS,12.70362765,27.9202051,alemtuzumab (Lemtrada),AA,training,61.05,45,0.745027271,9.996613531,NA,-0.06597573,50.90587221,0.955895753,6.5,60,15,5,130.377776,12.64262576,49.14066733,*07:01:01,*11:01:01,-95.20217068,no
S-181218-06127,pt378,41.85352498,Female,SP-MS,prog-MS,13.77686516,27.9202051,alemtuzumab (Lemtrada),AA,training,34.65,47,0.722633131,10.20136745,NA,0.234244523,53.99455616,1.366465056,6.5,54,15,6,182.94444,13.00421706,51.63005983,*07:01:01,*11:01:01,-99.37226487,no
S-181218-06128,pt379,24.11772758,Female,HD,HD,NA,23.82475818,Untreated,AA,HD,3.4,46,0.82741809,6.527957918,NA,-1.604824003,2.51741299,-2.822603129,0,100,0,0,NA,-21.76748999,NA,*08:04,*12:01,-27.45575938,current
S-181218-06130,pt380,25.29226557,Male,PP-MS,prog-MS,17.44010951,15.83333333,Untreated,W,training,179.9,24,0.731835207,10.40374756,0.693147181,1.263273768,79.5116739,3.541430237,7.5,43,24,8,308.444436,29.17400377,37.23579334,*04:04,*15:01,451.4219632,no
S-181218-06131,pt380,26.55441478,Male,PP-MS,prog-MS,18.70225873,15.52469136,rituximab,W,training,179.9,32,0.723151977,10.50528669,0,1.00429207,80.3251331,3.366085996,7.5,38,24,8,332.1111,32.33995943,37.28984393,*04:04,*15:01,704.018947,no
S-181218-06132,pt380,27.60848734,Male,PP-MS,prog-MS,19.75633128,14.41358025,mycophenolic acid,W,training,179.9,27,0.713964038,10.54112202,0,1.429908302,77.7524328,3.590704813,8,36,21,9,357.794434,25.90111458,31.67262638,*04:04,*15:01,637.5751385,no
S-181218-06133,pt380,28.19986311,Male,PP-MS,prog-MS,20.34770705,15.49382716,clemastine fumarate,W,training,179.9,28,0.712619144,10.54175607,NA,1.402218548,80.59954,3.713880576,8,29,22,9,435.861098,28.99974552,34.61188531,*04:04,*15:01,739.7713737,no
S-181218-06134,pt381,32.02737851,Female,RR-MS,RR-MS,10.49144422,28.38010204,Untreated,AA,training,4.35,53,0.803482762,8.564458384,0,-1.536593975,19.45942025,-1.894248027,2.5,82,2,0,15.8,-5.445259724,NA,*01:03,*03:02,2388.138015,current
S-181218-06135,pt381,33.01026694,Female,RR-MS,RR-MS,11.47433265,31.14370748,interferon beta-1b (Betaseron),AA,training,4.35,59,0.793724836,8.76623838,0.693147181,-1.672259418,19.90138337,-1.985286239,2.5,81,2,0,17.3,-3.770960587,NA,*01:03,*03:02,852.3180602,current
S-181218-06138,pt382,33.13073238,Female,HD,HD,NA,29.43579393,Untreated,W,HD,4.55,61,0.806120828,6.72982407,NA,-1.999888412,3.619913863,-3.097198546,0,100,0,0,NA,-17.07636631,NA,*03:01,*07:01:01,20.62091386,current
S-181218-06137,pt382,34.93223819,Female,HD,HD,NA,27.12622532,Untreated,W,HD,4.65,68,NA,NA,NA,NA,8.022782224,NA,1,98,0,0,NA,NA,72.30767974,*03:01,*07:01:01,45.73806591,current
S-181218-06139,pt382,35.77549624,Female,HD,HD,NA,24.34319664,Untreated,W,HD,4.7,67,0.797847446,6.532334292,NA,-2.162345068,11.57841603,-2.824210241,1,94,0,0,10,-10.35695089,70.08285272,*03:01,*07:01:01,9.687633529,current
S-181218-06140,pt383,50.06707734,Female,RR-MS,RR-MS,0.621492129,38.18709886,hydroxychloroquine,AA,training,5.5,35,0.807258765,7.983098941,0,-0.66944536,11.37696226,-1.582684161,1,89,5,2,19.5,-21.40458342,NA,*09,*11:01:02,413.9869544,no
S-181218-06141,pt383,51.1211499,Female,RR-MS,RR-MS,1.675564682,38.18709886,hydroxychloroquine,AA,training,9.25,33,0.81898395,9.500020447,0,-0.777125516,12.99302167,-1.589884259,1,89,5,2,19.5,-18.81039625,75.57142194,*09,*11:01:02,1003.266094,no
S-181218-06142,pt383,52.23271732,Female,RR-MS,RR-MS,2.787132101,40.15920255,interferon beta-1b (Extavia) & Hydroxychloroquine,AA,training,22.15,28,0.815443236,9.00540504,NA,-0.453423413,42.67403985,0.207725816,6,70,8,5,62.594444,7.930228607,73.7544895,*09,*11:01:02,299.5620466,no
S-181218-06143,pt383,53.34428474,Female,RR-MS,RR-MS,3.898699521,41.55760336,hydroxychloroquine,AA,training,20.4,36,0.809534855,8.460834458,NA,-0.762482151,26.90516863,-0.86225697,2,73,6,4,39.6,-5.031264347,70.70178962,*09,*11:01:02,216.4497956,no
S-181218-06144,pt384,19.69336071,Female,HD,HD,NA,36.33278549,Untreated,AA,HD,3.75,50,0.790494765,6.576469569,NA,-1.146320471,2.786371865,-2.424291242,0,100,0,0,NA,-25.66341206,NA,*08:04,*11,45.78668368,NA
S-181218-06145,pt385,24.95003422,Female,HD,HD,NA,33.76009755,Untreated,AA,HD,4.5,65,NA,NA,NA,NA,3.009020967,NA,0,100,0,0,NA,NA,NA,*03,*08,-67.11930846,NA
S-181218-06149,pt386,49.72210815,Male,PP-MS,prog-MS,5.612594114,25.05660107,glatiramer acetate (Copaxone),W,validation,16.75,28,0.734828388,10.9144337,0,1.001413598,49.15852437,1.76111799,6,58,17,4,165.555552,1.199497704,70.70938377,*08:01,*15:01,80.26275469,past
S-181218-06150,pt387,61.44832307,Male,PP-MS,prog-MS,8.432580424,30.76684394,Untreated,W,training,179.9,25,0.72522559,9.777640843,0,1.33059522,65.54238391,2.879597055,7,56,15,8,125.2,14.59318995,NA,NA,NA,-175.7596274,NA
S-181218-06151,pt387,62.21492129,Male,PP-MS,prog-MS,9.199178645,36.48574314,Untreated,W,training,179.9,NA,0.748542656,8.931287626,0,NA,69.37035399,NA,7,50,16,8,174.233332,NA,65.59257685,NA,NA,6.451283385,NA
S-181218-06152,pt387,64.49281314,Male,PP-MS,prog-MS,11.4770705,34.11423741,Untreated,W,training,179.9,19,0.74406763,9.233177606,NA,1.302321815,69.56244737,3.062595569,7.5,44,14,8,232.5777761,18.87007884,61.57268352,NA,NA,-60.26244434,NA
S-181218-06155,pt388,50.03148528,Male,PP-MS,prog-MS,8.670773443,22.03703704,natalizumab (Tysabri),AA,validation,20.25,32,NA,NA,0,NA,60.37900907,NA,6.5,35,20,6,311.255544,NA,46.43392702,*13:01,*15:01,-119.6112304,current
S-181218-06157,pt389,56.57494867,Male,SP-MS,prog-MS,24.72826831,29.28448345,Untreated,W,training,8.3,40,0.744621835,9.110961928,0,0.201144757,43.91713402,0.8205385,6,68,10,4,130.388888,3.227461278,54.43945093,*04:04:01,*13:01,326.1181931,past
S-181218-06158,pt389,59.43052704,Male,SP-MS,prog-MS,27.58384668,28.92771816,Untreated,W,training,8.75,36,0.742505999,9.231808279,NA,0.44717169,46.80410275,1.175291516,6,57,15,4,164.666664,3.87960996,52.16388348,*04:04:01,*13:01,473.4582833,past
S-181218-06159,pt390,23.14852841,Male,HD,HD,NA,23.71037967,Untreated,W,HD,2.4,80,0.784125919,7.692569648,NA,-2.590205495,0.701410725,-3.742280664,0,100,0,0,NA,-14.63264168,NA,*01:02,*04:05,30.94664614,no
S-181218-06160,pt390,24.50924025,Male,HD,HD,NA,27.37310672,Untreated,W,HD,2.6,76,NA,NA,NA,NA,7.785076882,NA,0,97,0,0,NA,NA,NA,*01:02,*04:05,44.34019521,no
S-181218-06161,pt391,44.45995893,Female,SP-MS,prog-MS,25.27036277,32.8731098,Untreated,W,training,20.1,42,0.723972383,10.10606098,0,0.46987904,50.75169776,1.397314154,6.5,61,16,6,162.2055521,7.62093958,42.13325648,04*:01:01,*15:01,-26.58501836,past
S-181218-06162,pt391,45.53319644,Female,SP-MS,prog-MS,26.34360027,30.20216963,Untreated,W,training,13.6,42,0.77215004,9.136801469,0.693147181,-0.399571691,49.14049698,0.58538209,6.5,61,16,5,158.4055521,13.90751609,42.42937689,04*:01:01,*15:01,117.0065408,past
S-181218-06165,pt392,53.87542779,Male,SP-MS,prog-MS,28.49828884,23.86062366,Untreated,W,validation,179.9,20,NA,NA,NA,NA,66.79717681,NA,7.5,52,19,8,252.744432,NA,NA,*13:02:01,*15:01,476.5026756,no
S-181218-06166,pt393,54.23682409,Male,PP-MS,prog-MS,7.175906913,30.75636776,fingolimod (Gilenya),W,validation,6.4,49,0.777531856,8.390722527,0,-0.860421196,28.81796616,-0.846030609,3,71,12,2,88.099998,-2.228823803,58.77977084,*04:03:01,*13:01,-96.55234668,NA
S-181218-06167,pt394,24.26557153,Male,HD,HD,NA,31.9118386,Untreated,NA,HD,4.1,57,0.77823803,7.45007957,NA,-1.288851237,3.110101758,-2.527165861,0,100,0,0,NA,-24.04498402,NA,*09,*12:02,-30.59033601,no
S-181218-06168,pt395,27.07734428,Male,PP-MS,prog-MS,9.935660507,23.44317027,Untreated,W,training,179.9,33,0.678691755,10.94277438,0,1.754694399,72.50624262,3.593303567,8,48,27,9,280.633332,17.70468447,47.72844702,*13:01,*13:03,76.95288048,no
S-181218-06170,pt396,48.09856263,Female,HD,HD,NA,23.98126115,Untreated,W,HD,4.05,73,0.814440676,6.230481448,NA,-2.773563563,8.281514106,-3.506276296,1,96,0,0,NA,-5.386979654,NA,*13:01:01,*14:01:01,115.2877613,past
S-181218-06171,pt396,50.4421629,Female,HD,HD,NA,23.95209581,Untreated,W,HD,4.55,71,0.780898977,5.549076085,NA,-2.064323017,12.4057371,-2.69947298,1.5,96,0,0,18,-9.606567628,59.54584762,*13:01:01,*14:01:01,321.3267955,past
S-181218-06174,pt397,26.74332649,Male,HD,HD,NA,25.57093426,Untreated,NA,HD,4.55,57,0.774393328,8.464425126,NA,-1.219466814,2.954440703,-2.47698685,0,100,0,0,NA,-24.83090819,NA,*04:02:01,*14:54:01,14.40776113,current
S-181218-06176,pt398,19.38672142,Male,HD,HD,NA,24.80055498,Untreated,W,HD,2.85,66,0.812402916,6.999422468,NA,-2.373063441,1.304685336,-3.529174474,0,100,0,0,NA,-16.00180728,NA,*08:01,*15:01,14.78465797,NA
S-181218-06177,pt399,46.05065024,Male,SP-MS,prog-MS,7.611225188,28.68514468,fingolimod (Gilenya),AA,training,16.45,44,0.717025224,10.87833017,0,0.491331296,43.86744275,1.061321987,6,65,9,4,77.088888,0.541819999,69.4028459,*11:01:02,*15:03,242.1111083,no
S-181218-06178,pt399,48.56125941,Male,SP-MS,prog-MS,10.12183436,28.86442683,fingolimod (Gilenya),AA,training,21.4,46,0.725177713,6.823286122,NA,0.240283792,55.28690731,1.437980676,6.5,51,14,6,156.84444,14.24170967,70.06319324,*11:01:02,*15:03,142.319705,no
S-181218-06179,pt400,40.59411362,Female,HD,HD,NA,30.5408225,Untreated,AA,HD,4.95,55,0.791443161,7.268223021,NA,-1.423239628,3.648177557,-2.612191176,0,100,0,0,NA,-22.28617248,NA,*08:04,*13:03,-110.9971827,NA
S-181218-06180,pt401,70.23682409,Female,HD,HD,NA,30.73060942,Untreated,AA,HD,5.75,44,0.745459483,9.503532238,NA,-0.021815021,13.0380822,-0.954194812,1,93,1,0,NA,-27.93435912,NA,*08:04,*13:03,-243.2116535,past
S-181218-06181,pt402,58.2477755,Female,PP-MS,prog-MS,15.12936345,25.20478891,Untreated,AA,training,13.7,17,0.651246551,9.40186941,0,3.081363249,55.36043788,3.824174547,6.5,57,13,5,176.388888,-11.49210228,52.89203278,*01:01:01,*15:03,138.7431529,past
S-181218-06182,pt402,59.39493498,Female,PP-MS,prog-MS,16.27652293,24.73429952,Untreated,AA,training,18.3,19,0.696180726,9.519735011,0,2.166525395,56.36655553,3.108762459,6.5,52,13,5,173.688888,-2.175927068,52.69960093,*01:01:01,*15:03,-59.17428539,past
S-181218-06183,pt403,24.44900753,Male,HD,HD,NA,22.99962876,Untreated,NA,HD,2.3,68,0.819500323,6.584791392,NA,-2.605070131,0.415391506,-3.769452347,0,100,0,0,NA,-14.7836359,NA,*04,NA,4.755368595,no
S-181218-06184,pt404,59.71800137,Female,SP-MS,prog-MS,31.70978782,19.97358134,glatiramer acetate (Copaxone),W,training,8.35,30,NA,NA,0,NA,43.3724308,NA,6,69,12,4,121.388888,NA,61.26724624,*04:02:01,*07:01:01,-10.39314834,NA
S-181218-06186,pt405,40.20807666,Female,RR-MS,RR-MS,15.16495551,23.39685276,fingolimod (Gilenya),W,training,4.1,45,0.770438085,9.406729186,0,-0.524558653,31.11084034,-0.446492842,3.5,72,5,2,81.327776,-2.986804,65.09829547,*07:01:01,*15:01,-40.39332901,NA
S-181218-06187,pt406,39.52361396,Female,RR-MS,RR-MS,3.178644764,34.17769376,Untreated,AA,training,11.9,12,0.736129906,9.976645073,2.564949357,1.809297185,49.97274169,2.480442314,6,62,12,4,143.788888,-5.324808507,71.8469049,*04:08:01,*07:01:01,4618.596764,past
S-181218-06188,pt406,40.53935661,Female,RR-MS,RR-MS,4.194387406,33.6399916,fingolimod (Gilenya),AA,training,13.5,23,0.679662308,9.561560465,0.693147181,2.256786418,51.1842943,2.917985239,6,62,12,4,143.788888,-8.178086915,57.35473481,*04:08:01,*07:01:01,677.3515413,past
S-181218-06189,pt407,39.94524298,Male,RR-MS,RR-MS,0.665297741,28.05555556,Untreated,W,training,5.7,25,0.764725944,7.531016332,0,0.617741715,23.43303385,0.116608782,3,78,7,2,38.294444,-21.04085561,65.43882644,*11:04:01,*15:54:01,443.362381,NA
S-181218-06190,pt408,30.87200548,Male,HD,HD,NA,26.00438276,Untreated,AA,HD,3.05,58,0.792123235,9.013351778,NA,-1.591394969,1.718713113,-2.852410398,0,100,0,0,NA,-22.68817437,NA,*01:02:01,*07:01:01,-91.71497529,NA
S-181218-06192,pt409,59.29637235,Female,SP-MS,prog-MS,8.73100616,25.80918946,Untreated,AA,training,5.2,42,0.798250936,9.242032819,0,-0.87060836,15.07543627,-1.56119958,1.5,90,0,1,24.4,-15.87881716,73.83129965,*04:01:01,*13:01,274.981041,past
S-181218-06198,pt410,71.31827515,Female,HD,HD,NA,33.93853091,Untreated,W,HD,6.85,46,0.76157637,8.900276349,NA,-0.416594124,12.64117822,-1.305648803,1,96,0,0,NA,-22.71158392,NA,*03:01,*11:01:01,-103.3616508,past
S-181218-06205,pt411,59.40588638,Female,RR-MS,RR-MS,20.95277207,NA,fingolimod (Gilenya),W,validation,4.45,39,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,past
S-181218-06206,pt411,59.42231348,Female,RR-MS,RR-MS,20.96919918,NA,IV steroids,W,validation,4.45,39,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1275.284213,past
S-181218-06207,pt411,59.46064339,Female,RR-MS,RR-MS,21.00752909,19.44710103,not untreated,W,validation,4.45,39,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,674.5462061,past
S-181218-06208,pt411,59.51540041,Female,RR-MS,RR-MS,21.06228611,20.28435391,oral steroids,W,validation,4.45,39,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,385.7397878,past
S-181218-06209,pt411,59.8220397,Female,RR-MS,RR-MS,21.36892539,20.53259871,oral steroids,W,validation,4.15,48,NA,NA,NA,NA,29.90661534,NA,4,71,2,1,73.19444409,NA,60.47906706,NA,NA,966.0378214,past
S-181218-06210,pt411,59.93702943,Female,RR-MS,RR-MS,21.48391513,20.53259871,oral steroids,W,validation,4.15,48,0.636954002,9.723942139,1.791759469,1.728514675,29.90661534,1.380922296,4,71,2,1,73.19444409,-24.65713563,NA,NA,NA,654.0025164,past
S-181218-06211,pt411,60.28747433,Female,RR-MS,RR-MS,21.83436003,22.19156964,oral steroids,W,validation,4.5,48,NA,NA,NA,NA,31.07251246,NA,4,71,3,2,69.23888805,NA,84.90533068,NA,NA,366.7089872,past
S-181218-06213,pt412,41.81519507,Female,RR-MS,RR-MS,0.624229979,31.76620076,Untreated,NA,training,4.75,61,0.784997062,8.882946799,0,-1.618672826,18.12537428,-2.031671234,2,82,1,0,21.7,-6.033730982,70.69703996,*11:01:01,*15:02,96.89256266,no
S-181218-06214,pt412,42.7926078,Female,RR-MS,RR-MS,1.60164271,32.00838272,glatiramer acetate (Copaxone),NA,training,5.1,56,0.780619925,8.731013415,0,-1.279875995,25.56741488,-1.364908172,3,76,2,0,48.31111,-1.669198768,73.54806021,*11:01:01,*15:02,-84.88467868,no
S-181218-06217,pt413,53.7467488,Female,RR-MS,RR-MS,18.37645448,31.08935986,Untreated,AA,training,6.75,40,NA,NA,0,NA,28.08077668,NA,3,76,11,2,77.177776,NA,NA,*07:01:01,*15:03,396.7751716,past
S-181218-06218,pt414,24.32580424,Male,HD,HD,NA,21.9138057,Untreated,W,HD,4,53,0.768667788,7.694392803,NA,-0.90829641,7.886616372,-1.962444794,1,97,0,0,NA,-23.13202199,65.57809644,*04,*11,75.44435842,no
S-181218-06219,pt415,31.75359343,Female,RR-MS,RR-MS,0.180698152,22.02717755,Untreated,W,validation,4.1,63,NA,NA,0.693147181,NA,14.67563066,NA,2,89,1,0,10.372222,NA,62.64747883,*01:01:01,*15:01,450.2279719,past
S-181218-06227,pt416,47.23887748,Female,RR-MS,RR-MS,4.260095825,44.2154094,fingolimod (Gilenya),AA,training,5.2,42,0.779848418,8.451694209,0,-0.53850249,30.5339951,-0.487846349,3.5,69,3,2,82.138888,-3.43698845,59.83669178,*07:01:01,*15:03,33.18507681,past
S-181218-06228,pt417,45.86173854,Female,SP-MS,prog-MS,0.410677618,38.42783766,Untreated,AA,training,5,37,NA,NA,0,NA,22.38307872,NA,3,75,5,2,28.00000002,NA,69.18211807,*11:02:01,*14:54:01,19.23026684,past
S-181218-06229,pt417,46.45585216,Female,SP-MS,prog-MS,1.004791239,38.12695109,glatiramer acetate (Glatopa),AA,training,4.65,39,0.817082966,7.932721027,NA,-1.054583325,31.84966087,-0.852960475,4,67,8,2,85.85000002,2.566569748,69.84377049,*11:02:01,*14:54:01,55.6059979,past
S-181218-06230,pt418,55.39767283,Male,PP-MS,prog-MS,6.028747433,21.41975309,Untreated,AA,training,13.3,23,0.623318887,11.39975677,0,3.273602751,54.49846749,3.941057118,6.5,44,19,5,240.54444,-14.10030708,NA,*01:05,*15:03,452.2013206,current
S-181218-06231,pt419,45.88364134,Female,SP-MS,prog-MS,20.15331964,29.1349481,natalizumab (Tysabri),NA,validation,60.8,21,0.721576688,10.4845293,NA,1.604289031,59.7484848,2.811189291,6.5,46,17,6,202.94444,6.313154841,41.42637075,*07:01,*15:01,245.1771814,past
S-181218-06232,pt420,59.57837098,Female,SP-MS,prog-MS,4.511978097,32.14532872,glatiramer acetate (Copaxone),W,training,22.2,32,NA,NA,NA,NA,49.24454702,NA,6.5,58,13,6,148.588888,NA,71.26725982,*08,*15:01,203.4050475,past
S-181218-06233,pt421,57.25941136,Female,PP-MS,prog-MS,4.161533196,27.84244245,Untreated,NA,training,12.95,50,0.804414954,7.114769448,0,-1.397534815,44.18986719,-0.506025136,6,65,9,4,113.233332,18.02202389,62.14424592,*01:01:01,*13:02:01,-95.27380236,past
S-181218-02999,pt422,49.5687885,Male,RR-MS,RR-MS,0.31211499,NA,Untreated,W,validation,NA,NA,NA,NA,0,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03725,pt423,33.64271047,Female,RR-MS,RR-MS,0.153319644,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-05744,pt424,43.68240931,Female,RR-MS,RR-MS,0.27652293,NA,Untreated,AA,training,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-02980,pt425,25.28131417,Female,RR-MS,RR-MS,0.511978097,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-05794,pt426,20.10403833,Female,RR-MS,RR-MS,1.253935661,NA,Untreated,AA,validation,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-05870,pt427,36.78028747,Female,RR-MS,RR-MS,NA,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03774,pt428,24.183436,Female,RR-MS,RR-MS,0.032854209,NA,Untreated,W,validation,NA,NA,NA,NA,0.693147181,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03765,pt429,38.30253251,Female,RR-MS,RR-MS,9.366187543,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03603,pt430,34.66119097,Female,RR-MS,RR-MS,NA,NA,Untreated,AA,training,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03727,pt431,46.28062971,Female,RR-MS,RR-MS,0.301163587,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-05893,pt432,44.45995893,Male,RR-MS,RR-MS,NA,NA,Untreated,W,validation,NA,NA,NA,NA,0,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03641,pt433,42.05612594,Female,RR-MS,RR-MS,0.700889802,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-05928,pt434,32.42710472,Female,RR-MS,RR-MS,0.27652293,NA,Untreated,W,validation,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03647,pt435,41.68651608,Female,RR-MS,RR-MS,14.55715264,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03802,pt436,39.93429158,Female,RR-MS,RR-MS,15.34565366,NA,Untreated,W,training,NA,NA,NA,NA,1.386294361,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03581,pt437,41.28131417,Female,RR-MS,RR-MS,0.038329911,NA,Untreated,W,training,NA,NA,NA,NA,0,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03891,pt438,45.70841889,Female,RR-MS,RR-MS,0.030116359,NA,Untreated,W,validation,NA,NA,NA,NA,0,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-181218-03857,pt439,27.68788501,Female,RR-MS,RR-MS,0.952772074,NA,Untreated,W,training,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA